10-K

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 10-K

x Annual report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 for the fiscal year ended December 31, 2010

OR

¨ Transition report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 for the transition period from                      to                     .

Commission file number: 000–33001

NATUS MEDICAL INCORPORATED

(Exact name of Registrant as specified in its charter)

Delaware	77–0154833
(State or other jurisdiction of incorporation or organization)	(I.R.S. Employer Identification Number)

1501 Industrial Road, San Carlos, California 94070

(Address of principal executive offices, including zip code)

(650) 802–0400

(Registrant’s telephone number, including area code)

Securities Registered Pursuant to Section 12(b) of the Act:

Title of each class	Name of each exchange on which registered
Common Stock, $0.001 par value per share	The NASDAQ Stock Market LLC (Nasdaq Global Select Market)

Securities Registered Pursuant to Section 12(g) of the Act: None

Indicate by check mark if the Registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act.    Yes  ¨    No  x

Indicate by check mark if the Registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.    Yes  ¨    No  x

Indicate by check mark whether the Registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports) and (2) has been subject to such requirements for the past 90 days.    Yes  x    No  ¨

Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files).    Yes  ¨    No  ¨

Indicate by check mark if disclosure of delinquent filers pursuant to Item 405 of Regulation S-K is not contained herein, and will not be contained, to the best of registrant’s knowledge, in definitive proxy or information statements incorporated by reference in Part III of the Form 10-K or any amendment to this Form 10-K.    x

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, or a non-accelerated filer. See definition of “accelerated filer and large accelerated filer” in Rule 12b-2 of the Exchange Act (Check one):

Large accelerated filer    ¨	Accelerated filer    x
Non-accelerated filer    ¨	Smaller reporting company    ¨
(Do not check if a smaller reporting company)

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Act).    Yes  ¨    No  x

As of June 30, 2010, the last business day of Registrant’s most recently completed second fiscal quarter, there were 28,658,910 shares of Registrant’s common stock outstanding, and the aggregate market value of such shares held by non-affiliates of Registrant (based upon the closing sale price of such shares on the Nasdaq Global Select Market on June 30, 2010) was $385,015,698. Shares of Registrant’s common stock held by each executive officer and director and by each entity that owns 5% or more of Registrant’s outstanding common stock have been excluded in that such persons may be deemed to be affiliates. This determination of affiliate status is not necessarily a conclusive determination for other purposes.

On March 7, 2011, the registrant had 28,974,250 shares of its common stock outstanding.

DOCUMENTS INCORPORATED BY REFERENCE

The Registrant has incorporated by reference, into Part III of this Form 10-K, portions of its Proxy Statement for the 2011 Annual Meeting of Stockholders.

NATUS MEDICAL INCORPORATED

ANNUAL REPORT ON FORM 10-K

TABLE OF CONTENTS

PART I		1
ITEM 1.	Business	1
ITEM 1A.	Risk Factors	20
ITEM 1B.	Unresolved Staff Comments	31
ITEM 2.	Properties	31
ITEM 3.	Legal Proceedings	32
ITEM 4.	(Reserved)	32
PART II		33
ITEM 5.	Market for Registrant’s Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities	33
ITEM 6.	Selected Financial Data	34
ITEM 7.	Management’s Discussion and Analysis of Financial Condition and Results of Operations	36
ITEM 7A.	Quantitative and Qualitative Disclosures About Market Risk	49
ITEM 8.	Financial Statements and Supplementary Data	49
ITEM 9A.	Controls and Procedures	51
PART III		54
ITEM 10.	Directors, Executive Officers and Corporate Governance	54
ITEM 11.	Executive Compensation	54
ITEM 12.	Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters	54
ITEM 13.	Certain Relationships and Related Transactions, and Director Independence	55
ITEM 14.	Principal Accountant Fees and Services	55
PART IV		56
ITEM 15.	Exhibits and Financial Statement Schedule	56
SIGNATURES		60

PART 1

ITEM 1. Business

This Annual Report on Form 10-K contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934 about Natus Medical Incorporated (“Natus,” “we,” “us,” or “our Company”). These statements include, among other things, statements concerning our expectations, beliefs, plans, intentions, future operations, financial condition and prospects, and business strategies. The words “may,” “will,” “continue,” “estimate,” “project,” “intend,” “believe,” “expect,” “anticipate,” and other similar expressions generally identify forward-looking statements. Forward-looking statements in this Item 1 include, but are not limited to, statements regarding the effectiveness and advantages of our products, factors relating to demand for and economic advantages of our products, our plan to develop and acquire additional technologies, products or businesses, our marketing, technology enhancement, and product development strategies.

Forward-looking statements are not guarantees of future performance and are subject to substantial risks and uncertainties that could cause the actual results to differ materially from those that we predicted in the forward-looking statements. Investors should carefully review the information contained under the caption “Risk Factors” contained in Item 1A for a description of risks and uncertainties that could cause actual results to differ from those that we predicted. All forward-looking statements are based on information available to us on the date hereof, and we assume no obligation to update forward-looking statements, except as required by Federal Securities laws.

Natus^®, AABR^®, ABaer^®, ALGO^®, AOAE^®, AuDX^®, Balance Manager^®, Balance Master^®, Biliband^®, Bio-logic^®, Ceegraph^®, CHAMP^®, Cochlea Scan^®, Cool Cap^®, Ear Couplers^®, Echo Screen^®, EquiTest^®, Fischer-Zoth^®, Flexicoupler^®, Gumdrop^®, Keypoint^®, Keypoint AU^®, Keypoint EU^®, Keypoint JP^®, MASTER^®, Medix^®, Medix I.C.S.A.^®, Navigator^®, Neatnick^®, neoBLUE^®, Neuromax^®, NeuroWorks^®, Oxydome^®, Servocuna^®, Sleeprite^®, Sleepscan^®, Smart Scale^®, Tootsweet^®, Traveler^®, Warmette^® and VAC PAC^® are registered trademarks of Natus Medical Incorporated and its subsidiaries. Accuscreen™, Bili-Lite Pad™, Bili-Lite™, Biomark™, Circumstraint™, Coherence™, Deltamed™, inVision™, MiniMuffs™, Neometrics™ and Smartpack™ are non-registered trademarks of Natus and its subsidiaries. Solutions for Newborn Care^SM is a non-registered service mark of Natus.

Overview

Natus is a leading provider of healthcare products used for the screening, detection, treatment, monitoring and tracking of common medical ailments in newborn care, hearing impairment, neurological dysfunction, epilepsy, sleep disorders, and balance and mobility disorders. Product offerings include computerized neurodiagnostic systems for audiology, neurology, polysomnography, and neonatalogy, as well as newborn care products such as hearing screening systems, phototherapy devices for the treatment of newborn jaundice, head-cooling products for the treatment of brain injury in newborns, incubators to control the newborn’s environment, and software systems for managing and tracking disorders and diseases for public health laboratories.

We have completed a number of acquisitions since 2003, consisting of either the purchase of a company, substantially all of the assets of a company, or individual products or product lines. Our significant acquisitions are as follows: Neometrics in 2003; Fischer-Zoth in 2004; Bio-logic, Deltamed, and Olympic in 2006; Xltek in 2007; Sonamed, Schwarzer Neurology, and Neurocom in 2008, Hawaii Medical and Alpine Biomed in 2009, and Medix in 2010.

Product Families

We categorize our products into the following product families:

• Hearing—Includes products for newborn hearing screening and diagnostic hearing assessment.

1

• Neurology—Includes products for diagnostic electroencephalography (EEG), electromyography (EMG), intra-operative monitoring (IOM), diagnostic sleep analysis, or polysomnography (PSG), newborn brain monitoring, and assessment of balance and mobility disorders.

• Newborn Care—Includes thermoregulation devices and products for the treatment of brain injury and jaundice in newborns.

Our principal product offerings within these product families are presented in the table on the following page.

2

Our Product Offerings

Hearing

Newborn Hearing Screening

Overview

Hearing impairment is the most common treatable chronic disorder in newborns, affecting as many as five babies out of every 1,000 newborns. It is estimated that 20,000 hearing-impaired babies are born in the United States (“U.S.”) every year, and as many as 60,000 more in the rest of the developed world. Until the introduction of universal newborn hearing screening programs, screening was generally performed only on those newborns that had identifiable risk factors for hearing impairment. However, screening only those newborns with risk factors for hearing impairment overlooks approximately half of newborns with some level of hearing impairment.

Early identification of hearing impairment and early intervention has been shown to improve language development significantly. Undetected hearing impairment often results in the failure to learn, process spoken language, and speak. If hearing impairment is not detected prior to discharge from the hospital it is often not detected until the child is 18 months of age or older. A 1997 study conducted at the University of Colorado, Boulder evaluated the impact of hearing impairment on language and speech. All of the children evaluated in the study were born with a hearing impairment but differed by the age at which the hearing impairment was detected. The study concluded that those children whose hearing loss was detected early and who received appropriate treatment had significantly better language skills and vocabularies than those children whose hearing loss was detected later.

Newborn Hearing Screening in the United States

We estimate that today approximately 95% of the children born in the U.S. are being screened for hearing impairment prior to discharge from the hospital. In 1999, the American Academy of Pediatrics Task Force on Newborn and Infant Hearing first published specific guidelines for universal newborn hearing screening programs. In 2000 and 2007, the Joint Committee on Infant Hearing (“JCIH”) Position Statements outlined principles, guidelines, and benchmarks for early hearing detection and intervention programs. These principles and guidelines are considered the standard of care today. Because “positive” results are referred to an audiologist or an Ear, Nose and Throat physician (“ENT”) for additional testing and evaluation, limiting the number of “refers” stemming from false positive results reduces the cost of a newborn screening program. In addition, false positive results can cause unnecessary emotional distress for parents.

The 2007 JCIH Position Statement updated and expanded the definition of targeted hearing loss and recommended a specific protocol for babies admitted to the Neonatal Intensive Care Unit (“NICU”) for more than 5 days. Additionally, the document expressed increased awareness, not only of the need for diagnostic audiology evaluation for children diagnosed with hearing impairment at birth, but also for surveillance and hearing screening for children at risk of delayed onset and progressive hearing impairment during the first three years of life.

Newborn Hearing Screening Techniques

The two traditional technologies used to screen newborns and infants for hearing impairment are auditory brainstem response and otoacoustic emissions.

Auditory brainstem response (“ABR”).    ABR technology is the most accurate and comprehensive method for screening and diagnosing hearing impairment. ABR technology is based on detecting the brain’s electric impulses resulting from a specific auditory stimulus. ABR screening devices, used for newborn hearing screening, detect and analyze the brainwave response resulting from audible click stimuli presented to the

3

infant’s ears. Automated Auditory Brainstem Response (“AABR”) devices were developed to automatically analyze the ABR waveform resulting from the auditory stimuli with computerized detection algorithms and statistical analysis. These devices can be used by any level of hospital personnel with a minimal amount of training and will deliver a clinically valid and accurate screen. The detection algorithms indicate a PASS or REFER result that requires no interpretation, thereby reducing staffing requirements, test times, and total hearing screening program costs. A REFER test result indicates that the patient should be referred to an Audiologist or ENT for further diagnostic evaluation.

Otoacoustic emission (“OAE”).    OAEs are sounds created by the active biomechanical processes within the sensory cells of the cochlea. They occur both spontaneously and in response to acoustic stimuli. OAE screening uses a probe placed in the ear canal to deliver auditory stimuli and to measure the response of the sensory cells with a sensitive microphone. OAE screening devices have technology that allows them to discriminate between randomly occurring OAEs, OAEs created by interfering room noise present in the test environment, and the OAEs that are a response to specific test stimuli. Automated OAE screening devices are capable of filtering non-specific OAEs in order to detect and analyze the OAEs that lead to an accurate screen of the infant’s hearing. While a PASS test result indicates a proper functioning cochlea, a REFER test result indicates that the OAEs are absent or small compared to normal data. A REFER test result indicates that the patient should be referred to an Audiologist or ENT for further diagnostic evaluation. OAE technology is unable to detect hearing disorders affecting the neural pathways, such as auditory neuropathy. Estimates of the incidence rate of auditory neuropathy among hearing impaired newborns vary widely, but are thought to be in the range of 5% to 15%.

Newborn Hearing Screening Product Lines

Our newborn hearing screening product lines consist of the ALGO, ABaer, AuDX, and Echo-Screen newborn hearing screeners. These hearing screening products utilize proprietary signal detection technologies to provide accurate and non-invasive hearing screening for newborns and are designed to detect hearing loss at 35 dB nHL or higher. Each of these devices is designed to generate a PASS or REFER result.

• ALGO 5 and 3i Newborn Hearing Screeners.    These AABR devices deliver thousands of soft audible clicks to the newborn’s ears through sound cables and disposable earphones connected to the instrument. Each click elicits an identifiable brain wave, which is detected by disposable electrodes placed on the head of the child and analyzed by the screening device. These devices use our proprietary AABR signal detection algorithm.

• ABaer Newborn Hearing Screener.    The ABaer, which is a PC-based newborn hearing screening device, offers a combination of AABR, OAE, and diagnostic ABR technologies in one system. The automatic ABR technology utilizes our patented Point Optimized Variance Ratio (“POVR”) signal detection algorithm developed by the House Ear Institute. Like our ALGO newborn hearing screeners, this device delivers thousands of soft audible clicks to the newborn’s ears through sound cables and disposable earphones. Each click elicits an identifiable brain wave, which is detected by disposable electrodes placed on the head of the child and analyzed by the screening device. The ABaer OAE software is the same technology used in our AuDX product and the diagnostic ABR software is the same technology used in our Navigator diagnostic hearing assessment product.

• AuDX and Echo-Screen.    Our AuDX product is a hand-held OAE screening device that can be used for newborn hearing screening, as well as for patients of all ages, from children through adults. Our Echo-Screen product is a hand-held combination AABR and OAE device for newborn screening that can also used for children through adults in OAE-only mode. These devices record and analyze OAEs generated by the cochlea through sound cables and disposable ear probes inserted into the patient’s ear canal. OAE technology is unable to detect hearing disorders affecting the neural pathways, such as auditory neuropathy.

4

Hearing Screening Supply Products

For infection control, accuracy, and ease of use, the supply products used with our newborn hearing screening devices are designed as single-use, disposable products. Each screening supply product is designed for a specific hearing screening technology.

• ABR Screening Supply Kits.    Each ABR screen is carried out with single-use earphones and electrodes, which are alcohol and latex-free. The adhesives used in these supply products are specially formulated for use on the sensitive skin of newborns. To meet the needs of our customers we offer a variety of packaging options.

• OAE Supply Products.    Each OAE screen is carried out with single-use ear tips that are supplied in a variety of sizes and packaging options.

Diagnostic Hearing Assessment

Overview

We design and manufacture a variety of products used to screen for or diagnose hearing loss, or to identify abnormalities affecting the peripheral and central auditory nervous systems in patients of all ages. The technology used in most of these systems is either electrodiagnostic in nature or measures a response from the cochlea known as an OAE.

Electrodiagnostic systems record electrical activity generated in the central nervous system. An electrodiagnostic testing device delivers acoustic stimuli to the ears while electrodes placed on the scalp record the brain’s electrical response. The most common auditory test performed with electrodiagnostic equipment is the ABR test. This test, which records brainwaves that correspond to responses from the inner ear and brainstem, is used to screen for and define hearing loss characteristics, particularly for patients who cannot reliably respond to standard behavioral tests of hearing, either verbally or through motor response. A technician with minimal training can operate an instrument that performs an automated ABR screening test. More advanced ABR testing techniques that either define the nature of the hearing loss or that screen for other auditory abnormalities such as an acoustic tumor, require the expertise of a trained clinician, usually an audiologist or an ENT physician, an understanding of the technology being used, and the ability to interpret complex waveforms that represent the brain’s electrical activity.

In the follow up evaluation of newborns diagnosed with hearing impairment, the clinician can distinguish between hearing impairments caused by mechanical or sensory dysfunction of the ear versus auditory neuropathy. Recent studies confirm the importance of making this distinction, as appropriate treatments for these impairments differ. One study showed that for patients diagnosed with auditory neuropathy, approximately 15% reported some benefit from hearing aids for language learning, while improvement in speech comprehension and language acquisition was reported in 85% of patients who received cochlear implants.

Diagnostic Hearing Assessment Product Lines

Our diagnostic hearing assessment products consist of the Navigator Pro system, the Scout Sport portable diagnostic device and the AuDX PRO.

• Navigator PRO.    Our Navigator PRO for hearing assessment consists of a base system that is augmented by discrete software applications that are marketed as enhancements to the system. The Navigator Pro System is a PC-based, configurable device that utilizes evoked potentials, which are electrical signals recorded from the central nervous system that appear in response to repetitive stimuli, such as a clicking noise. The evoked potentials are used to record and display human physiological data associated with auditory and hearing-related disorders. The Navigator Pro System can be used for patients of all ages, from children to adults, including infants and geriatric patients. The device can be configured with additional proprietary software programs for various applications. These additional software programs include: CHAMP, MASTER, AEP, VEMP, ABaer, and Scout.

5

• Scout SPORT.    The Scout SPORT is a PC-based OAE system. The ultra-portable Scout Sport can be carried from one computer to another to test in different locations. For office-based environments, the Scout Sport can be used with a dedicated notebook computer to create an independent portable system.

• AuDX PRO.    The AuDX PRO is a hand-held OAE screening device with a large color display that can be used for patients of all ages. The AuDX PRO records and analyzes OAEs generated by the cochlea through sound cables and disposable ear probes inserted into the patient’s ear canal.

Diagnostic Hearing Supply Products

For infection control, accuracy, and ease of use, most supply products used with our diagnostic hearing devices and systems are designed as single-use, disposable products. Each screening supply product is designed for a specific diagnostic hearing technology, and is similar in nature to our previously described OAE supply products for use in newborn hearing screening.

Neurology

Our monitoring systems for neurology represent a comprehensive line of products that are used by physicians, nurses and medical technologists to assist in the diagnosis and monitoring of neurological disorders of the central and peripheral nervous system and as an aid in monitoring patients during surgery, while under sedation, or in post-operative care. Our product lines consist of the following:

• Electroencephalography or “EEG”—Equipment that monitors and visually displays the electrical activity generated by nerve cells in the brain for both diagnosis and monitoring of neurological disorders in the hospital, laboratory, physician office or patient’s home.

• Electromyography or “EMG”—Equipment that measures electrical activity in nerves, muscles, and the spinal cord.

• Intra-operative Monitoring or “IOM”—Products that assist surgeons in preserving the functional integrity of a patient’s nervous system during and after complex surgical procedures.

• Polysomnography or “PSG”—Equipment that measures a variety of respiratory and neurological functions to assist in the diagnosis and monitoring of sleep disorders, such as snoring and obstructive sleep apnea, a condition that causes a person to stop breathing intermittently during sleep.

• Balance and Mobility—Systems to diagnose and assist in treating balance disorders in an evidence-based, multidisciplinary approach.

Diagnostic EEG Monitoring

Overview

We design, manufacture, and market a full line of computerized instruments used to help diagnose the presence of seizure disorders and epilepsy, look for causes of confusion, evaluate head injuries, tumors, infections, degenerative diseases, and metabolic disturbances that affect the brain, and assist in surgical planning. This type of testing is also done to diagnose brain death in comatose patients. These systems and instruments work by detecting, amplifying, and recording the brain’s electrical impulses (EEGs). Routine EEG recording is done by placing electrodes on a patient’s scalp over various areas of the brain to record and detect patterns of activity and specific types of electrical events. EEG technologists perform the tests, and neurologists review and interpret the results.

Routine outpatient EEG testing is performed in both hospital neurology laboratories and physician offices, providing physicians with a clinical assessment of a patient’s condition. For patients with seizures that do not respond to conventional therapeutic approaches, long-term inpatient testing of EEGs and behavior is used to determine if surgical solutions are appropriate.

6

Diagnostic Electroencephalograph Monitoring Product Lines

Our diagnostic electroencephalograph (“EEG”) monitoring product lines for neurology consist of devices operating with our proprietary software augmented by signal amplifiers. These products are typically used in concert, as part of an EEG “system” by the neurology department of a hospital to assist in the diagnosis of assorted neurological conditions.

• NeuroWorks; Coherence; Harmonie.    Our computerized EEG Systems include a broad range of products, from software licenses and ambulatory monitoring systems to advanced laboratory systems with multiple capabilities for EEG, ICU monitoring, long-term epilepsy monitoring of up to 256 channels, and physician review stations with quantitative EEG analysis capabilities.

• Stellate/Gotman Spike and Seizure; GridView.    Our proprietary Spike and Seizure detection algorithm detects, summarizes, and reports EEG events that save health care professionals time by increasing the speed and accuracy of interpretation. GridView is a tool that allows the clinician to correlate EEG patterns with electrode contacts on a 3D view of the patient brain using magnetic resonance (MR) or computed tomography (CT) images, thus enabling the visualization and annotation of the brain surface and internal structures involved in the diagnosis of epilepsy.

• Proprietary Signal Amplifiers.    Our proprietary signal amplifiers function as the interface between the patient and the computer, and are also known as the headbox. The headbox connects electrodes attached to the patient’s head to our EEG monitoring systems. Our proprietary headbox products are sold for a wide variety of applications under the following brand names: Bio-logic Netlink, Xltek Trex, EEG32, EMU128, EMU40, Brain Monitor, and Schwarzer epas. Recent innovations in electronics technology and advanced internet-protocol data transmission enable certain of our amplifiers to record and transmit up to 32 channels of digital data using Ethernet communication.

Several additional options are available to enhance our EEG products, including: a digital video option, which provides synchronized video recording of a patient’s behavior while recording electrical activity from the brain; our patented SmartPack software option, which is an innovative data compression process that reduces the size of data files by as much as 60%, and our Universal Reader which is a physician’s review station that permits fast and easy data analysis in a graphical format.

Diagnostic Electromyography Monitoring

Overview

Electromyography (“EMG”) involves the measurement of electrical activity of muscles both at rest and during contraction. Measuring the electrical activity in muscles and nerves can help diagnose diseases that damage muscle tissue or nerves. An electromyogram is done to determine if there is any disease present that damages muscle tissue, nerves, or the junctions between nerve and muscle (neuromuscular junctions). An electromyogram can also be used to diagnose the cause of weakness, paralysis, and muscle twitching and is also used as a primary diagnosis for carpal tunnel syndrome, which is the most frequently encountered peripheral compressive neuropathy.

Diagnostic EMG Product Lines

• Xltek NeuroMax.    A dedicated EMG device focused entirely on signal quality and clinical efficiency. The device gathers neurophysiological data that is saved to a fully customizable report, allowing physicians to take care of patients with the most informed advice.

• Xltek XCalibur.    An EMG system that uses advanced circuit design and digital signal processing to deliver clean signals, making the process of acquiring patient data reliable and quick. The system provides enhanced data acquisition, reporting, and review capabilities.

• Dantec Keypoint.    The Dantec Keypoint EMG and EP family of products feature superior amplifiers, stimulators, and outstanding signal quality. The Keypoint is used for advanced neurodiagnostic

7

applications such as single fiber EMG, visual and auditory evoked potentials, and in routine nerve conduction studies. The Keypoint system is also available in a portable laptop configuration.

• Dantec Clavis.    The Dantec Clavis device is a hand-held EMG and current stimulation (“STIM”) device that provides muscle and nerve localization information to assist with botulinum toxin injections (i.e. Botox). In conjunction with the Bo-ject hypodermic needle and electrodes, it delivers a precise dose of the agent.

• Schwarzer Topas.    The Topas system offers a wide range of sophisticated EMG and evoked potential (“EP”) examination protocols, as well as an attractive and functional design. The Topas system can be configured as a two or four channel system, as trolley-based or portable version, depending on the needs of the hospital or private practice.

Intra Operative Monitoring

Overview

Intra-operative monitoring (“IOM”) is the use of electrophysiological methods such as EMG and EEG to monitor the functional integrity of neural structures (i.e. brain, nerves, spinal cord) during surgery. The most common applications are in neurosurgery such as spinal surgery, some brain surgeries, ENT procedures, and peripheral nerve surgery. IOM is used to localize neural structures and test the function of these structures for early detection of intra-operative injury, allowing for immediate corrective measures.

Intra-operative Monitoring Products

• Protektor.    The Protector system is an IOM system that provides medical professionals with all information necessary to make immediate and critical surgical decisions. The system combines flexibility with multi-modality allowing full coverage of IOM techniques. The Protektor is available in a 16 or 32 channel configuration.

Diagnostic Polysomnography Monitoring

Overview

Increasing public awareness of sleep disorders has made sleep medicine a rapidly growing specialty. Polysomnography (“PSG”), which involves the analysis of respiratory patterns, brain electrical activity and other physiological data, has proven critical for the diagnosis and treatment of sleep-related diseases such as apnea, insomnia, and narcolepsy. A sleep study entails whole-night recordings of brain electrical activity, muscle movement, airflow, respiratory effort, oxygen levels, electrical activity of the heart (ECG or EKG), and other parameters. These recordings typically result in over 1,000 pages of data that are reviewed, analyzed, and scored by a technician, and summarized in a report for the physician. We market configured laboratory systems, portable systems, and ambulatory recorders for home monitoring.

Diagnostic PSG Monitoring Product Lines

Our diagnostic PSG monitoring products can be used individually or as part of a networked system for overnight sleep studies to assist in the diagnosis of sleep disorders. These products include software licenses, ambulatory monitoring systems, and laboratory systems that combine multiple capabilities, including EEG monitoring, physician review stations, and quantitative EEG analysis capabilities.

• SleepWorks; Coherence; Harmonie.    Our diagnostic PSG systems capture and store all data digitally and provide time-saving features and software for acquiring and analyzing the data. The systems enable users to specify rules and personal preferences to be used during analysis, summarizing the results graphically and incorporating them in detailed reports. Software packages include customized analysis, tools and interfaces with third party equipment.

8

• Proprietary Amplifiers.    Our data acquisition systems incorporate recent developments in superior amplifiers for sleep analysis. Sold under the brand names Xltek Trex and Connex, Bio-logic Netlink, Schwarzer epas duo 44 and comlab PSG, our amplifiers are used in stand-alone clinics and hospital settings. In addition to exceptional signal quality, headboxes include various tools such as built-in oximeters, and controls to allow the user to start and stop a study or perform electrode impedance testing either at the patient’s bedside or from the monitoring room.

We also market a broad line of disposable products and accessories for the PSG laboratory. The Airflow Pressure Transducer uses pressure changes as an indicator of patient airflow levels, as contrasted to other monitoring devices that use temperature to indicate these levels. This product detects shallow breathing in situations where temperature related transducers might remain substantially unchanged. This method has been documented in industry publications to produce the signature waveform used in identifying a respiratory disorder known as Upper Airway Resistance Syndrome.

Balance and Mobility

Overview

Balance disorders impact a large percentage of the population in all age ranges from children to adults. Common complaints include dizziness, vertigo, or an inability to walk or drive a vehicle, which can all lead to the curtailment of daily life activities. These symptoms are exacerbated in elderly patients and can result in falls, orthopedic injuries, and sometimes death.

Balance problems are difficult to diagnose and treat because they can be caused by a combination of diseases or movement dysfunctions. Healthcare professionals who take a traditional clinical approach to the examination and treatment of balance problems typically explore one component of the balance system at a time. This approach often requires patients to consult multiple specialists, leading to patient dissatisfaction and increased health care costs, frequently without achieving an optimal outcome.

We believe the most effective strategy for diagnosing and treating balance disorders is an evidence-based, multidisciplinary approach applying a broad range of patient information. Our Balance Manager systems are designed to facilitate the assessment and management of complex balance problems in the context of the total patient to support this process. These systems are used in a broad spectrum of medical disciplines including otolaryngology, neurology, physiatry, orthopedics/sports medicine, geriatrics, and physical rehabilitation.

Balance and Mobility Products

Our principal balance and mobility products are sold under the Neurocom brand:

• EquiTest.    Proprietary protocols in the EquiTest family of devices objectively quantify and differentiate among sensory, motor, and central adaptive impairments to balance control. This approach is commonly referred to as computerized dynamic posturography (“CDP”). CDP is complementary to clinical tests designed to localize and categorize pathological mechanisms of balance disorders in that it can identify and differentiate the functional impairments associated with the identified disorders.

• Balance Master.    A family of devices providing objective assessment and retraining of the sensory and voluntary motor control of balance. With visual biofeedback on either a stable or dynamic support surface and in a stable or dynamic visual environment, the clinician can both assess and retrain patients performing tasks ranging from essential daily living activities through high-level athletic skills. The objective data captured by the device supports the design of effective treatment and/or training programs focused on the specific sensory and motor components underlying a patient’s functional limitations.

9

• inVision.    Our inVision device incorporates a set of proprietary diagnostic tests that quantify a patient’s ability to maintain visual acuity and stable gaze while actively moving the head. The objective information enables the clinician to assess the patient’s ability to live and move safely in a dynamic world and to participate in daily-life functions such as driving, walking through a grocery store, or actively engaging in family activities.

Newborn Care

Newborn Care Products

We manufacture a wide variety of products used in the medical care of newborns. These product lines include products to diagnose and treat newborn brain injury, as well as phototherapy lights to treat newborn jaundice. We also sell a variety of newborn care products to meet the needs of clinicians in the nursery and NICU. With our recent acquisition of Medix, we now offer a full range of thermoregulation devices use for the care of newborns.

Newborn Brain Injury

Overview

For many years, newborn infants admitted to the NICU of a hospital have routinely been monitored for heart activity, temperature, respiration, oxygen saturation, and blood pressure. Only recently has it also been considered important to monitor brain activity using continuous EEG. A cerebral function monitor, utilizing amplitude-integrated EEGs (“aEEGs”), is a device for monitoring background neurological activity.

Neurological Assessment and Treatment Options

Early diagnosis of brain injury in newborns, when combined with early intervention, has been shown to reduce the severity of these brain injuries and in some cases, save the patient’s life. These brain injuries, which can occur in as many as three out of every 1,000 newborns, are caused by conditions such as hypoxic ischemic encephalopathy (“HIE”), subclinical seizures, or neurological disorders. Diagnosing these conditions shortly after birth is imperative, as patients who undergo therapy within six hours after birth show a greater potential for improved outcomes. We believe that diagnoses utilizing aEEG technology can have a marked and positive impact upon the outcomes of some newborns suffering from brain injury.

Newborn Brain Injury Diagnostic Products

Our newborn brain injury diagnostic products record and display parameters that the neonatologist uses to diagnose neurological disorders or brain injury in the newborn. These devices continuously monitor and record brain activity, aiding in the detection and treatment of HIE and seizures. The devices also monitor the effects of drugs and other therapies on brain activity and improve the accuracy of newborn neurological assessments. They are used with electrodes attached to the head of the newborn to acquire an EEG signal that is then filtered, compressed, and displayed graphically on the device or as a hardcopy printout. The monitors have touch screens for easy navigation and onscreen keyboards for data entry at the bedside.

• Olympic Brainz Monitor.    The Olympic Brainz Monitor (“OBM”) is our latest generation Cerebral Function Monitor (“CFM”). The device can be used as a single channel, two-channel or three-channel device to continuously monitor and record brain activity. The OBM displays up to three channels of both aEEG and EEG data. Sophisticated networking, archiving and viewing functions facilitate consultation among medical professionals. Continuous impedance and corresponding EEG signals are also displayed, aiding better clinical management of the newborn.

• Brainz BRM3.    The Brainz BRM3 is a bedside monitor that collects and measures electrical activity from both the right and left hemispheres of the brain. The monitor presents a simplified 2-channel EEG display, along with the option to view three channels of time-compressed amplified EEG’s (“aEEG”), providing practitioners with the ability to monitor infants with a wider variety of neurological concerns

10

when compared to single-channel EEG. Outside the U.S. the BRM3 is sold with an optional spike and event detection algorithm called Recognize.

• Olympic CFM-6000.    The Olympic CFM-6000 is a single-channel aEEG/EEG system that allows the neonatologist to diagnose neurological disorders or brain injury in the newborn. It helps determine the need for further neurological examination or transport to a tertiary-care center.

Newborn Brain Injury Treatment

• Olympic Cool-Cap System.    The Olympic Cool-Cap is the only FDA-approved device for the treatment of moderate to moderately-severe HIE. A four-year clinical trial for the Cool-Cap was completed in 2003, and the FDA approved the product in December 2006. The clinical trial validated the benefit of selective head cooling as a means of reducing the temperature of the brain to diminish the severity of brain injury resulting from HIE in newborns. The device conforms to the clinical trial protocol and is designed to assist the clinician in safely administering treatment, thereby preventing or significantly reducing the severity of neurological injury associated with HIE. The Olympic Cool-Cap brain cooling system uses a single-patient, disposable, cooling “cap” to continuously circulate sterile water to the patient during the 72-hour treatment period.

Thermoregulation Products

Overview

Incubators offer a controlled, consistent microenvironment for thermoregulation and humidification within a closed system to maintain skin integrity and body temperature. This controlled microenvironment reduces noise and light, supporting developmental care while still providing access for clinical staff and family. Closed incubators are used for premature or sick babies who need a thermal and developmental environment to thrive and grow in the NICU. Transport incubators are designed to offer a controlled environment during transport either intra-hospital from one care area to another within a hospital building or inter-hospital between hospitals. Open infant warmers are the preferred device for labor and delivery rooms and NICU admission.

We currently offer the following thermoregulation products:

• Medix Incubators.    Medix incubators provide high thermal performance with a double wall design. The Natal Care line of incubators includes easy to use control panels and features such as improved weighing functionality with automatic centering and an electronic tilting mechanism. The easy to clean, smooth design, and choice of options make these customizable incubators appropriate for different use environments.

• Medix Open Warmers.    Medix open warmers include a full range of options including Apgar timers and resuscitation systems. Available with an attached bed or in free-standing configurations, the warmers feature a microprocessor controlled display module with easy to read display. The heater module has lateral movement capabilities to facilitate X-ray procedures while maintaining heat delivery.

• Medix Transport Incubators.    Medix transport incubators are light in weight and easy to clean. They incorporate long lasting batteries and a choice of carts to meet the needs of different care environments.

Jaundice Management

Overview

The American Academy of Pediatrics estimates that each year 60% of the approximately four million newborns in the U.S. become jaundiced. According to the Journal of the American Medical Association, neonatal jaundice is the single largest cause for hospital readmission of newborns in the U.S., and accounts for 50% of readmissions. Because of the serious consequences of hyperbilirubinemia, the American Academy of Pediatrics recommends that all newborns be closely monitored for jaundice and has called for the physician to determine the presence or absence of an abnormal rate of hemolysis to establish the appropriate treatment for the newborn.

11

In 2004, the American Academy of Pediatrics issued new guidelines for the treatment of jaundice in newborns. The guidelines recommend phototherapy as the standard of care for the treatment of hyperbilirubinemia in infants born at 35 weeks or more of gestation. The guidelines further highlight the need for “intense” phototherapy, and specifically recommend the use of the “blue” light treatment incorporated into our neoBLUE products.

Jaundice Management Products

• neoBLUE Product Family.    This product line consists of our neoBLUE, neoBLUE Mini, and neoBLUE Cozy devices, which utilize light emitting diodes (“LEDs”) to generate a high-intensity, narrow spectrum of blue light that is clinically proven to be most effective in the treatment of newborn jaundice. The neoBLUE phototherapy devices emit significantly less ultraviolet light and heat than conventional phototherapy devices, reducing the risk of skin damage and dehydration for infants undergoing treatment. Because of the high intensity of these lights, the treatment time associated with phototherapy is reduced.

• Bili-Lite Product Family.    These devices utilize fluorescent light bulbs for the treatment of hyperbilirubinemia. The Bili-Bassinet provides intensive phototherapy from both under and over the baby for maximum surface area coverage. The Bili-Lite pad is a product designed for both hospital and home-based phototherapy.

• MediLED Product Family.    This product line from Medix includes a full-size, free-standing LED phototherapy system and a MediLED mini light to be used on top of an incubator or attached to the Medix radiant warmer. The MediLED incorporates an array of blue and white LEDs, while the mini system utilizes blue “super LEDs” that provide high intensity phototherapy.

Other Newborn Care Product Lines

Medical Devices.    These products include devices such as: photometers, radiometers, patient warming lamps, neonatal heatshields, pediatric scales, blanket warming cabinets, exam lights, oxygen hoods, restraining boards, and our newborn circumstraint.

• Hawaii Medical Products.    These single-use disposable products are sold into the NICU and nursery in hospitals. The Hawaii Medical line includes Gumdrop pacifiers, TootSweet sucrose solution, and NeatNick heel lancets, among a range of positioning devices, electrodes, and other newborn care products.

• Disposable Supplies.    These products include other disposable supplies such as neonatal noise attenuators, phototherapy eye masks and x-ray shields for newborn gonads.

• Newborn Screening Data Management Product Line.    Our suite of newborn screening data management products consists of proprietary software that collects, tracks, manages and reports newborn screening data to regional government health laboratories and national disease control centers. While all states have laws and/or regulations requiring newborn screening for metabolic disorders, the laws and regulations vary widely in the extent of screening required. Some states use tandem mass spectrometry in their newborn metabolic screening programs, which increases the number of treatable disorders that can be detected. Revenue from installation and upgrades of our newborn screening data management systems is classified as devices and systems revenue, and revenue from maintenance contracts on the systems is classified as supplies and services revenue.

Segment and Geographic Information

We operate in one reportable segment in which we provide healthcare products used for the screening, detection, treatment, monitoring and tracking of common medical ailments in newborn care, hearing impairment, neurological dysfunction, epilepsy, sleep disorders, and balance and mobility disorders.

12

Our end-user customer base includes hospitals, clinics, laboratories, physicians, nurses, audiologists, and governmental agencies. Most of our international sales are to distributors, who in turn, resell our products to end users or sub-distributors.

Information regarding our sales and long-lived assets in the U.S. and in countries outside the U.S. is contained in Note 16 – Segment, Customer and Geographic Information of our consolidated financial statements included in this report and is incorporated in this section by this reference.

Revenue by Product Family and Product Category

For the years ended December 31, 2010, 2009 and 2008, revenue from our four product families as a percent of total revenue was approximately as follows:

	Year Ended December 31,
	2010			2009			2008
Neurology		45	%		39	%		34	%
Hearing		32	%		40	%		41	%
Newborn Care		19	%		16	%		19	%
Other		4	%		5	%		6	%
Total		100	%		100	%		100	%

We also look at revenue as either being generated from sales of Devices and Systems, which are generally non-recurring, or related Supplies and Services, which are generally recurring. The products that are attributable to these categories are described above. Revenue from Devices and Systems, and Supplies and Services, as a percent of total revenue for the years ending December 31, 2010, 2009 and 2008 is as follows:

	Year Ended December 31,
	2010			2009			2008
Devices and Systems		62	%		58	%		63	%
Supplies and Services		37	%		40	%		35	%
Other		1	%		2	%		2	%
Total		100	%		100	%		100	%

In 2010, 2009 and 2008, sales to no single end-user customer comprised more than 10% of our revenue, and revenue from services was less than 10% of our revenue.

Backlog

As of December 31, 2010, our backlog was approximately $6.0 million, compared to $8.9 million at December 31, 2009 and $2.1 million at December 31, 2008.

Marketing and Sales

Marketing

Our marketing strategy differentiates our products by their level of quality, performance, and customer benefit. We educate customers and potential customers worldwide about our products through several traditional methods, including, but not limited to:

• Trade conference exhibits;

• Direct presentations to healthcare professionals;

• Publications in professional journals and trade magazines;

13

• The Internet via our website, www.natus.com;

• Print and direct mail advertising campaigns; and

• Sponsorship of and participation in clinical education seminars and workshops.

Educational efforts directed at government agencies, physicians, and clinicians about the benefits of universal screening in terms of patient outcomes and long-term treatment costs are a key element of our marketing strategy.

Domestic Direct and Distributor Sales

We sell our products in the United States primarily through a direct sales organization. We believe this direct sales organization allows us to maintain a higher level of customer service and satisfaction than would otherwise be possible by other distribution methods. We also sell certain products under private label and distribution arrangements.

Domestic revenue as a percent of total revenue was 58%, 66%, and 69% in 2010, 2009 and 2008, respectively.

As a percent of total revenue, domestic sales through our direct and other sales channels, respectively, was 52% and 6% in 2010, 59% and 7% in 2009, and 62% and 7% in 2008.

International Direct and Distributor Sales

We sell some of our products outside the U.S. through direct sales channels in Canada and in the French and German speaking regions of Europe, in Denmark, and in parts of Latin America; we sell other products in those regions and into more than 100 other countries through a distributor sales channel.

International revenue as a percent of total revenue was 42%, 34%, and 31% in 2010, 2009 and 2008, respectively.

As a percent of total revenue, international sales through our direct and other sales channels, respectively, was 17% and 25% in 2010, 11% and 23% in 2009, and 16% and 15% in 2008.

We sell products to our distributors under substantially the same terms as sales through our direct sales channels. Terms of sales to international distributors are generally EXW, reflecting that goods are shipped “ex works,” in which title and risk of loss are assumed by the distributor at the shipping point. Distributors are generally given exclusive rights in their territories to purchase products from Natus and resell to end users or subdistributors. Our distributors typically perform marketing, sales, and technical support functions in their respective markets. Each distributor may sell Natus products to their customer directly, via other distributors or resellers, or both. We actively train our distributors in product marketing, selling, and technical service techniques.

Seasonality in Revenue

We experience seasonality in our revenue. Our revenue typically drops from our fourth quarter to our first quarter. This seasonality results from the purchasing habits of our hospital-based customers, whose purchases are often governed by calendar year budgets, and the manner in which our direct sales force is compensated, as their compensation is based on annual sales plans that are tied to our December year end.

Group Purchasing Organizations

More than 90% of the hospitals in the U.S. are members of group purchasing organizations (“GPO”s), which negotiate volume purchase agreements for member hospitals, group practices, and other clinics. Direct

14

purchases by GPO members accounted for approximately 18%, 24% and 31% of our revenue in 2010, 2009 and 2008, respectively. Direct purchases by members of one GPO, Novation, accounted for approximately 6%, 8% and 10% of our revenue in 2010, 2009 and 2008, respectively.

Third-Party Reimbursement

In the U.S., health care providers generally rely on third-party payors, including private health insurance plans, federal Medicare, state Medicaid, and managed care organizations, to reimburse all or part of the cost of the procedures they perform. Third-party payors can affect the pricing or the relative attractiveness of our products by regulating the maximum amount of reimbursement these payors provide for services utilizing our products. For this reason, we are not able to measure a reimbursement success rate for our products.

Customer Service and Support

We provide a one-year warranty on all medical device products. We also sell extended service agreements on our medical device products. Service, repair, and calibration services for our domestic customers are provided by Company-owned service centers and our field service specialists. Service for our international customers is provided by a combination of our Company-owned authorized service centers and third-party vendors on a contract basis.

Manufacturing

Other companies manufacture a significant portion of the components used in our products; however, we perform final assembly, testing, and packaging of most of the devices ourselves to control quality and manufacturing efficiency. We also use contract vendors to manufacture some of our disposable supply and medical device products. We perform regular quality audits of these vendors.

We purchase materials and components from qualified suppliers that are subject to our quality specifications and inspections. We conduct quality audits of our key suppliers, several of which are experienced in the supply of components to manufacturers of finished medical devices, or supplies for use with medical devices. Most of our purchased components are available from more than one supplier.

Our manufacturing, service, and repair facilities are subject to periodic inspection by federal, state, and foreign regulatory authorities. Our quality assurance system is subject to regulation by the FDA and other state government agencies. We are required to conduct our product design, testing, manufacturing, and control activities in conformance with the FDA’s quality system regulations and to maintain our documentation of these activities in a prescribed manner. In addition, our production facilities have received ISO 13485 certification. ISO 13485 certification standards for quality operations have been developed to ensure that medical device companies meet the standards of quality on a worldwide basis. We have also received the EC Certificate pursuant to the European Union Medical Device Directive 93/42/EEC, which allows us to place a CE mark on our products.

Research and Development

We are committed to introducing new products and supporting current product offerings in our markets through a combination of internal as well as external efforts that are consistent with our corporate strategy.

Internal product development capabilities.    We believe that product development capabilities are essential to provide our customers with new product offerings. We plan to leverage our core technologies by introducing product line extensions as well as new product offerings.

Partnerships that complement our expertise.    We continue to seek strategic partners in order to develop products that may not otherwise be available to us. By taking advantage of our core competencies, we believe that we can bring products to market in an efficient manner and leverage our distribution channels.

15

New opportunities through technology acquisition.    We continue to evaluate new, emerging, and complementary technologies in order to identify new product opportunities. With our knowledge of our current markets we believe that we can effectively develop technologies into successful new products.

Our research and development expenses were $21.3 million or 9.7% of total revenue in 2010, $16.7 million or 10.0% of total revenue in 2009, and $15.5 million or 9.6% of total revenue in 2008.

Proprietary Rights

We protect our intellectual property through a combination of patent, copyright, trade secret, and trademark laws. We attempt to protect our intellectual property rights by filing patent applications for new features and products we develop. We enter into confidentiality or license agreements with our employees, consultants, and corporate partners, and seek to control access to our intellectual property, distribution channels, documentation, and other proprietary information. However, we believe that these measures afford only limited protection.

The intellectual rights to some of the original patents for technology incorporated into our products are now in the public domain. However, we do not consider these patents, or any currently viable patent or related group of patents, to be of such importance that their expiration or termination would materially affect our business.

We capitalize the cost of purchased technology and intellectual property, as well as certain costs incurred in obtaining patent rights, and amortize these costs over the estimated economic lives of the related assets.

Competition

We sell our products in competitive and rapidly evolving markets. We face competition from other companies in all of our product lines. Our competitors range from small privately-held companies to multinational corporations and their product offerings vary in scope and breadth. We do not believe that any single competitor is dominant in any of our product lines.

We derive a significant portion of our revenue from the sale of disposable supplies that are used with our medical devices. In the U.S., we sell our supply products in a mature market. Because these products can generate high margins, we expect that our products, particularly our hearing screening supply products, could face increasing competition, including competitors offering lower prices, which could have an adverse affect on our revenue and margins.

We believe the principal factors that will draw clinicians and other buyers to our products, include:

• Level of specificity, sensitivity, and reliability of the product;

• Time required to obtain results with the product, such as to test for or treat a clinical condition;

• Relative ease of use of the product;

• Depth and breadth of the products features;

• Quality of customer support for the product;

• Frequency of product updates;

• Extent of third-party reimbursement of the cost of the product or procedure;

• Extent to which the products conform to standard of care guidelines; and

• Price of the product.

16

We believe that our primary competitive strength relates to the functionality and reliability of our products. Different competitors may have competitive advantages in one or more of the categories listed above and they may be able to devote greater resources to the development, promotion, and sale of their products.

Government Regulation

FDA’s Premarket Clearance and Approval Requirements

Unless an exemption applies, the medical devices we sell in the United States, with the exception of some disposable products, must first receive one of the following types of FDA premarket review authorizations under the Food, Drug, and Cosmetics Act, as amended:

• Clearance via Section 510(k); or

• Premarket approval via Section 515 if the FDA has determined that the medical device in question poses a greater risk of injury.

The FDA’s 510(k) clearance process usually takes from three to 12 months, but can take longer. The process of obtaining premarket approval via Section 515 is much more costly, lengthy, and uncertain. Premarket approval generally takes from one to three years, but can take longer. We cannot be sure that the FDA will ever grant either 510(k) clearance or premarket approval for any product we propose to market in the United States.

The FDA decides whether a device must undergo either the 510(k) clearance or premarket approval process based upon statutory criteria. These criteria include the level of risk that the Agency perceives to be associated with the device and a determination of whether the product is a type of device that is substantially equivalent to devices that are already legally marketed. The FDA places devices deemed to pose relatively less risk in either Class I or Class II, which requires the manufacturer to submit a premarket notification requesting 510(k) clearance, unless an exemption applies. The premarket notification under Section 510(k) must demonstrate that the proposed device is substantially equivalent in intended use and in safety and effectiveness to a previously cleared 510(k) device or a device that was in commercial distribution before May 28, 1976 for which the FDA has not yet called for the submission of premarket approval applications.

The FDA places devices deemed to pose the greatest risk, such as life-sustaining, life-supporting or implantable devices, or devices deemed to be not substantially equivalent to a predicate device, in its Class III classification. The FDA requires these devices to undergo the premarket approval process via Section 515 in which the manufacturer must prove the safety and effectiveness of the device. A premarket approval application must provide extensive pre-clinical and clinical trial data.

The FDA may require results of clinical trials in support of a 510(k) submission and generally requires clinical trial results for a premarket approval application. In order to conduct a clinical trial on a significant-risk device, the FDA requires manufacturers to apply for and obtain, in advance, an investigational-device exemption. The investigational-device exemption application must be supported by appropriate data, such as animal and laboratory testing results. If the FDA and the Institutional Review Boards at the clinical trial sites approve the investigational-device exemption application for a significant-risk device, the manufacturer may begin the clinical trial. An investigational-device exemption approval provides for a specified clinical protocol, including the number of patients and study sites. If the manufacturer deems the product a non-significant risk device, the product will be eligible for more abbreviated investigational-device exemption requirements. If the Institutional Review Boards at the clinical trial sites concur with the non-significant risk determination, the manufacturer may begin the clinical trial.

We received approval for our Olympic Cool-Cap product as a Class III device from the FDA through the premarket approval process. Most of our other products have been cleared by the FDA as Class II devices. Some of our disposable products and newborn care products, such as our neonatal headshields and oxygen delivery systems, have received FDA clearance as Class I devices.

17

FDA Regulation

Numerous FDA regulatory requirements apply to our products. These requirements include:

• FDA quality system regulations which require manufacturers to create, implement, and follow design, testing, control, documentation, and other quality assurance procedures;

• Medical device reporting regulations, which require that manufacturers report to the FDA certain types of adverse and other events involving their products; and

• FDA general prohibitions against promoting products for unapproved uses.

Class II and III devices may also be subject to special controls applied to them, such as performance standards, post-market surveillance, patient registries, and FDA guidelines that may not apply to Class I devices. We believe we are in compliance with applicable FDA guidelines, but we could be required to change our compliance activities or be subject to other special controls if the FDA changes existing regulations or adopts new requirements.

We are subject to inspection and market surveillance by the FDA to determine compliance with regulatory requirements. If the FDA finds that we have failed to adequately comply, the Agency can institute a wide variety of enforcement actions, including:

• Issuance of a Form 483 citation;

• Fines, injunctions, and civil penalties;

• Recall or seizure of our products;

• Issuance of public notices or warnings;

• Imposition of operating restrictions, partial suspension, or total shutdown of production;

• Refusal of our requests for 510(k) clearance or pre-market approval of new products;

• Withdrawal of 510(k) clearance or pre-market approval already granted; or

• Criminal prosecution.

The FDA also has the authority to require us to repair, replace, or refund the cost of any medical device manufactured or distributed by us.

Other Regulations

We also must comply with numerous additional federal, state, and local laws relating to matters such as safe working conditions, manufacturing practices, environmental protection, biohazards, fire hazard control, and hazardous substance disposal. We believe we are currently in compliance with such regulations.

Countries outside of the U.S. regulate medical devices in a manner similar to that of the FDA. Our manufacturing facilities are subject to audit and have been certified to be ISO 13485:2003, Medical Device Directive 93/42/EEC, and CMDCAS compliant, which allows us to sell our products in Canada, Europe, and other territories around the world. Our manufacturing facilities in North America are subject to ISO 13485 inspections by our notified body, British Standards Institution Management Systems, and by other notified bodies outside of North America. We plan to seek approval to sell our products in additional countries, while maintaining our current approvals. The time and cost of obtaining new, and maintaining existing, market authorizations from countries outside of North America, and the requirements for licensing products in these countries may differ significantly from FDA requirements.

Employees

On December 31, 2010, we had approximately 750 full time employees worldwide. In Argentina, some of our production employees are represented by labor unions; none of our other employees are so represented. We have not experienced any work stoppages and consider our relations with our employees to be good.

18

Executive Officers

The following table lists our executive officers and their ages as of March 1, 2011:

Name	Age		Position(s)
James B. Hawkins		55	Chief Executive Officer and Director
John T. Buhler		50	President and Chief Operating Officer
Steven J. Murphy		59	Vice President Finance and Chief Financial Officer
William L. Mince		59	Vice President North American Operations
Kenneth M. Traverso		50	Vice President Marketing and Sales
D. Christopher Chung, M.D.		47	Vice President Medical Affairs and R&D

James B. Hawkins has served as Chief Executive Officer, and as a member of the Board of Directors, since joining Natus in April 2004, and formerly as President from April 2004 through January 2011. Mr. Hawkins has over 25 years of combined medical device and financial management experience. Prior to joining Natus, he was President and Chief Executive Officer of Nasdaq-traded Invivo Corporation for 19 years. Invivo Corporation, a maker of multi-parameter vital sign monitoring equipment used in hospitals, was acquired in early 2004 by Intermagnetics General Corporation. He earned a Bachelor of Commerce degree, specialized in Management from Santa Clara University and a Masters of Business Administration – Finance degree from San Francisco State University. Mr. Hawkins is a Director of Iridex Corp.

John T. Buhler has served as President and Chief Operating Officer since February, 2011. Mr. Buhler was employed by Avantis Medical Systems as President and Chief Executive officer from January 2011 to February 2011. He held various positions at SenoRx from May 2008 through July 2010, including President and Chief Executive Officer from March 2010 through July 2010, President and Chief Operating Officer from October 2009 to March 2010, Senior Vice President and Chief Commercial Officer from April 2009 to October 2009, Vice President of Global Sales and Business Development from October 2008 until April 2009, and Vice President of International Sales and Business Development from May 2008 until October 2008. From August 2005 to May 2008, Mr. Buhler served as President and Chief Executive Officer at Ultrasonix Medical Corporation, a privately held manufacturer of diagnostic ultrasound imaging equipment. From 1998 to 2005, Mr. Buhler held various positions at General Electric, last serving as Vice President and General Manager of GE’s Ultrasound Performance Technologies Division in Shanghi, China.

Steven J. Murphy has served as Chief Financial Officer since February 2006, Vice President Finance since June 2003, and joined Natus in September 2002 as Director of Finance. From February 2002 through September 2002, Mr. Murphy was interim Controller at Travel Nurse International, a temporary staffing firm that was acquired by Medical Staffing Network in December 2002. From October 1998 through January 2002, Mr. Murphy was Controller of AdvisorTech Corporation, an international software development company providing IT-based solutions in the field of investments, where he was responsible for financial reporting of domestic, Asian and European operations with significant reporting responsibilities to the board of directors and investor groups. From 1996 to 1998 he was Vice President Finance of RWS Group, LLC, an international service company providing management of language-related projects. Mr. Murphy holds a Bachelor of Science degree in Business Administration from California State University, Chico. Mr. Murphy is a certified public accountant.

William L. Mince has served as our Vice President, North American Operations since September 2007 and joined Natus as Vice President Operations in October 2002. From November 2000 to September 2002, Mr. Mince served as President and Founder of My Own Jukebox, an Internet retail company. From July 1998 to October 2000, Mr. Mince was a consultant with the majority of his time spent as Senior Vice President Network Solutions for Premier Retail Network, a media broadcasting company. From July 1997 to June 1998, Mr. Mince served as President and Chief Operating Officer of Ophthalmic Imaging Systems, a publicly-held medical device company. From July 1994 to June 1997, Mr. Mince was Vice President Operations with Premier Retail Network. From May 1988 to June 1994, Mr. Mince was Director of Operations for Nellcor, a medical device company. Mr. Mince holds a Bachelor of Science degree in Business Administration from the University of Redlands and a Masters of Business Administration degree from National University.

19

Kenneth M. Traverso has served as our Vice President Marketing and Sales since April 2002. From September 2000 to April 2002, he served as our Vice President Sales. From October 1999 to July 2000, Mr. Traverso served as President of DinnerNow.com Inc., an internet aggregator for the restaurant industry. From January 1998 to September 1999, Mr. Traverso served as Vice President Sales, Western Region of Alere Medical, an outpatient chronic disease management company. From May 1995 to January 1998, Mr. Traverso served as Vice President Marketing and Sales of AbTox, Inc., a low temperature sterilization company. From August 1990 to May 1995, Mr. Traverso served in various capacities at Natus, including Vice President Sales. From September 1984 to July 1990 Mr. Traverso served various positions at Nellcor, a medical device company, including Regional Sales Manager, Western Region. Mr. Traverso holds a Bachelor of Science degree in Administration & Marketing from San Francisco State University.

D. Christopher Chung, M.D., has served as our Vice President Medical Affairs and R&D since June 2003, and has served as our Vice President Medical Affairs since February 2003. Dr. Chung also served as our Medical Director from October 2000 to February 2003. From August 2000 to December 2007, Dr. Chung also served as a Pediatric Hospitalist at the California Pacific Medical Center in San Francisco. Dr. Chung has been a member of the Medical Advisory Board of eHealth Global Technologies, Inc. since April 2007 and has served as a member of their Board of Directors since November 2007. From June 1997 to June 2000, Dr. Chung trained as a pediatric resident at Boston Children’s Hospital and Harvard Medical School. From May 1986 to July 1993, Dr. Chung worked as an Engineer at Nellcor, a medical device company. Dr. Chung holds a Bachelor of Arts degree in Computer Mathematics from the University of Pennsylvania and a Doctor of Medicine degree from the Medical College of Pennsylvania-Hahnemann University School of Medicine. He is a licensed physician and is a Fellow of the American Academy of Pediatrics.

Other Information

Natus was incorporated in California in May 1987 and reincorporated in Delaware in August 2000.

We maintain corporate offices at 1501 Industrial Road, San Carlos, California 94070. Our telephone number is (650) 802-0400. We maintain a corporate website at www.natus.com. References to our website address do not constitute incorporation by reference of the information contained on the website, and the information contained on the website is not part of this document.

We make available, free of charge on our corporate website, copies of our Annual Reports on Form 10-K, Quarterly Reports on Form 10-Q, Current Reports on Form 8-K, Proxy Statements, and all amendments to these reports, as soon as reasonably practicable after such material is electronically filed with or furnished to the Securities and Exchange Commission pursuant to Section 13(a) or 15(d) of the Securities Exchange Act. We also show detail about stock trading by corporate insiders by providing access to SEC Forms 3, 4 and 5. This information may also be obtained from the SEC’s on-line database, which is located at www.sec.gov. Our common stock is traded on the Nasdaq Stock Market under the symbol “BABY”.

ITEM 1A. Risk Factors

We have completed a number of acquisitions and expect to complete additional acquisitions in the future. There are numerous risks associated with acquisitions and we may not achieve the expected benefit of any of our acquisitions

Our acquisitions of products, technology assets, or businesses may have a negative impact on our business if we fail to achieve the anticipated financial, strategic, and other benefits of acquisitions or investments, and our operating results may suffer because of this.

Our significant acquisitions are as follows: Neometrics in 2003; Fischer-Zoth in 2004; Bio-logic, Deltamed, and Olympic in 2006; Xltek in 2007; Sonamed, Schwarzer Neurology, and Neurocom in 2008; Hawaii Medical and Alpine Biomed in 2009, and Medix in 2010.

20

We expect to continue to pursue opportunities to acquire other businesses in the future. The acquisitions that we have completed may not result in improved operating results for us, or in our achieving a financial condition superior to that which we would have achieved had we not completed them. Our results of operations may be adversely impacted by costs associated with our acquisitions, including one-time charges associated with restructurings. Further, our acquisitions could fail to produce the benefits that we anticipate, or could have other adverse effects that we currently do not foresee. In addition, some of the assumptions that we have relied upon, such as achievement of operating synergies, may not be realized. In this event, one or more of the acquisitions could result in reduced earnings of Natus as compared to the earnings that would have been achieved by Natus if the acquisition had not occurred.

We have assumed contingent obligations associated with earnout provisions in some of our acquisitions. We believe these provisions help us to negotiate mutually agreeable purchase terms between us and the sellers. However, a disagreement between us and a seller about the terms of an earnout provision could result in our paying more for an acquisition then we intended. For example, such a disagreement arose in connection with our acquisition of Alpine Biomed, which we have subsequently resolved. The stockholders of Schwarzer Neurology have recently asserted claims relating to the earnout provision of our agreement with those stockholders that have not yet been resolved. Disputes over these types of contingent obligations may not be resolved on terms that are favorable to us and the payment of additional purchase consideration could impact our results of operations and financial position.

We have incurred indebtedness to fund some of our acquisitions. The use of debt to fund our acquisitions may have an adverse impact on our liquidity and cause us to place more reliance on cash flow from operations for our liquidity. If our cash flow from operations is not sufficient for our needs, our business could be adversely affected. If we are required to seek additional external financing to support our need for cash to fund future acquisitions, we may not have access to financing on terms that are acceptable to us, or at all. Alternatively, we may feel compelled to access additional financing on terms that are dilutive to existing holders of our common stock or that include covenants that restrict our business, or both. If the recent lack of liquidity in credit markets persists into the future, our ability to obtain debt financing for future acquisitions may be impaired.

If we fail to successfully manage the combined operations of Natus and the businesses we have acquired, we may not realize the potential benefits of our acquisitions. Our corporate headquarters are located in San Carlos, California. We also have the following operating divisions: Olympic in Washington; Neurocom in Oregon; Bio-logic in Illinois; Neometrics in New York; Xltek and Stellate in Canada; Medix in Argentina; Alpine Biomed in Denmark; Fischer-Zoth, Schwarzer Neurology, IT-Med, and Alpine Biomed Germany (collectively “Natus Europe”) in Germany; and Deltamed and Alpine Biomed France (collectively “Natus France”) in France. If we fail to manage these disparate operations effectively, our results of operations could be harmed, employee morale could decline, key employees could leave, and customers could cancel existing orders or choose not to place new ones. In addition, we may not achieve the synergies or other benefits of these and future acquisitions that we anticipate. We may encounter the following additional difficulties and delays involved in integrating and managing these operations, and the operations of companies we may acquire:

• Failure of customers to continue using the products and services of the combined company;

• Failure to successfully develop the acquired technology into the desired products or enhancements;

• Assumption of unknown liabilities;

• Failure to understand products or technologies with which we have limited previous experience;

• Failure to compete effectively in new markets;

• Decreased liquidity, restrictive bank covenants, and incremental financing costs associated with debt we may incur to complete future acquisitions; and

• Diversion of the attention of management from other ongoing business concerns.

21

Our reported operating results may suffer because of impairment charges incurred to write down the carrying amount of intangible assets, including goodwill, generated as a result of the acquisitions.

Our growth in recent years has depended substantially on the completion of acquisitions and we may not be able to complete acquisitions of this nature or of a relative size in the future to support a similar level of growth

The acquisitions that we have completed have been the primary source of our growth in revenue in recent years. We expend considerable effort in seeking to identify attractive acquisition candidates and, upon doing so, to convince the potential target to consider a sale to us and, ultimately, to negotiate mutually agreeable acquisition terms. If we are not successful in these efforts in the future, our growth rate will not increase at a rate corresponding to that which we have achieved in recent years. Further, as we grow larger it will be necessary to complete the acquisition of larger companies and product lines to support a growth similar to that which we have achieved in the past. The market for attractive acquisitions is competitive and others with greater financial resources than we have may be better positioned than we are to acquire desirable targets. Further, we may not be able to negotiate acquisition terms with target companies that will allow us to achieve positive financial returns from the transaction.

Adverse economic conditions in markets in which we operate may harm our business

Unfavorable changes in U.S. and international economic environments may adversely affect our business and financial results. Economic conditions in the countries in which we operate and sell products worsened and global financial markets subsequently experienced significant volatility and declines throughout much of 2009. Although these conditions improved in 2010, we are unable to foresee when, or if, these factors might return to historical levels. During challenging economic times, and in tight credit markets, our customers may delay or reduce capital expenditures. This could result in reductions in sales of our products, longer sales cycles, difficulties in collection of accounts receivable, slower adoption of new technologies, and increased price competition, all of which could impact our results of operations and financial condition. In addition, we expect these factors will cause us to be more cautious in evaluating potential acquisition opportunities, which could hinder our ability to grow through acquisition while these conditions persist.

We have initiated changes to our information systems that could disrupt our business and our financial results.

We plan to continuously improve our enterprise resource planning, customer relationship management, and document lifecycle management systems to support the form, functionality, and scale of our business. These types of transitions frequently prove disruptive to the underlying business of an enterprise and may cause us to incur higher costs than we anticipate. Failure to manage a smooth transition to the new systems and the ongoing operations and support of the new systems could materially harm our business operations.

For example, we are currently in the process of implementing the rollout of an enterprise resource planning application (“ERP”) in our European operating divisions. Until we have completed this ERP implementation, we will be dependent on multiple platforms. We may experience difficulties in implementing the ERP and we may fail to gain the efficiencies the implementation is designed to produce. The implementation could also be disruptive to our operations, including the ability to timely ship and track product orders to customers, project inventory requirements, manage our supply chain and otherwise adequately service our customers.

Future changes in technology or market conditions could result in adjustments to our recorded asset balance for intangible assets, including goodwill, resulting in additional charges that could significantly impact our operating results

Our balance sheet includes significant intangible assets, including goodwill and other acquired intangible assets. The determination of related estimated useful lives and whether these assets are impaired involves significant judgment. Our ability to accurately predict future cash flows related to these intangible assets might

22

be hindered by events over which we have no control. Due to the highly competitive nature of the medical device industry, new technologies could impair the value of our intangible assets if they create market conditions that adversely affect the competitiveness of our products. Any future determination that these assets are carried at greater than their fair value could result in substantial impairment charges, which could significantly impact our operating results.

We may not be able to preserve the value of our intellectual property because we may not be able to protect access to it or we may lose our intellectual property rights due to expiration of our licenses or patents

If we fail to protect our intellectual property rights or if our intellectual property rights do not adequately cover the technology we employ, other medical device companies could sell products with features similar to ours, and this could reduce demand for our products. We protect our intellectual property through a combination of patent, copyright, trade secret and trademark laws. Despite our efforts to protect our proprietary rights, others may attempt to copy or otherwise improperly obtain and use our products or technology. Policing unauthorized use of our technology is difficult and expensive, and we cannot be certain that the steps we have taken will prevent misappropriation. Our means of protecting our proprietary rights may be inadequate. Enforcing our intellectual property rights could be costly and time consuming and may divert our management’s attention and resources. Failing to enforce our intellectual property rights could also result in the loss of those rights.

If health care providers are not adequately reimbursed for procedures conducted with our devices or supplies, or if reimbursement policies change adversely, we may not be successful marketing and selling our products or technologies

Clinicians, hospitals, and government agencies are unlikely to purchase our products if they are not adequately reimbursed for the procedures conducted with our devices or supplies. Unless a sufficient amount of conclusive, peer-reviewed clinical data about our products has been published, third-party payors, including insurance companies and government agencies, may refuse to provide reimbursement. Furthermore, even if reimbursement is provided, it may not be adequate to fully compensate the clinicians or hospitals. Some third-party payors may impose restrictions on the procedures for which they will provide reimbursement. If health care providers cannot obtain sufficient reimbursement from third-party payors for our products or the screenings conducted with our products, we may not achieve significant market acceptance of our products. Acceptance of our products in international markets will depend upon the availability of adequate reimbursement or funding within prevailing healthcare payment systems. Reimbursement, funding, and healthcare payment systems vary significantly by country. We may not obtain approvals for reimbursement in a timely manner or at all.

Adverse changes in reimbursement policies in general could harm our business. We are unable to predict changes in the reimbursement methods used by third-party health care payors, particularly those in countries and regions outside the U.S. For example, some payors are moving toward a managed care system in which providers contract to provide comprehensive health care for a fixed cost per person. In a managed care system, the cost of our products may not be incorporated into the overall payment for patient care or there may not be adequate reimbursement for our products separate from reimbursement for other procedures.

Healthcare reforms, changes in healthcare policies, and changes to third-party reimbursements for our products may affect demand for our products

In March 2010 the U. S. government signed into law the Patient Protection and Affordable Care Act and the Health Care & Education Reconciliation Act. These laws are intended to, among other things, curb rising healthcare costs, including those that could significantly affect reimbursement for our products. The policies supporting these laws include: basing reimbursement policies and rates on clinical outcomes; the comparative effectiveness and costs of different treatment technologies and modalities; imposing price controls; and other measures. Future significant changes in the healthcare systems in the United States or elsewhere could also have a negative impact on the demand for our current and future products. These include changes that may reduce

23

reimbursement rates for our products and changes that may be proposed or implemented by the U.S. Presidential administration or Congress.

There are numerous steps required to implement these laws. Because of the unsettled nature of these reforms, we cannot predict what additional healthcare reforms will be implemented at the federal or state level, or the effect that any future legislation or regulation will have on our business. There is also considerable uncertainty of the impact of these reforms on the medical device market as a whole. If we fail to effectively react to the implementation of health care reform, our business may be adversely affected. In addition, if the excise tax on the sale of medical devices is imposed as enacted, this could increase our costs and have an adverse effect on our results of operations, financial position, and cash flows.

If we fail in our efforts to educate clinicians, government agency personnel, and third-party payors on the effectiveness of our products, we may not achieve future sales growth

It is critical to the success of our sales efforts that we educate a sufficient number of clinicians, hospital administrators, and government agencies about our products and the costs and benefits of their use. The commercial success of our products depends upon clinician, government agency, and other third-party payer confidence in the economic and clinical benefits of our products as well as their comfort with the efficacy, reliability, sensitivity and specificity of our products. We believe that clinicians will not use our products unless they determine, based on published peer-reviewed journal articles and experience, that our products provide an accurate and cost-effective alternative to other means of testing or treatment. Our customers may choose to use competitive products, which may be less expensive or may provide faster results than our devices. Clinicians are traditionally slow to adopt new products, testing practices and clinical treatments, partly because of perceived liability risks and the uncertainty of third-party reimbursement. If clinicians, government agencies and hospital administrators do not adopt our products, we may not maintain profitability. Factors that may adversely affect the medical community’s acceptance of our products include:

• Publication of clinical study results that demonstrate a lack of efficacy or cost-effectiveness of our products;

• Changing governmental and physician group guidelines;

• Actual or perceived performance, quality, price, and total cost of ownership deficiencies of our products relative to other competitive products;

• Our ability to maintain and enhance our existing relationships and to form new relationships with leading physicians, physician organizations, hospitals, state laboratory personnel, and third-party payers;

• Changes in state and third-party payer reimbursement policies for our products; and

• Repeal of laws requiring universal newborn hearing screening and metabolic screening.

Sales through group purchasing organizations and sales to high volume purchasers may reduce our average selling prices, which could reduce our operating margins

We have entered, and expect in the future to enter into agreements with customers who purchase high volumes of our products. Our agreements with these customers may contain discounts from our normal selling prices and other special pricing considerations, which could cause our operating margins to decline. In addition, we have entered into agreements to sell our products to members of GPOs, which negotiate volume purchase prices for medical devices and supplies for member hospitals, group practices and other clinics. While we make sales directly to GPO members, the GPO members receive volume discounts from our normal selling price and may receive other special pricing considerations from us. Sales to members of all GPOs accounted for approximately 18%, 24% and 31% of our total revenue during 2010, 2009 and 2008, respectively, and sales to members of one GPO, Novation, accounted for approximately 6%, 8% and 10% of our total revenue in 2010, 2009 and 2008, respectively. Other of our existing customers may be members of GPOs with which we do not

24

have agreements. Our sales efforts through GPOs may conflict with our direct sales efforts to our existing customers. If we enter into agreements with new GPOs and some of our existing customers begin purchasing our products through those GPOs, our operating margins could decline.

Demand for some of our products depends on the capital spending policies of our customers, and changes in these policies could harm our business

A majority of customers for our products are hospitals, physician offices, and clinics. Many factors, including public policy spending provisions, available resources, and economic cycles have a significant effect on the capital spending policies of these entities and therefore the amount that they can spend on our equipment products. If budget resources limit the capital spending of our customers, they will be unlikely to either purchase any new equipment from us or upgrade to any of our newer equipment products. Lack of liquidity in credit markets and uncertainty about future economic conditions can have an adverse effect on the spending patterns of our customers. These factors can have a significant adverse effect on the demand for our products.

Our markets are very competitive and in the United States we sell certain of our products in a mature market

We face competition from other companies in all of our product lines. Our competitors range from small privately held companies to multinational corporations and their product offerings vary in scope and breadth. We do not believe that any single competitor is dominant in any of our product lines.

The markets for certain of our products in the U.S., including the newborn hearing screening and EEG monitoring markets, are mature and we are unlikely to see significant growth for such products in the U.S. In the U.S. we derive a significant portion of our revenue from the sale of disposable supplies that are used with our hearing screening devices. Because these disposable supply products can generate high margins, we expect that our products, particularly our hearing screening disposable supply products, could face increasing competition, including competitors offering lower prices, which could have an adverse affect on our revenue and margins.

Our competitors may have certain competitive advantages, which include the ability to devote greater resources to the development, promotion, and sale of their products. Consequently, we may need to increase our efforts, and related expenses for research and development, marketing, and selling to maintain or improve our position.

We expect recurring sales to our existing customers to generate a majority of our revenue in the future, and if our existing customers do not continue to purchase products from us, our revenue may decline.

Our operating results may decline if we do not succeed in developing, acquiring, and marketing additional products or improving our existing products

We intend to develop additional products and technologies, including enhancements of existing products, for the screening, detection, treatment, monitoring and tracking of common medical ailments. Developing new products and improving our existing products to meet the needs of current and future customers requires significant investments in research and development. If we fail to successfully sell new products, update our existing products, or timely react to changes in technology, our operating results may decline as our existing products reach the end of their commercial life cycles.

Our plan to expand our international operations will result in increased costs and is subject to numerous risks; if our efforts are not successful, this could harm our business

We have expanded our international operations through acquisitions and plan to expand our international sales and marketing efforts to increase sales of our products in foreign countries. We may not realize

25

corresponding growth in revenue from growth in international unit sales, due to the lower average selling prices we receive on sales outside of the U.S. Even if we are able to successfully expand our international selling efforts, we cannot be certain that we will be able to create or increase demand for our products outside of the U.S. Our international operations are subject to other risks, which include:

• Impact of possible recessions in economies outside the U.S.;

• Political and economic instability, including instability related to war and terrorist attacks;

• Contractual provisions governed by foreign law, such as local law rights to sales commissions by terminated distributors;

• Decreased healthcare spending by foreign governments that would reduce international demand for our products;

• Continued strengthening of the U.S. dollar relative to foreign currencies that could make our products less competitive because approximately half of our international sales are denominated in U.S. dollars;

• Greater difficulty in accounts receivable collection and longer collection periods;

• Difficulties of staffing and managing foreign operations;

• Reduced protection for intellectual property rights in some countries and potentially conflicting intellectual property rights of third parties under the laws of various foreign jurisdictions;

• Difficulty in obtaining and maintaining foreign regulatory approval; and

• Attitudes by clinicians, and cost reimbursement policies, towards use of disposable supplies that are potentially unfavorable to our business.

In particular, our international sales could be adversely affected by a strengthening of the U.S. dollar relative to other foreign currencies, which makes our products more costly to international customers for sales denominated in U.S. dollars.

Our operating results may suffer because of our exposure to foreign currency exchange rate fluctuations

Substantially all of our sales contracts with our U.S. based customers provide for payment in U.S. dollars. With the exception of our Canadian operations, substantially all of the revenue and expenses of our foreign subsidiaries are denominated in the applicable foreign currency. To date we have executed only limited foreign currency contracts to hedge these currency risks. Our future revenue and expenses may be subject to volatility due to exchange rate fluctuations that could result in foreign exchange gains and losses associated with foreign currency transactions and the translation of assets and liabilities denominated in foreign currencies.

Substantially all our sales from our U.S. operations to our international distributors provide for payment in U.S. dollars. A strengthening of the U.S. dollar relative to other foreign currencies could increase the effective cost of our products to our international distributors as their functional currency is typically not the U.S. dollar. This could have a potential adverse effect on our ability to increase or maintain average selling prices of our products to our foreign-based customers.

If guidelines mandating universal newborn hearing screening do not continue to develop in foreign countries and governments do not mandate testing of all newborns as we anticipate, or if those guidelines have a long phase-in period, our sales of newborn hearing screening products may not achieve the revenue growth we have achieved in the past

We estimate that approximately 95% of the children born in the U.S. are currently being tested for hearing impairment prior to discharge from the hospital. To date, there has been only limited adoption of newborn hearing screening prior to hospital discharge by foreign governments, and when newborn hearing screening

26

programs are enacted by foreign governments there can be a phase-in period spanning several years. The widespread adoption of guidelines depends, in part, on our ability to educate foreign government agencies, neonatologists, pediatricians, third-party payors, and hospital administrators about the benefits of universal newborn hearing screening as well as the use of our products to perform the screening and monitoring. Our revenue from our newborn hearing screening product lines may not grow if foreign governments do not require universal newborn hearing screening prior to hospital discharge, if physicians or hospitals are slow to comply with those guidelines, or if governments provide for a lengthy phase-in period for compliance.

Because we rely on distributors or sub-distributors to sell our products in most of our markets outside of the U.S., our revenue could decline if our existing distributors reduce the volume of purchases from us, or if our relationship with any of these distributors is terminated

We currently rely on our distributors or sub-distributors for a majority of our sales outside the U.S. Some distributors also assist us with regulatory approvals and education of clinicians and government agencies. We intend to continue our efforts to increase our sales in Europe, Japan, and other developed countries. If we fail to sell our products through our international distributors, we would experience a decline in revenues unless we begin to sell our products directly in those markets. We cannot be certain that we will be able to attract new international distributors to market our products effectively or provide timely and cost-effective customer support and service. Even if we are successful in selling our products through new distributors, the rate of growth of our revenue could be harmed if our existing distributors do not continue to sell a large dollar volume of our products. None of our existing distributors are obligated to continue selling our products.

We may be subject to foreign laws governing our relationships with our international distributors. These laws may require us to make payments to our distributors if we terminate our relationship for any reason, including for cause. Some countries require termination payments under local law or legislation that may supersede our contractual relationship with the distributor. Any required payments would adversely affect our operating results.

If we lose our relationship with any supplier of key product components or our relationship with a supplier deteriorates or key components are not available in sufficient quantities, our manufacturing could be delayed and our business could suffer

We contract with third parties for the supply of some of the components used in our products and the production of our disposable products. Some of our suppliers are not obligated to continue to supply us. We have relatively few sources of supply for some of the components used in our products and in some cases we rely entirely on sole-source suppliers. In addition, the lead-time involved in the manufacturing of some of these components can be lengthy and unpredictable. If our suppliers become unwilling or unable to supply us with components meeting our requirements, it might be difficult to establish additional or replacement suppliers in a timely manner, or at all. This would cause our product sales to be disrupted and our revenue and operating results to suffer.

Replacement or alternative sources might not be readily obtainable due to regulatory requirements and other factors applicable to our manufacturing operations. Incorporation of components from a new supplier into our products may require a new or supplemental filing with applicable regulatory authorities and clearance or approval of the filing before we could resume product sales. This process may take a substantial period of time, and we may not be able to obtain the necessary regulatory clearance or approval. This could create supply disruptions that would harm our product sales and operating results.

We depend upon key employees in a competitive market for skilled personnel, and, without additional employees, we cannot grow or maintain profitability

Our products and technologies are complex, and we depend substantially on the continued service of our senior management team. The loss of any of our key employees could adversely affect our business and slow our

27

product development process. Our future success also will depend, in part, on the continued service of our key management personnel, software engineers, and other research and development employees, and our ability to identify, hire, and retain additional personnel, including customer service, marketing, and sales staff. Demand for these skilled employees in our industry is very competitive due to the limited number of people available with the necessary technical skills and understanding of our product technologies. We may be unable to attract and retain personnel necessary for the development of our business.

Our ability to market and sell products depends upon receipt of domestic and foreign regulatory approval of our products and manufacturing operations. Our failure to obtain or maintain regulatory approvals and compliance could negatively affect our business

Our products and manufacturing operations are subject to extensive regulation in the United States by the FDA and by similar regulatory agencies in other countries. Our products are classified as medical devices. Medical devices are subject to extensive regulation by the FDA pursuant to regulations that are wide ranging and govern, among other things: design and development; manufacturing and testing; labeling; storage and record keeping; advertising, promotion, marketing, sales distribution and export; and surveillance and reporting of deaths or serious injuries.

Unless an exemption applies, each medical device that we propose to market in the U.S. must first receive one of the following types of FDA premarket review authorizations:

• Clearance via Section 510(k) of the Food, Drug, and Cosmetics Act of 1938, as amended; or

• Premarket approval via Section 515 of the Food, Drug, and Cosmetics Act if the FDA has determined that the medical device in question poses a greater risk of injury.

The FDA will clear marketing of a medical device through the 510(k) process if it is demonstrated that the new product is substantially equivalent to other 510(k)-cleared products. The premarket approval application process is much more costly, lengthy and uncertain than the 510(k) process, and must be supported by extensive data from preclinical studies and human clinical trials. The FDA may not grant either 510(k) clearance or premarket approval for any product we propose to market. Further, any modification to a 510(k)-cleared device that could significantly affect its safety or effectiveness, or that would constitute a major change in its intended use, design or manufacture, requires a new 510(k) clearance or, possibly, approval of a premarket approval application. The FDA requires every manufacturer to make this determination in the first instance, but the FDA may review any manufacturer’s decision. If the FDA requires us to seek 510(k) clearance or premarket approval for modification of a previously cleared product for which we have concluded that new clearances or approvals are unnecessary, we may be required to cease marketing or to recall the modified product until we obtain clearance or approval, and we may be subject to significant regulatory fines or penalties. Further, our products could be subject to recall if the FDA determines, for any reason, that our products are not safe or effective.

Delays in receipt of, or failure to receive, clearances or approvals, the loss of previously received clearances or approvals, or the failure to comply with existing or future regulatory requirements could adversely impact our operating results. If the FDA finds that we have failed to comply with these requirements, the Agency can institute a wide variety of enforcement actions, ranging from a public warning letter to more severe sanctions such as:

• Fines, injunctions and civil penalties;

• Recall or seizure of our products;

• Issuance of public notices or warnings;

• Imposition of operating restrictions, partial suspension, or total shutdown of production;

• Refusal of our requests for Section 510(k) clearance or premarket approval of new products;

• Withdrawal of Section 510(k) clearance or premarket approvals already granted; or

• Criminal prosecution.

28

Domestic regulation of our products and manufacturing operations, other than that which is administered by the FDA, includes the Environmental Protection Act, the Occupational Safety and Health Act, and state and local counterparts to these Acts.

Our business would be harmed if the FDA determines that we have failed to comply with applicable regulations governing the manufacture of our products and/or we do not pass an inspection

We and our suppliers are required to demonstrate and maintain compliance with the FDA’s Quality System Regulation. The Quality System Regulation sets forth the FDA’s requirements for good manufacturing practices of medical devices and includes requirements for, among other things, the design, testing, production processes, controls, quality assurance, labeling, packaging, storage and shipping of such products. In addition, we and our suppliers must engage in extensive recordkeeping and reporting and must make available our manufacturing facility and records for periodic unscheduled inspections by federal, state and foreign agencies, including the FDA. We cannot assure you that we and our suppliers are or will continue to be in full compliance with the Quality System Regulation, and that we will not encounter any manufacturing difficulties.

Failure of our third party suppliers and manufacturers or us to comply with applicable regulations could result in sanctions being imposed on us, including, among other things, fines, injunctions, civil penalties, failure of regulatory authorities to grant marketing approval of our products, delays, suspension or withdrawal of approvals, seizures or recalls of products and manufacturing restrictions, any of which could harm our business.

Our Olympic Cool-Cap product is subject to greater products liability exposure and FDA regulation

The FDA classifies medical devices into one of three classes depending on the degree of risk associated with each medical device and the extent of controls that are needed to ensure safety and effectiveness. Devices deemed to pose lower risk are placed in either Class I or Class II. Devices deemed by the FDA to pose the greatest risk, such as life-sustaining, life supporting or implantable devices, or a device deemed to not be substantially equivalent to a previously cleared 510(k) device are placed in class III, and generally require premarket approval from the FDA before they may be marketed.

Our Olympic Cool-Cap is a Class III minimally invasive medical device, and as such we may be subject to an increased product liability risk relative to our other Class I and Class II non-invasive products. In addition, this type of product is subject to greater FDA oversight than our other products and there is greater risk that sales of the product could be interrupted due to the premarket approval processes of the FDA and other regulatory bodies.

Our business may suffer if we are required to revise our labeling or promotional materials, or if the FDA takes an enforcement action against us for off-label uses

We are prohibited by the FDA from promoting or advertising our medical device products for uses not within the scope of our clearances or approvals, or from making unsupported promotional claims about the benefits of our products. If the FDA determines that our claims are outside the scope of our clearances, or are unsupported, it could require us to revise our promotional claims or take enforcement action against us. If we were subject to such an action by the FDA, our sales could be delayed, our revenue could decline, and our reputation among clinicians could be harmed. Likewise, if we acquire new products, either through the purchase of products, technology assets, or businesses, that are subsequently deemed to have inadequate supporting data, we may be required to (i) obtain adequate data, which could be costly and impede our ability to market these products, or (ii) modify the labeling on these products, which could impair their marketability, as described above.

If we deliver products with defects, we may incur costs to repair and, possibly, recall that product and market acceptance of our products may decrease.

The manufacturing and marketing of our products involve an inherent risk of our delivering a defective product or products that do not otherwise perform as we expect. We may incur substantial expense to repair any

29

such products and may determine to recall such a product, even if not required to do so under applicable regulations. Any such recall would be time consuming and expensive. Product defects or recalls may adversely affect our customers’ acceptance of the recalled and other of our products. As an example, in the second quarter of 2010 we discontinued selling the Sonamed Clarity newborn hearing screening product line and incurred costs associated with sales concessions awarded customers who traded in a Clarity device for one of our existing newborn hearing screening devices and the write-down of inventory. We also recorded an impairment charge to write-off the carrying value of the Sonamed and Clarity tradenames.

If we fail to comply with healthcare regulations, we could face substantial penalties and our business, operations and financial condition could be adversely affected.

We do not provide healthcare services, control the referral of patients for healthcare services, nor bill Medicare, Medicaid or other third-party payors; however, due to the breadth of many healthcare laws and regulations, we could be subject to healthcare fraud regulation and enforcement by both the federal government and the states in which we conduct our business. The laws that may affect our ability to operate include: (i) the federal healthcare programs Anti-Kickback Law, which prohibits, among other things, persons from knowingly and willfully soliciting, receiving, offering or paying remuneration, directly or indirectly, in exchange for or to induce either the referral of an individual for, or the purchase, order or recommendation of, any good or service for which payment may be made under federal healthcare programs such as Medicare or Medicaid, (ii) federal false claims laws which prohibit, among other things, individuals or entities from knowingly presenting, or causing to be presented, claims for payment from Medicare, Medicaid, or other third-party payors that are false or fraudulent, and which may apply to entities like us which provide coding and billing advice to customers, and/or (iii) state law equivalents of each of the above federal laws, such as anti-kickback and false claims laws which may apply to items or services reimbursed by any third-party payor, including commercial insurers, many of which differ from their federal counterparts in significant ways, thus complicating compliance efforts.

If our operations are found to be in violation of any of the laws described above or any other governmental regulations that apply to us, we may be subject to penalties, including civil and criminal penalties, damages, fines and the curtailment or restructuring of our operations. Any penalties, damages, fines, curtailment or restructuring of our operations could adversely affect our ability to operate our business and our financial results. The risk of our being found in violation of these laws is increased by the fact that their provisions are open to a variety of interpretations. Any action against us for violation of these laws, even if we successfully defend against it, could cause us to incur significant legal expenses and divert our management’s attention from the operation of our business.

Our operating results would suffer if we were subject to a protracted infringement claim

The medical technology industry is characterized by a substantial amount of litigation and related administrative proceedings regarding patents and intellectual property rights. We expect that medical screening and diagnostic products may become increasingly subject to third-party infringement claims as the number of competitors in our industry grows and the functionality of products overlap. Third parties such as individuals, educational institutions, or other medical device companies may claim that we infringe their intellectual property rights. Any claims, with or without merit, could have any of the following negative consequences:

• Result in costly litigation and damage awards;

• Divert our management’s attention and resources;

• Cause product shipment delays or suspensions; or

• Require us to seek to enter into royalty or licensing agreements.

A successful claim of infringement against us could result in a substantial damage award and materially harm our financial condition. Our failure or inability to license the infringed or similar technology, or design and build non-infringing products, could prevent us from selling our products and adversely affect our business and financial results.

30

We may also find it necessary to bring infringement actions against third parties to seek to protect our intellectual property rights. Litigation of this nature, even if successful, is often expensive and disruptive of our management’s attention, and in any event may not lead to a successful result relative to the resources dedicated to any such litigation.

We license intellectual property rights from third parties and would be adversely affected if our licensors do not appropriately defend their proprietary rights or if we breach any of the agreements under which we license commercialization rights to products or technology from others

We license rights from third parties for products and technology that are important to our business. If our licensors are unsuccessful in asserting and defending their proprietary rights, including patent rights and trade secrets, we may lose the competitive advantages we have through selling products that we license from third parties. Additionally, if it is found that our licensors infringe on the proprietary rights of others, we may be prohibited from marketing our existing products that incorporate those proprietary rights. Under our licenses, we are subject to commercialization and development, sublicensing, royalty, insurance and other obligations. If we fail to comply with any of these requirements, or otherwise breach a license agreement, the licensor may have the right to terminate the license in whole or to terminate the exclusive nature of the license.

Product liability suits against us could result in expensive and time consuming litigation, payment of substantial damages, and an increase in our insurance rates

The sale and use of our products could lead to the filing of a product liability claim by someone claiming to have been injured using one of our products or claiming that one of our products failed to perform properly. A product liability claim could result in substantial damages and be costly and time consuming to defend, either of which could materially harm our business reputation or financial condition. Our product liability insurance may not protect our assets from the financial impact of defending a product liability claim. Any product liability claim brought against us, with or without merit, could increase our product liability insurance rates or prevent us from securing any coverage in the future.

We have experienced seasonality in the sale of our products

We experience seasonality in our revenue. For example, our sales typically decline from our fourth fiscal quarter to our first fiscal quarter, due to patterns in the capital budgeting and purchasing cycles of our customers, many of which are government agencies, and the compensation arrangements of our direct sales employees, as those arrangements are tied to calendar-year sales plans. We may also experience declining sales in the third fiscal quarter due to summer holiday and vacation schedules. We anticipate that we will continue to experience these seasonal fluctuations, which may lead to fluctuations in our quarterly operating results. We believe that you should not rely on our results of operations for interim periods as an indication of our expected results in any future period.

ITEM 1B. Unresolved Staff Comments.

None.

ITEM 2. Properties

Our corporate headquarters are located in San Carlos, California, in facilities covering 26,300 square feet pursuant to a lease that expires in June 2015.

We also utilize the following properties:

Company-owned Facilities:

• 44,900 square feet in Oakville, Ontario, Canada, utilized substantially for the operations of Xltek;

• 26,000 square feet in Mundelein, Illinois, utilized substantially for the operations of Bio-logic;

• 116,000 square feet in Buenos Aires, Argentina, utilized substantially for the operations of Medix.

31

Leased Facilities:

• 65,000 square feet in Seattle, Washington, pursuant to a lease that expires in December 2011, that is utilized substantially for the operations of Olympic Medical;

• 12,000 square feet in Clackamas, Oregon, pursuant to a lease that expires in April, 2014, that is utilized substantially for the operations of Neurocom;

• 2,900 square feet in Hauppauge, New York, pursuant to a lease that expires in October 2012, that is utilized substantially for the operations of Neometrics;

• 48,000 square feet in Skovlunde, Denmark, pursuant to a lease that expires with six months notice that is utilized for the operations of Alpine Biomed;

• 29,000 square feet in Munich, Germany, pursuant to a lease that expires in March, 2012, that is utilized substantially for the operations of Schwarzer Neurology and Fischer-Zoth; and 1,700 square feet in Langenfeld, Germany, pursuant to a lease on a month to month basis, that is utilized substantially for the operations of Alpine Biomed Germany; and

• 3,250 square feet in Paris and 7,500 square feet in Bordeaux, both in France, pursuant to leases that expire in October 2019, and March 2012, respectively, that are utilized substantially for the operations of Deltamed.

ITEM 3. Legal Proceedings

We may from time to time become a party to various legal proceedings or claims that arise in the ordinary course of business. We are not currently involved in any legal or administrative proceedings that we believe are likely to have a materially adverse effect on our business, financial condition, or results of operations, although we cannot be assured of the outcome of such matters.

ITEM 4. (Reserved)

32

PART II

ITEM 5. Market for Registrant’s Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities

Our common stock trades on the Nasdaq Global Select Market under the symbol “BABY”. The following table sets forth, for the periods indicated, the high and low sale price per share of our common stock, as reported on the Nasdaq Global Select Market.

	High		Low
Fiscal Year Ended December 31, 2010:
Fourth Quarter	$	15.18	$	12.91
Third Quarter		16.58		11.75
Second Quarter		17.93		15.41
First Quarter		15.91		12.82
Fiscal Year Ended December 31, 2009:
Fourth Quarter	$	16.22	$	12.59
Third Quarter		17.51		9.92
Second Quarter		11.72		7.08
First Quarter		13.00		6.46

As of March 7, 2011, there were 28,974,250 shares of our common stock issued and outstanding and held by approximately 41 stockholders of record. We estimate that there are approximately 11,000 beneficial owners of our common stock.

Dividends

We have never declared or paid cash dividends on our capital stock. We currently expect to retain future earnings, if any, for use in the operation and expansion of our business and do not anticipate paying any cash dividends in the foreseeable future. Based on the terms of our Amended and Restated Credit Agreement with Wells Fargo Bank, National Association, we are prevented from paying dividends without the prior approval of the bank.

33

Stock Performance Graph

The following information of Part II Item 5 is being furnished and shall not be deemed to be “soliciting material” or to be “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that Section, nor will it be deemed incorporated by reference into any filing under the Securities Act of 1933, as amended, or the Securities Exchange Act of 1934, as amended, except to the extent that we specifically incorporate such information by reference thereto.

The following graph shows a comparison, from January 1, 2005 through December 31, 2010, of cumulative total return for our common stock, the Nasdaq Composite Index and the Standard & Poor’s 500 Health Care Equipment Index. Such returns are based on historical results and are not intended to suggest future performance. Data for the Nasdaq Composite Index and the Standard & Poor’s 500 Health Care Equipment Index assumes reinvestment of dividends.

		2005		2006		2007		2008		2009		2010
Natus Medical Inc.	Return %				2.91		16.49		(33.08)		14.21		(4.12)
	Cum $		$100.00		102.91		119.88		80.23		91.63		87.85
NASDAQ Composite-Total Returns	Return %				10.39		10.65		(39.98)		45.36		18.16
	Cum $		$100.00		110.39		122.15		73.32		106.58		125.93
S&P 500 Health Care Equipment Index	Return %				4.11		5.15		(27.63)		28.75		(2.70)
	Cum $		$100.00		104.11		109.47		79.22		102.00		99.24

ITEM 6. Selected Financial Data

The following tables set forth certain selected consolidated financial data as of December 31, 2010, 2009, 2008, 2007 and 2006 and for each of the years in the five-year period ended December 31, 2010, and is derived from the consolidated financial statements of Natus Medical Incorporated and its subsidiaries. The consolidated financial statements as of December 31, 2010 and 2009 and for each of the years in the three-year period ended December 31, 2010 are included elsewhere in this report. The selected consolidated balance sheet data as of December 31, 2008, 2007 and 2006 and the consolidated statements of operations data for the years ended December 31, 2007 and 2006 are derived from our consolidated financial statements, which are not included in this report. The selected consolidated financial data set forth below is qualified in its entirety by, and should be

34

read in conjunction with, the Consolidated Financial Statements and Notes thereto and “Management’s Discussion and Analysis of Financial Condition and Results of Operations” included elsewhere in this report.

	Year ended December 31,
	2010			2009		2008		2007		2006
	(in thousands, except per share data)
Consolidated Statement of Operations Data:
Revenue	$	218,655		$	166,425	$	161,831	$	118,269	$	89,915
Cost of Revenue		88,698			66,077		61,332		42,704		33,665
Gross profit		129,957			100,348		100,499		75,565		56,250
Operating expenses:
Marketing and selling		54,857			45,304		39,998		28,024		21,944
Research and development		21,283			16,732		15,520		15,645		10,604
General and administrative		35,986			22,979		19,808		15,214		11,004
Acquired in-process research and development		—			—		—		300		9,800
Total operating expense		112,126			85,015		75,326		59,183		53,352
Income from operations		17,831			15,333		25,173		16,382		2,898
Other income (expense), net		(118	)		1,750		2,142		101		225
Income before provision for income taxes		17,713			17,083		27,315		16,483		3,123
Provision for income tax expense		5,794			5,701		10,033		6,417		4,050
Net income (loss)	$	11,919		$	11,382	$	17,282	$	10,066	$	(927	)
Earnings (loss) per share:
Basic	$	0.42		$	0.41	$	0.68	$	0.47	$	(0.05	)
Diluted	$	0.41		$	0.40	$	0.65	$	0.44	$	(0.05	)
Weighted average shares used in the calculation of earnings (loss) per share:
Basic		28,092			27,651		25,278		21,600		19,548
Diluted		29,217			28,476		26,557		22,815		19,548
	December 31,
	2010			2009		2008		2007		2006
	(in thousands)
Balance Sheet Data:
Cash, cash equivalents, and short-term investments	$	29,388		$	33,551	$	56,915	$	11,916	$	15,392
Working capital		83,922			75,207		97,593		19,448		30,803
Total assets		331,047			292,090		258,158		190,353		124,163
Long-term debt (including current portion)		893			1,109		1,288		36,816		—
Total stockholders’ equity		263,255			243,557		226,312		116,007		101,026

Results of operations and financial position of the business we have acquired are included from their acquisition dates as follows: Bio-logic in January 2006, Deltamed in September 2006, Olympic in October 2006, Xltek in November 2007, Sonamed in May 2008, Schwarzer Neurology in July 2008, Neurocom in October 2008, Hawaii Medical in July 2009, Alpine Biomed in September 2009, and Medix in October 2010.

Acquired in-process research and development charges in 2007 are associated with our acquisition of Xltek, and in 2006 with our acquisitions of Bio-logic and Olympic.

The selected financial data gives effect to the corrections discussed in Note 20, Immaterial Corrections to Prior Period Financial Statements in the Notes to Consolidated Financial Statements of our Consolidated Financial Statements contained herein.

35

ITEM 7. Management’s Discussion and Analysis of Financial Condition and Results of Operations

The following Management’s Discussion and Analysis of Financial Condition and Results of Operations (“MD&A”) should be read in conjunction with our financial statements and the accompanying footnotes. MD&A includes the following sections:

• Our Business.    A general description of our business.

• Year 2010 Overview.    A summary of key information concerning the financial results for 2010 and changes from 2009.

• Application of Critical Accounting Policies.    A discussion of the accounting policies that are most important to the portrayal of our financial condition and results of operations and that require critical judgments and estimates.

• Results of Operations.    An analysis of our results of operations for the three years presented in the financial statements.

• Liquidity and Capital Resources.    An analysis of capital resources, sources and uses of cash, investing and financing activities, and contractual obligations.

• Quantitative and Qualitative Disclosures about Market Risk.    A summary of currency exchange issues and interest rate hedging.

• Off-Balance Sheet Arrangements.    An analysis of off-balance sheet arrangements.

• Recent Accounting Pronouncements.    A recap of recently issued accounting pronouncements that may have an impact on our results of operations, financial position or cash flows.

• Cautionary Information Regarding Forward-Looking Statements.    Cautionary information about forward-looking statements.

Business

Natus is a leading provider of healthcare products used for the screening, detection, treatment, monitoring and tracking of common medical ailments in newborn care, hearing impairment, neurological dysfunction, epilepsy, sleep disorders, and balance and mobility disorders. Product offerings include computerized neurodiagnostic systems for audiology, neurology, polysomnography, and neonatalogy, as well as newborn care products such as hearing screening systems, phototherapy devices for the treatment of newborn jaundice, head-cooling products for the treatment of brain injury in newborns, incubators to control the newborn’s environment, and software systems for managing and tracking disorders and diseases for public health laboratories.

We have completed a number of acquisitions since 2003, consisting of either the purchase of a company, substantially all of the assets of a company, or individual products or product lines. Our significant acquisitions are as follows: Neometrics in 2003, Fischer-Zoth in 2004, Bio-logic, Deltamed, and Olympic in 2006, Xltek in 2007, Sonamed, Schwarzer Neurology, and Neurocom in 2008, Hawaii Medical and Alpine Biomed in 2009, and Medix in 2010.

Year 2010 Overview

We faced an uncertain business in 2010 as the global economy continued its recovery from the recessionary economic conditions that existed in many parts of the world during 2008 and 2009, particularly in North America and Europe where we conduct the majority of our business.

Our consolidated revenue increased $52.2 million for the year ended December 31, 2010 compared to 2009, primarily as a result of improved economic conditions. Revenue increased across all of our business units. Alpine Biomed and Hawaii Medical, that we acquired in 2009, contributed to $22.7 of incremental revenue in 2010, while Medix, that was acquired in 2010, contributed to $7.1 of revenue in 2010.

36

During the second fiscal quarter of 2010 we substantially completed the reorganization plan adopted in January 2010 that was designed to eliminate redundant costs resulting from our acquisition of Alpine Biomed and to improve efficiencies in operations. Under the plan, Alpine operations in Montreal, Canada were transitioned to our existing Xltek facility in Oakville, Ontario, Canada. Alpine’s sales organization was merged into the Company’s global sales organization during the first fiscal quarter of 2010.

Also in the second fiscal quarter of 2010 we discontinued the Sonamed Clarity hearing screening product line and began converting users to our other newborn hearing screening products. This action resulted in a non-recurring charge totaling $1.4 million that reduced reported gross profit by $1.1 million or 0.8 percentage points and increased operating expenses by $300,000. The conversion was substantially complete as of December 31, 2010.

During the third quarter of 2010 we received a purchase order from the Kingdom of Saudi Arabia for our newborn care products. The order, valued at over $2.9 million, was for our ALGO newborn hearing screeners, Cool-Cap selective head-cooling devices, Olympic Cerebral Functions Monitors (CFM), and associated disposable supplies. We completed the shipment of this purchase order in the fourth quarter.

We acquired Medix in October 2010 for $14.1 million in cash. Medix, based in Buenos Aires, Argentina, manufactures incubators for use in hospital nurseries and NICU’s, transport incubators for use in ambulances and other emergency vehicles, infant warmers, and LED-based phototherapy devices.

We do not believe that our markets have yet returned to the level of activity that prevailed prior to the commencement of the credit crisis in the third quarter of 2008 that precipitated the global economic crisis. As a result of cost containment and other measures we have implemented, and our recent acquisitions, we believe that we continue to be well-positioned to capitalize on improving market conditions as, and to the extent, that such conditions develop.

Application of Critical Accounting Policies

We prepare our financial statements in accordance with accounting principles generally accepted in the United States of America (“GAAP”). In so doing, we must often make estimates and use assumptions that can be subjective and, consequently, our actual results could differ from those estimates. For any given individual estimate or assumption we make, there may also be other estimates or assumptions that are reasonable.

We believe that the following critical accounting policies require the use of significant estimates, assumptions, and judgments. The use of different estimates, assumptions, and judgments could have a material effect on the reported amounts of assets, liabilities, revenue, expenses, and related disclosures as of the date of the financial statements and during the reporting period.

Revenue recognition

Revenue, net of discounts, is recognized from sales of medical devices and supplies, including sales to distributors, when the following conditions have been met: a purchase order has been received, title has transferred, the selling price is fixed or determinable, and collection of the resulting receivable is reasonably assured. Terms of sale for most domestic sales are FOB origin, reflecting that title and risk of loss are assumed by the purchaser at the shipping point; however, terms of sale for some neurology, sleep-diagnostic, and head cooling systems are FOB destination, reflecting that title and risk of loss are assumed by the purchaser upon delivery. Terms of sales to international distributors are generally EXW, reflecting that goods are shipped “ex works,” in which title and risk of loss are assumed by the distributor at the shipping point.

We have historically applied the software revenue recognition rules as prescribed by Accounting Standards Codification (“ASC”) Subtopic 985-605 to sales of certain of our diagnostic neurology and hearing systems (“products containing embedded software”). In October 2009, the Financial Accounting Standards Board

37

(“FASB”) issued Accounting Standards Update No. (“ASU”) 2009-14, Certain Revenue Arrangements That Include Software Elements, which amended ASC Subtopic 985-605, and we prospectively adopted the provisions of ASU 2009-14 on January 1, 2010. This ASU removes tangible products containing software components and non-software components that function together to deliver the product’s essential functionality from the scope of the software revenue recognition rules. In the case of the Company’s products containing embedded software, we have determined that the hardware and software components function together to deliver the products’ essential functionality, and therefore, the revenue from the sale of these products no longer falls within the scope of the software revenue recognition rules. Our revenue recognition policies for sales of these products are now substantially the same as for our other tangible products.

Revenue from sales of certain of our products that remain within the scope of the software revenue recognition rules under ASC Subtopic 985-605 is not significant.

We previously accounted for arrangements with multiple deliverables under ASC Topic 605, where revenue was allocated to the deliverables based on vendor specific objective evidence (“VSOE”). In October 2009 the FASB issued ASU 2009-13, Multiple Deliverable Revenue Arrangements, which amends ASC Topic 605, and we prospectively adopted the provisions of ASU 2009-13 on January 1, 2010. Under the revenue recognition rules for tangible products as amended by ASU 2009-13, we now allocate revenue from arrangements with multiple deliverables to each of the deliverables based upon their relative selling prices as determined by a selling-price hierarchy. A deliverable in an arrangement qualifies as a separate unit of accounting if the delivered item has value to the customer on a stand-alone basis. The principal deliverables in our multiple deliverable arrangements that qualify as separate units of accounting consist of (i) sales of medical devices and supplies, (ii) installation services, (iii) extended service and maintenance agreements, and (iv) upgrades to embedded software.

The new rules establish a hierarchy to determine the selling price to be used for allocating revenue to deliverables as follows: (i) vendor-specific objective evidence of fair value (“VSOE”), (ii) third-party evidence of selling price (“TPE”), and (iii) best estimate of the selling price (“ESP”). VSOE of fair value is defined as the price charged when the same element is sold separately, or if the element has not yet been sold separately, the price for the element established by management having the relevant authority when it is probable that the price will not change before the introduction of the element into the marketplace. VSOE generally exists only when we sell the deliverable separately and is the price actually charged for that deliverable. We have previously established VSOE for substantially all of the deliverables in our multiple element arrangements; however, in the future we may rely on ESPs, reflecting our best estimates of what the selling prices of elements would be if they were sold regularly on a stand-alone basis, to establish the amount of revenue to allocate to the deliverable. TPE generally does not exist for our products because of their uniqueness.

For products shipped under FOB origin or EXW terms, delivery is generally considered to have occurred when shipped. Undelivered elements in our sales arrangements, which are not considered to be essential to the functionality of a product, generally include installation or training services that are performed after the related products have been delivered. Revenue related to undelivered installation services is deferred until such time as installation is complete at the customer’s site. Revenue related to training services is recognized when the service is provided. Fair value for installation or training services is based on the price charged when the service is sold separately. The fair value of installation and training services is based upon billable hourly rates and the estimated time to complete the service.

Revenue from extended service and maintenance agreements, for both medical devices and data management systems, is recognized ratably over the service period. Freight charges billed to customers are included in revenue and freight-related expenses are charged to cost of revenue. Advance payments from customers are recorded as deferred revenue and recognized as revenue as otherwise described above. We generally do not provide rights of return on products. We accept trade-ins of our own and competitive medical devices. Trade-ins are recorded as a reduction of the replacement medical device sale. Provisions are made for initial standard warranty obligations that are generally one year in length.

38

Inventory is carried at the lower of cost or market value

We may be exposed to a number of factors that could result in portions of our inventory becoming either obsolete or being held in quantities that exceed anticipated usage. These factors include, but are not limited to: technological changes in our markets, competitive pressures in products and prices, and our own introduction of new product lines.

We regularly evaluate our ability to realize the value of our inventory based on a combination of factors, including historical usage rates, forecasted sales, product life cycles, and market acceptance of new products. When we identify inventory that is obsolete or in excess of anticipated usage we write it down to realizable salvage value. The estimates we use in projecting future product demand may prove to be incorrect. Any future determination that our inventory is overvalued could result in increases to our cost of sales and decreases to our operating margins and results of operations.

Carrying value of intangible assets and goodwill

We amortize intangible assets with finite lives over their useful lives; any future changes that would limit their useful lives or any determination that these assets are carried at amounts greater than their estimated fair value could result in additional charges. We carry goodwill and any other intangible assets with indefinite lives at original cost but do not amortize them. Any future determination that these assets are carried at amounts greater than their estimated fair value could result in additional charges, which could significantly impact our operating results.

We test our definite-lived intangible assets for impairment whenever changes in circumstances indicate the carrying value of these assets may be impaired. Impairment indicators include, but are not limited to, net book value as compared to market capitalization, significant negative industry and economic trends, and significant underperformance relative to historical and projected future operating results. Impairment is considered to have occurred when the estimated undiscounted future cash flows related to the asset are less than its carrying value. Estimates of future cash flows involve consideration of many factors including the marketability of new products, product acceptance and lifecycle, competition, appropriate discount rates, and operating margins.

Goodwill and indefinite-lived intangible assets are tested for impairment at least annually as of October 1st; this assessment is also performed whenever there is a change in circumstances that indicates the carrying value of these assets may be impaired. The determination of whether any potential impairment of goodwill exists is based upon a two step process. In the first analysis, the fair value of the reporting unit is compared to the unit’s fair value, including goodwill, to determine if there is a potential impairment. If the fair value exceeds the carrying amount, the goodwill of the reporting unit is considered not impaired and no further analysis or action is required. If the first analysis indicates that the carrying value exceeds the fair value, a second analysis is performed to determine the amount of the goodwill impairment loss, if any.

In step two of the impairment test, the implied fair value of a reporting unit’s goodwill is compared to the carrying amount of that goodwill. The implied fair value of the goodwill shall be determined in the same manner as the amount of goodwill recognized in a business combination is determined. That is, the entity shall allocate the fair value of a reporting unit to all the assets and liabilities of that reporting unit, including unrecognized intangible assets as if the reporting unit had been acquired in a business combination and the fair value of the reporting unit was the price paid to acquire the reporting unit. The excess of the fair value of the reporting unit over the amounts assigned to its assets and liabilities is the implied fair value of that goodwill.

To determine the estimated fair value of reporting units, three valuation methodologies are utilized: (i) discounted cash flow analyses, (ii) market multiples, and (iii) comparative transactions. The valuations indicated by these three methodologies are averaged, with the greatest weight placed on discounted cash flow analyses. Discounted cash flow analyses are dependent upon a number of quantitative and qualitative factors including estimates of forecasted revenue, profitability, earnings before interest, taxes, depreciation and amortization (i.e. EBITDA) and terminal values. The discount rates applied in the discounted cash flow analyses also have an impact on the estimates of fair value, as use of a higher rate will result in a lower estimate of fair value. The estimated total fair value of reporting units is reconciled to the Company’s market capitalization.

39

Liability for product warranties

Our medical device products are covered by standard one-year product warranty plans. A liability has been established for the expected cost of servicing our medical device products during these service periods. We base the liability on actual warranty costs incurred to service those products. On new products, additions to the reserve are based on a combination of factors including the percentage of service department labor applied to warranty repairs, as well as actual service department costs and other judgments, such as the degree to which the product incorporates new technology applied to the number of units sold. As warranty costs are incurred, the reserve is reduced.

The estimates we use in projecting future product warranty costs may prove to be incorrect. Any future determination that our product warranty reserves are understated could result in increases to our cost of sales and reductions in our operating profits and results of operations.

Share-based compensation

We record the fair value of share-based compensation awards as expenses in the consolidated statement of operations. In order to determine the fair value of stock options on the date of grant, we apply the Black-Scholes option-pricing model. Inherent in this model are assumptions related to expected dividend yield, risk-free interest rate, expected stock-price volatility, expected term, and forfeiture rate. While the risk-free interest rate and dividend yield are less subjective assumptions, typically based on factual data derived from public sources, expected stock-price volatility, expected life, and forfeiture rate assumptions require a greater level of judgment which makes them critical accounting estimates. If we used different assumptions, we would have recorded different amounts of share-based compensation.

Results of Operations

The discussion to follow gives effect to the correction of errors detailed in Note 20, Immaterial Corrections to Prior Period Financial Statements in the Notes to Consolidated Financial Statements of our Consolidated Financial Statements contained herein.

The following table sets forth for the periods indicated selected consolidated statement of operations data as a percentage of total revenue. Our historical operating results are not necessarily indicative of the results for any future period.

	Percent of Revenue
	Years Ended December 31,
	2010			2009			2008
Revenue		100.0	%		100.0	%		100.0	%
Cost of revenue		40.6			39.7			37.9
Gross profit		59.4			60.3			62.1
Operating expenses:
Marketing and selling		25.1			27.2			24.7
Research and development		9.7			10.0			9.6
General and administrative		16.5			13.8			12.2
Total operating expenses		51.3			51.0			46.5
Income from operations		8.1			9.3			15.6
Other income (expense), net		(0.1	)		1.0			1.3
Income before provision for income tax		8.0			10.3			16.9
Income tax provision		2.6			3.4			6.2
Net income		5.4	%		6.9	%		10.7	%

40

Acquisitions

We completed six significant acquisitions during 2010, 2009 and 2008, and the timing of these acquisitions had an impact on the comparison of our results of operations for the years ended December 31, 2010, 2009 and 2008.

• Medix—Completed on October 12, 2010. Medix reported revenue of approximately $25.2 million during its last completed fiscal year prior to the acquisition.

• Alpine Biomed—Completed on September 14, 2009. Alpine Biomed reported revenue from its neurology business of approximately $38.1 million during its last completed fiscal year prior to the acquisition.

• Hawaii Medical—Completed on July 2, 2009. Hawaii Medical reported revenue of approximately $3.2 million during its last completed fiscal year prior to the acquisition.

• Neurocom—Completed on October 2, 2008. Neurocom reported revenue of approximately $11.4 million during its last completed fiscal year prior to the acquisition.

• Schwarzer Neurology—Completed on July 2, 2008. Schwarzer Neurology reported revenue of approximately $7.1 million during its last completed fiscal year prior to the acquisition.

• Sonamed—Completed on May 27, 2008. Sonamed reported revenue of approximately $3.5 million during its last completed fiscal year prior to the acquisition.

The pre-acquisition revenue of our acquired companies may not be indicative of their contribution to revenue in the future.

Comparison of 2010 and 2009

Operating Results

Because our acquisitions have been significant, we measure the contribution to consolidated revenue of the businesses we acquire. We also analyze our revenue as coming from two sources: devices and systems, and supplies and services. We report freight revenue separate from these two sources.

Our consolidated revenue increased $52.2 million for the year ended December 31, 2010 compared to 2009, primarily as a result of improved economic conditions. Revenue increased across all of our business units. The companies that were acquired in 2009, Alpine Biomed and Hawaii Medical, contributed to $22.7 of incremental revenue in 2010, while Medix, that was acquired in 2010, contributed to $7.1 million of revenue in 2010. Revenue from our hearing products increased $3.4 million, while revenue from our existing neurology and newborn care products increased by $19.0 million.

Revenue from devices and systems was $134.8 million in 2010, representing an increase of 40% or $38.6 million, from $96.2 million reported in 2009. Alpine Biomed contributed to $13.0 million of incremental devices and systems revenue in 2010, while Medix contributed to $4.1 million of devices and systems revenue in 2010. Revenue from our hearing products increased $5.1 million, to $30.3 million, while revenue from our existing neurology and newborn care products increased by $17.8 million to $62.1 million, offset by a $1.4 million decrease in balance monitoring products.

Revenue from supplies and services was $80.3 million in 2010, representing an increase of 20%, or $13.2 million from $67.1 million in 2009. Alpine Biomed, Medix and Hawaii Medical contributed to $6.8 million, $3.0 million and $2.7 million, respectively, of incremental revenue from supplies and services. Supplies and service revenue from our existing products increased by $700,000 to $67.8 million.

Revenue from devices and systems was 62% of consolidated revenue in 2010 compared to 58% of total revenue in 2009, and revenue from supplies and services was 37% of total revenue in 2010 compared to 40% of revenue in 2009. Freight revenue of $3.6 million in 2010 and $3.2 million in 2009 represented 1% and 2% of total revenue in 2010 and 2009, respectively.

41

No customer accounted for more than 10% of our revenue in either 2010 or 2009. Revenue from domestic sales increased 15% to $126.9 million in 2010, from $109.7 million in 2009. Revenue from international sales increased 62% to $91.8 million in 2010, compared to $56.8 million in 2009. Revenue from domestic sales was 58% of total revenue in 2010, compared to 66% in 2009, and revenue from international sales was 42% of total revenue in 2010 compared to 34% of revenue in 2009. The changes in the percentages from 2010 to 2009 resulted primarily from the contribution of Alpine Biomed and Medix, whose sales are primarily in Europe and South America and related international markets, respectively.

Our cost of revenue increased $22.6 million, or 34%, to $88.7 million in 2010, from $66.1 million in 2009. The increase was due mainly to our increased sales. In addition, our discontinuance of the Sonamed Clarity hearing screening line resulted in a non-recurring charge totaling $1.1 million or 1.2% to our cost of revenue. Gross profit increased $29.6 million, or 30%, to $130.0 million in 2010 from $100.3 million in 2009. Gross profit as a percentage of revenue was 59% in 2010 compared with 60% in 2009.

Total operating costs increased $27.1 million, or 32%, to $112.1 million in 2010, from $85.0 million in 2009. The operations of Alpine Biomed and Medix contributed to $11.7 million of the increase in operating costs. We also recorded a restructuring charge of $3.1 million and other severance related costs of $842,000 for which there was no comparable cost in 2009. The remainder of the increase in operating costs was proportionate to our increased sales as our operating costs as a percentage of revenue was 51% in 2010 and 2009.

Our marketing and selling expenses increased $9.6 million, or 21%, to $54.9 million in 2010, from $45.3 million in 2009. The operations of Alpine Biomed and Medix contributed to $5.0 million of the increase and the remainder of the increase was primarily related to higher sales commission and sales related costs associated with the increase in our revenue. Marketing and selling expenses as a percent of total revenue decreased to 25.1 % in 2010 from 27.2% in 2009.

Our research and development expenses increased $4.6 million, or 27%, to $21.3 million in 2010 from $16.7 million in 2009. The operations of Alpine Biomed and Medix contributed to $3.1 million of research and development expense. Research and development expenses as a percent of total revenue decreased to 9.7% in 2010 from 10.0% in 2009.

Our general and administrative expenses increased $13.0 million, or 57%, to $36.0 million in 2009 from $23.0 million in 2009. General and administrative expenses as a percent of revenue increased from 13.8% in 2009 to 16.5% in 2010. $3.5 million of the increase in general and administrative expenses was attributable to the operations of Alpine Biomed and Medix. We recorded a restructuring charge of $3.1 million and other severance related costs of $842,000 for which there were no comparable costs in 2009. Other expenses exclusive of those associated with Alpine Biomed, Medix, restructuring and severance related costs were $5.6 million higher in 2010 compared to 2009, which resulted primarily from increased payroll and related benefit costs, professional fees, travel and outside consulting costs.

Other income (expense), net consists of investment income, interest expense, net currency exchange gains and losses, and other miscellaneous income and expense. We reported other income (expense), net of $(118,000) in 2010, compared to $1.7 million in 2009. Investment income of $36,000 in 2010 was $192,000 less than the amount reported for 2009 reflecting lower interest rates. We reported $521,000 of foreign currency exchange losses in 2010 versus $520,000 of foreign exchange gains in 2009. Interest expense was marginally lower in 2010 compared to 2009 due primarily to lower outstanding balances on our credit facilities.

We recorded income tax expense of $5.8 million in 2010, compared to $5.7 million recorded in 2009. Our effective tax rate for 2010 decreased to 32.7 % from 33.4% in 2009 because more of our income was taxed in foreign jurisdictions with tax rates lower than in the U.S. At December 31, 2010, we had federal net operating loss carryforwards of approximately $4.6 million available to offset future taxable income. Income tax expense related to our international operations is based on the statutory rates in those jurisdictions.

42

Comparison of 2009 and 2008

Operating Results

Our revenue increased 3%, or $4.6 million, to $166.4 million in 2009, from $161.8 million in 2008. Alpine Biomed, Neurocom and Schwarzer Neurology contributed $17.4 million to this increase in our revenue in 2009. This was offset by a $12.2 million net decrease in equipment sales across the Company’s other product lines, resulting from a weakness in demand that we believe was due to the economic recession during 2009.

Revenue from devices and systems was $96.2 million in 2009, representing a decrease of 6% or $6.3 million, from $102.5 million reported in 2008. The operations of Alpine Biomed, Neurocom and Schwarzer Neurology contributed to $12.1 million of the increase in revenue from devices and systems offset by a $6.8 million decrease in hearing revenue, a $5.3 million decrease in neurology revenue, and a $3.1 million decrease in newborn care revenue. Revenue from supplies and services was $67.1 million in 2009, representing an increase of 18%, or $10.4 million, from $56.7 million in 2008. The operations of Alpine Biomed, Neurocom and Schwarzer Neurology contributed to $5.1 million of the increase. Hearing supplies increased by $1.3 million and newborn care supplies increased by $2.0 million.

Revenue from devices and systems was 58% of consolidated revenue in 2009 compared to 63% of total revenue in 2008, and revenue from supplies and services was 40% of total revenue in 2009 compared to 35% of revenue in 2008. Freight revenue of $3.2 million in 2009 and $2.7 million in 2008 represented 2% of total revenue in both periods.

No customer accounted for more than 10% of our revenue in either 2009 or 2008. Revenue from domestic sales decreased 3% to $109.7 million in 2009, from $112.6 million in 2008. Revenue from international sales increased 15% to $56.8 million in 2009, compared to $49.2 million in 2008. Revenue from domestic sales was 66% of total revenue in 2009, compared to 70% in 2008, and revenue from international sales was 34% of total revenue in 2009 compared to 30% of revenue in 2008. The changes in the percentages from 2009 to 2008 resulted primarily from the contribution of Alpine Biomed, whose sales are primarily in Europe.

Our cost of revenue increased $4.7 million, or 8%, to $66.1 million in 2009, from $61.3 million in 2008. The increase was primarily due to our increased sales and higher materials costs. Gross profit decreased $151,000, or less than half a percent to $100.3 million in 2009 from $100.5 million in 2008. Gross profit as a percentage of revenue was 60% in 2009 compared to 62% in 2008. The decline in gross profit as a percentage of sales was due in part to the Alpine Biomed products having a lower gross margin than our existing products. In addition, the gross profit percentage of our European operations, excluding Alpine, was approximately 50% for 2009 compared to approximately 59% for 2008, due primarily to the impact that a lower revenue base had on manufacturing overhead as a percentage of revenue, as this cost is largely fixed.

Total operating costs increased $9.7 million, or 13%, to $85.0 million in 2009, from $75.3 million in 2008. The operations of Alpine Biomed, Neurocom and Schwarzer Neurology contributed to $12.5 million of the increase in operating costs partially offset by a $2.8 million decrease in operating costs in our North American divisions resulting from restructuring activities initiated in early 2008 that were substantially completed in that year. Our operating costs increased as a percentage of revenue from 47% in 2008 to 51% in 2009.

Our marketing and selling expenses increased $5.3 million, or 13%, to $45.3 million in 2009, from $40.0 million in 2008. The operations of Alpine Biomed, Neurocom, and Schwarzer Neurology contributed to $6.7 million of the increase offset by a decrease of $1.2 million in sales compensation costs resulting from decreased direct sales of devices. Marketing and selling expenses as a percent of total revenue increased from 24.7% in 2008 to 27.2% in 2009.

Our research and development expenses increased $1.2 million, or 8%, to $16.7 million in 2008 from $15.5 million in 2008. The operations of Alpine Biomed, Neurocom, and Schwarzer Neurology contributed to

43

$2.2 million of research and development expense, partially offset by reduced costs resulting from restructuring activities implemented in February 2008 for which we did not receive a benefit until late in 2008 and continuing into 2009. Research and development expenses as a percent of total revenue increased from 9.6% in 2008 to 10.0% in 2009.

Our general and administrative expenses increased $3.2 million, or 16%, to $23.0 million in 2009 from $19.8 million in 2008. General and administrative expenses as a percent of revenue increased from 12.2% in 2008 to 13.8% in 2009. General and administrative expenses of Alpine Biomed, Neurocom and Schwarzer Neurology represented $3.6 million of the increase. Direct costs of acquisitions completed in 2009 totaled $460,000 and were reported as a component of general and administrative expense; we had no similar costs in 2008 under prior accounting rules. General and administrative expenses other than those mentioned above were approximately $560,000 lower in 2009 compared to 2008.

Other income, net consists of investment income, interest expense, net currency exchange gains and losses, and other miscellaneous income and expense. We reported other income, net of $1.7 million in 2009, compared to $2.1 million in 2008. Investment income of $228,000 in 2009 was $801,000 less than the amount reported for 2008 reflecting lower interest rates and a lower investment portfolio due to our recent acquisitions. Net foreign currency exchange gains reported in 2009 were $1.1 million less than the amount reported for 2008. We reported $582,000 less in interest expense in 2009 compared to 2008 due primarily to lower outstanding balances on our credit facilities. In 2009 we also recorded a $650,000 adjustment to the value of a contingent liability associated with the acquisition of Alpine Biomed that resulted in an increase to other income for which there was no similar item in 2008.

We recorded income tax expense of $5.7 million in 2009, compared to $10.0 million recorded in 2008. Our effective tax rate for 2009 decreased to 33.4% compared to 36.7% in 2008 because more of our income was taxed in foreign jurisdictions with tax rates lower than in the U.S. At December 31, 2009, we had federal net operating loss carryforwards of approximately $8.2 million available to offset future taxable income. Income tax expense related to our international operations is based on the statutory rates in those jurisdictions.

Liquidity and Capital Resources

Comparison of 2010 and 2009

Liquidity is our ability to generate sufficient cash flows from operating activities to meet our obligations and commitments. In addition, liquidity includes the ability to obtain appropriate financing and to raise capital. Therefore, liquidity cannot be considered separately from capital resources that consist of our current funds and the potential to increase those funds in the future. We plan to use these resources in meeting our commitments and in achieving our business objectives.

As of December 31, 2010, we had cash, cash equivalents, and short-term investments of $29.4 million, stockholders’ equity of $263.3 million, and working capital of $83.9 million, compared with cash and cash equivalents of $33.6 million, stockholders’ equity of $243.6 million, and working capital of $75.2 million as of December 31, 2009.

We believe that our current cash and cash equivalents and any cash generated from operations will be sufficient to meet our ongoing operating and capital requirements for the foreseeable future. We completed the acquisition of Medix at the beginning of the fourth quarter of 2010, two acquisitions in 2009, four acquisitions in 2008, one in 2007, and three in 2006. We intend to continue to acquire additional technologies, products, or businesses and these acquisitions could be significant. These actions would likely affect our future capital requirements and the adequacy of our available funds. In order to finance future acquisitions, we may be required to raise additional funds through public or private financings, strategic relationships or other arrangements. Any equity financing may be dilutive to stockholders and debt financing, if available, may involve restrictive covenants and increase our cost of capital.

44

We have a $50 million revolving credit facility with Wells Fargo Bank, National Association (“Wells Fargo”). The revolving credit facility contains covenants, including covenants relating to liquidity and other financial measurements, and provides for events of default, including failure to pay any interest when due, failure to perform or observe covenants, bankruptcy or insolvency events and the occurrence of a material adverse effect. We have granted Wells Fargo a security interest in substantially all of our assets. We did not draw on the facility during 2010. We have no other significant credit facilities.

Global capital markets have been, and may continue to be, disrupted and volatile. The cost and availability of equity and debt funding has been and may continue to be adversely affected by illiquid capital and credit markets. Some lenders have reduced or, in some cases, ceased to provide funding to borrowers. We believe that we have adequate liquidity to meet our present needs. Continued turbulence in the United States and international financial markets, however, could adversely affect the cost and availability of financing to us in the future and limit our ability to acquire products, other assets, or businesses.

Cash provided by operations decreased by $15.0 million for the year ended December 31, 2010 to $11.5 million, compared to $26.6 million in 2009. The sum of our net income and certain non-cash expense items, such as reserves, depreciation and amortization, and share based compensation was approximately $27.6 million in 2010, compared to $24.7 million in 2009. The aggregate impact of changes in certain operating assets and liabilities was a cash outflow of $16.1 million in 2010 compared to a cash inflow of $1.9 million in 2009, in particular accounts receivable, inventories and accounts payable.

Cash used in investing activities was $17.9 million for the year ended December 31, 2010, compared to $51.8 million in 2009. We used $4.2 million and $2.6 million of cash to acquire property and equipment, during the years ended December 31, 2010 and 2009, respectively. We used $13.4 million of cash to acquire businesses during the year ended December 31, 2010 compared with $47.2 million during the year ended December 31, 2009. During the year ended December 31, 2010 we capitalized $344,000 of internal use software development costs compared with $1.0 million in 2009. In addition, we purchased and sold $975,000 of marketable securities in 2010 and purchased $965,000 of marketable securities during the year ended December 31, 2009.

Cash provided by financing activities was $1.7 million in the year ended December 31, 2010, compared to $489,000 in 2009. We received cash from sales of our stock pursuant to our stock awards plans and our employee stock purchase plan in the amount of $2.5 million and $1.1 million in the year ended December 31, 2010 and 2009, respectively. In 2010, we realized an excess tax benefit of $551,000 on the exercise of employee stock options that was recorded as an increase to stockholders’ equity. In 2009 our after-tax cost of stock-based compensation was $159,000 more than the tax benefit we received from those arrangements which was recorded as a decrease to stockholders’ equity. We repaid $1.4 million and $429,000 under term loan agreements in the years ended December 31, 2010 and 2009, respectively.

Comparison of 2009 and 2008

As of December 31, 2009, we had cash, cash equivalents, and short-term investments of $33.5 million, stockholders’ equity of $243.6 million, and working capital of $75.2 million, compared with cash and cash equivalents of $56.9 million, stockholders’ equity of $226.4 million, and working capital of $97.6 million as of December 31, 2008.

We believe that our current cash and cash equivalents and any cash generated from operations will be sufficient to meet our ongoing operating and capital requirements for the foreseeable future. We completed two acquisitions in 2009 including Alpine Biomed at the end of the third quarter, four acquisitions in 2008, one in 2007, and three in 2006. We intend to continue to acquire additional technologies, products, or businesses and these acquisitions could be significant. These actions would likely affect our future capital requirements and the adequacy of our available funds. In order to finance future acquisitions, we may be required to raise additional funds through public or private financings, strategic relationships or other arrangements. Any equity financing

45

may be dilutive to stockholders and debt financing, if available, may involve restrictive covenants and increase our cost of capital.

We have a $25 million revolving credit facility with Wells Fargo Bank, National Association (“Wells Fargo”). The revolving credit facility contains covenants, including covenants relating to liquidity and other financial measurements, and provides for events of default, including failure to pay any interest when due, failure to perform or observe covenants, bankruptcy or insolvency events and the occurrence of a material adverse effect. We have granted Wells Fargo a security interest in all of our assets. We did not draw on the facility during 2009. We have no other significant credit facilities.

Global capital markets have been, and may continue to be, disrupted and volatile. The cost and availability of equity and debt funding has been and may continue to be adversely affected by illiquid capital and credit markets. Some lenders have reduced or, in some cases, ceased to provide funding to borrowers. We believe that we have adequate liquidity to meet our present needs. Continued turbulence in the United States and international financial markets, however, could adversely affect the cost and availability of financing to us in the future and limit our ability to acquire products, other assets, or businesses.

Cash provided by operations increased by $14.7 million for the year ended December 31, 2009 to $26.6 million, compared to $11.8 million in 2008. The sum of our net income and certain non-cash expense items, such as reserves, depreciation and amortization, and share based compensation was approximately $24.7 million in 2009, compared to $26.4 million in 2008. The aggregate impact of changes in certain operating assets and liabilities was a cash inflow of $1.9 million in 2009 compared to a cash outflow of $14.6 million in 2008. In particular, while the carrying amounts of accounts receivable and inventory, exclusive of those items acquired in acquisitions, resulted in a use of cash of $10.3 million in 2008, they resulted in a source of cash of $662,000 in 2009.

Cash used in investing activities was $51.8 million for the year ended December 31, 2009, compared to $34.0 million in 2008. We used $2.6 million and $3.6 million of cash to acquire property and equipment, during the years ended December 31, 2009 and 2008, respectively. We used $47.2 million of cash to acquire businesses during the year ended December 31, 2009 compared with $29.0 million during the year ended December 31, 2008. During the year ended December 31, 2009 we recorded $1.0 million of internal use software development costs compared with $1.5 million in 2008. In addition, we purchased $965,000 of marketable securities in 2009 and purchased and sold $12.1 million of marketable securities during the year ended December 31, 2008.

Cash provided by financing activities was $489,000 in the year ended December 31, 2009, compared to $69.1 million in 2008. We raised an aggregate of $99.3 million through underwritten registered public offerings of our common stock in April and May 2008 with no similar transactions in 2009. We received cash from sales of our stock pursuant to our stock awards plans and our employee stock purchase plan in the amount of $1.1 million and $2.9 million in the year ended December 31, 2009 and 2008, respectively. In 2009 our after-tax cost of stock-based compensation was $159,000 more than the tax benefit we received from those arrangements, compared with an excess tax benefit of $2.2 million in 2008. These amounts were recorded as a decrease to stockholders’ equity in 2009 and as an increase to stockholders’ equity in 2008. We repaid $429,000 under term loan agreements in the year ended December 31, 2009. During the year ended December 31, 2008, we borrowed $6.0 million under our revolving line of credit and we repaid $25.2 million on our term loan agreements and $16.1 million on our revolving credit facility.

Future Liquidity

Our future liquidity and capital requirements will depend on numerous factors, including the:

• Amount and timing of revenue;

• Extent to which our existing and new products gain market acceptance;

46

• Extent to which we make acquisitions;

• Cost and timing of product development efforts and the success of these development efforts;

• Cost and timing of marketing and selling activities; and

• Availability of borrowings under line of credit arrangements and the availability of other means of financing.

Contractual Obligations

In the normal course of business, we enter into obligations and commitments that require future contractual payments. The commitments result primarily from firm, noncancellable purchase orders placed with contract vendors that manufacture some of the components used in our medical devices and related disposable supply products, as well as commitments for leased office equipment and term loans. The following table summarizes our contractual obligations and commercial commitments as of December 31, 2010 (in thousands):

	Payments Due by Period
	Total		Less than 1 Year		1-3 Years		4-5 Years		More than 5 Years
Unconditional purchase obligations	$	15,667	$	13,998	$	804	$	356	$	509
Operating lease obligations		5,261		1,882		2,591		788		—
Other contractual obligations		3,267		2,519		748		—		—
Long-term liabilities (including interest)		1,569		756		813		—		—
Total	$	25,764	$	19,155	$	4,956	$	1,144	$	509

Purchase obligations are defined as agreements to purchase goods or services that are enforceable and legally binding. Included in the purchase obligations category above are obligations related to purchase orders for inventory purchases under our standard terms and conditions and under negotiated agreements with vendors. We expect to receive consideration (products or services) for these purchase obligations. The purchase obligation amounts do not represent all anticipated purchases in the future, but represent only those items for which we are contractually obligated. The table above does not include obligations under employment agreements for services rendered in the ordinary course of business.

We are not able to reasonably estimate the timing of any potential payments for uncertain tax positions under ASC 740, Accounting for Uncertainty in Income Taxes – an interpretation of FASB Statement 109. As a result, the preceding table excludes any potential future payments related to our ASC 740 liability for uncertain tax positions. See Note 14 of our consolidated financial statements for further discussion on income taxes.

Quantitative and Qualitative Disclosures about Market Risk

We develop products in the U.S, Canada, Argentina, and Europe and sell those products into more than 100 countries throughout the world. As a result, our financial results could be affected by factors such as changes in foreign currency exchange rates or weak economic conditions in foreign markets. Most of our sales in Europe and Asia are denominated in U.S. Dollars and Euros and with the acquisitions of Xltek in November 2007 and Medix in 2010, a small portion of our sales are now denominated in Canadian dollars and Argentine pesos. As our sales in currencies other than the U.S. dollar increase, our exposure to foreign currency fluctuations may increase.

In addition, changes in exchange rates also may affect the end-user prices of our products compared to those of our foreign competitors, who may be selling their products based on local currency pricing. These factors may make our products less competitive in some countries.

47

If the U.S. Dollar uniformly increased or decreased in strength by 10% relative to the currencies in which our sales were denominated, our net income would have correspondingly increased or decreased by an immaterial amount for the year ended December 31, 2010. Our interest income is sensitive to changes in the general level of interest rates in the U.S. However, because current market conditions have resulted in historically low rates of return on our investments, a hypothetical decrease of 10% in market interest rates would not result in a material decrease in interest income earned on investments held at December 31, 2010.

When able, we invest excess cash in bank money-market funds or discrete short-term investments. The fair value of our short-term investments and cash equivalents (“investments”) is sensitive to changes in the general level of interest rates in the U.S., and the fair value of these investments will fall if market interest rates increase. However, since we generally have the ability to hold the investments to maturity, these declines in fair value may never be realized. If market interest rates were to increase by 10% from levels at December 31, 2010, the fair value of our investments would decline by an immaterial amount.

All of the potential changes noted above are based on sensitivity analyses performed on our financial position as of December 31, 2010. Actual results may differ as our analysis of the effects of changes in interest rates does not account for, among other things, sales of securities prior to maturity and repurchase of replacement securities, the change in mix or quality of the investments in the portfolio, and changes in the relationship between short-term and long-term interest rates.

Off-Balance Sheet Arrangements

Under our bylaws, we have agreed to indemnify our officers and directors for certain events or occurrences arising as a result of the officer or director’s serving in such capacity. We have a directors and officers liability insurance policy that limits our exposure and enables us to recover a portion of any future amounts paid resulting from the indemnification of our officers and directors. In addition, we enter into indemnification agreements with other parties in the ordinary course of business. In some cases we have obtained liability insurance providing coverage that limits our exposure for these other indemnified matters. We have not incurred material costs to defend lawsuits or settle claims related to these indemnification agreements. We believe the estimated fair value of these indemnification agreements is minimal and have not recorded a liability for these agreements as of December 31, 2010. We had no other off-balance sheet arrangements during any of fiscal 2010, 2009 or 2008 that had, or are reasonably likely to have, a material effect on our consolidated financial condition, results of operations, or liquidity.

Recent Accounting Pronouncements

See Note 1—Organization and Significant Accounting Policies to the Consolidated Financial Statements contained herein for a full description of recent accounting pronouncements including the respective expected dates of adoption and effects on results of our operations and financial condition.

48

Cautionary Information Regarding Forward Looking Statements

This report contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934 about Natus Medical Incorporated. These statements include, among other things, statements concerning our expectations, beliefs, plans, intentions, future operations, financial condition and prospects, and business strategies. The words “may,” “will,” “continue,” “estimate,” “project,” “intend,” “believe,” “expect,” “anticipate,” and other similar expressions generally identify forward-looking statements. Forward-looking statements in this Item 7 include, but are not limited to, statements regarding the following: our ability to capitalize on improving market conditions, the sufficiency of our current cash, cash equivalents and short-term investment balances, and any cash generated from operations to meet our ongoing operating and capital requirements for the foreseeable future, and our intent to acquire additional technologies, products or businesses.

Forward-looking statements are not guarantees of future performance and are subject to substantial risks and uncertainties that could cause the actual results predicted in the forward-looking statements as well as our future financial condition and results of operations to differ materially from our historical results or currently anticipated results. Investors should carefully review the information contained under the caption “Risk Factors” contained in Item 1A of this report for a description of risks and uncertainties. All forward-looking statements are based on information available to us on the date hereof, and we assume no obligation to update forward-looking statements.

ITEM 7A. Quantitative and Qualitative Disclosures About Market Risk

The information required by this Item is set forth in the section entitled Management’s Discussion and Analysis of Financial Condition and Results of Operations—Quantitative and Qualitative Disclosures About Market Risk, and is incorporated by reference in this section.

ITEM 8. Financial Statements and Supplementary Data

The Consolidated Financial Statements and Supplementary Data required by this Item are set forth where indicated in Item 15 of this report.

49

Selected Quarterly Financial Data (Unaudited)

The following table presents our operating results for each of the eight quarters in the period ending December 31, 2010. The information for each of these quarters is unaudited and has been prepared on the same basis as our audited financial statements appearing elsewhere in this report. As discussed in Note 20, Immaterial Corrections to Prior Period Financial Statements in the Notes to Consolidated Financial Statements of our Consolidated Financial Statements contained herein, subsequent to the issuance of our consolidated financial statements for the fiscal year ended December 31, 2009 and our quarterly consolidated financial statements for the quarter ended September 30, 2010, we discovered immaterial errors in previously issued financial statements. These errors were corrected for all quarters and years that were affected. The quarterly information presented below reflects the correction of these errors. The impact of the errors was immaterial to all of the period presented.

In the opinion of our management, all necessary adjustments, consisting only of normal recurring adjustments, other than the correction discussed in the preceding paragraph, have been included to present fairly the unaudited quarterly results when read in conjunction with our audited consolidated financial statements and the related notes appearing elsewhere in this report. These operating results are not necessarily indicative of the results of any future period.

	Quarters Ended
	Dec. 31, 2010			Sept. 30, 2010			June 30, 2010			March 31, 2010			Dec. 31, 2009			Sept. 30, 2009			June 30, 2009			March 31, 2009
	(in thousands, except per share)
Revenue	$	63,170		$	53,179		$	53,031		$	49,275		$	51,449		$	44,251		$	37,263		$	33,462
Cost of revenue		25,998			21,757			21,532			19,411			21,860			17,617			13,772			12,828
Gross profit		37,172			31,422			31,499			29,864			29,589			26,634			23,491			20,634
Gross profit percentage		58.8	%		59.1	%		59.4	%		60.6	%		57.5	%		60.2	%		63.0	%		61.7	%
Operating expenses:
Marketing and selling		14,523			12,817			13,553			13,964			13,298			11,661			10,171			10,174
Research and development		6,095			4,820			5,238			5,130			4,878			4,176			3,955			3,723
General and administrative		9,111			8,074			7,791			11,010			6,652			5,527			5,280			5,520
Total operating expenses		29,729			25,711			26,582			30,104			24,828			21,364			19,406			19,417
Income (loss) from operations		7,443			5,711			4,917			(240	)		4,761			5,270			4,085			1,217
Other income (expense), net		(127	)		(176	)		240			(55	)		1,166			71			387			126
Income (loss) before provision for income tax		7,316			5,535			5,157			(295	)		5,927			5,341			4,472			1,343
Provision for income tax		2,067			1,898			1,793			36			1,987			1,736			1,495			483
Net income (loss)	$	5,249		$	3,637		$	3,364		$	(331	)	$	3,940		$	3,605		$	2,977		$	860
Earnings (loss) per share:
Basic	$	0.19		$	0.12		$	0.12		$	(0.01	)	$	0.14		$	0.13		$	0.11		$	0.03
Diluted	$	0.18		$	0.12		$	0.12		$	(0.01	)	$	0.14		$	0.13		$	0.10		$	0.03
Weighted average shares used in the calculation of net earnings per share:
Basic		28,303			28,212			27,809			27,829			27,686			27,669			27,644			27,606
Diluted		29,297			29,261			29,110			27,829			28,769			28,668			28,276			28,136
Impact of error corrections:
Net Income
As previously reported		—		$	3,743		$	3,105		$	(303	)	$	4,287		$	3,669		$	2,336		$	787
As corrected		—		$	3,637		$	3,364		$	(331	)	$	3,940		$	3,605		$	2,977		$	860
Diluted earnings (loss) per share
As previously reported		—		$	0.12		$	0.12		$	(0.01	)	$	0.15		$	0.14		$	0.08		$	0.03
As corrected		—		$	0.12		$	0.12		$	(0.01	)	$	0.14		$	0.13		$	0.10		$	0.03

50

We acquired Medix in October 2010, Alpine Biomed in September 2009, and Hawaii Medical in July 2009. Results of operations of each of the acquired entities are included in the above table from the date of acquisition forward.

ITEM 9A. Controls and Procedures

Evaluation of Disclosure Controls and Procedures

Under the rules of the Securities and Exchange Commission, “disclosure controls and procedures” are controls and other procedures that are designed to ensure that information required to be disclosed in the reports that we file or submit under the Securities Exchange Act of 1934 is recorded, processed, summarized and reported within the time periods specified in the rules and forms of the Securities and Exchange Commission. Disclosure controls and procedures include, “without limitation, controls and procedures designed to ensure that information required to be disclosed by us in our reports that we file or submit under the Securities Exchange Act of 1934 is accumulated and communicated to our management, including our chief executive officer and chief financial officer, as appropriate, to allow timely decisions regarding required disclosure.

Our management, with the participation of our chief executive officer and our chief financial officer, has evaluated the effectiveness of our disclosure controls and procedures as of December 31, 2010. Our chief executive officer and chief financial officer determined that as of December 31, 2010 our disclosure controls and procedures were effective for the purpose set forth above.

Internal Control Over Financial Reporting

(a) Management’s Report on Internal Control Over Financial Reporting

Our management is responsible for establishing and maintaining adequate internal control over financial reporting as defined in Rule 13a-15-(f) promulgated under the Securities Exchange Act of 1934. Under the supervision and with the participation of our management, including our principal executive officer and our principal financial officer, we assessed the effectiveness of our internal control over financial reporting as of December 31, 2010. In making this assessment, our management used the criteria set forth by the Committee of Sponsoring Organizations of the Treadway Commission (COSO) in the Internal Control-Integrated Framework. Our management has concluded that, as of December 31, 2010, our internal control over financial reporting is effective based on these criteria.

We acquired Medix Industrial y Commercial S.A. (“Medix) in October 2010 and as permitted by SEC guidance, we excluded from our assessment of the effectiveness of our internal control over financial reporting as of December 31, 2010, the internal control over financial reporting of this entity. Total assets including goodwill and intangible assets related to Medix of $30.2 million as of December 31, 2010, and revenue of $7.1 million for the period from the date of acquisition to December 31, 2010, were included in our consolidated financial statements as of and for the year ended December 31, 2010. Our assessment of our internal control over financial reporting excluded an evaluation of the internal control over financial reporting of this entity as of December 31, 2010.

Our independent registered public accounting firm, Deloitte & Touche LLP. have audited the consolidated financial statements and financial statement schedule included in this annual report. They also audited the effectiveness of our internal control over financial reporting as of December 31, 2010 as stated in their report included in this annual report.

(b) Attestation Report of the Independent Registered Public Accounting Firm

51

REPORT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM

To the Board of Directors and Stockholders of Natus Medical Incorporated

San Carlos, California

We have audited the internal control over financial reporting of Natus Medical Incorporated and subsidiaries (the “Company”) as of December 31, 2010, based on criteria established in Internal Control—Integrated Framework issued by the Committee of Sponsoring Organizations of the Treadway Commission. As described in Management’s Report on Internal Control Over Financial Reporting, management excluded from its assessment the internal control over financial reporting of Medix I.C.S.A. (“Medix”) which was acquired on October 12, 2010, whose financial statements constitute 10% of total assets, 5% of net assets, 3% of revenues, and 2% of net income of the consolidated financial statement amounts as of and for the year ended December 31, 2010. Accordingly, our audit did not include the internal control over financial reporting at Medix. The Company’s management is responsible for maintaining effective internal control over financial reporting and for its assessment of the effectiveness of internal control over financial reporting, included in the accompanying Management’s Report on Internal Control over Financial Reporting. Our responsibility is to express an opinion on the Company’s internal control over financial reporting based on our audit.

We conducted our audit in accordance with the standards of the Public Company Accounting Oversight Board (United States). Those standards require that we plan and perform the audit to obtain reasonable assurance about whether effective internal control over financial reporting was maintained in all material respects. Our audit included obtaining an understanding of internal control over financial reporting, assessing the risk that a material weakness exists, testing and evaluating the design and operating effectiveness of internal control based on the assessed risk, and performing such other procedures as we considered necessary in the circumstances. We believe that our audit provides a reasonable basis for our opinion.

A company’s internal control over financial reporting is a process designed by, or under the supervision of, the Company’s principal executive and principal financial officers, or persons performing similar functions, and effected by the Company’s board of directors, management, and other personnel to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles. A company’s internal control over financial reporting includes those policies and procedures that (1) pertain to the maintenance of records that, in reasonable detail, accurately and fairly reflect the transactions and dispositions of the assets of the Company; (2) provide reasonable assurance that transactions are recorded as necessary to permit preparation of financial statements in accordance with generally accepted accounting principles, and that receipts and expenditures of the Company are being made only in accordance with authorizations of management and directors of the Company; and (3) provide reasonable assurance regarding prevention or timely detection of unauthorized acquisition, use, or disposition of the Company’s assets that could have a material effect on the financial statements.

Because of the inherent limitations of internal control over financial reporting, including the possibility of collusion or improper management override of controls, material misstatements due to error or fraud may not be prevented or detected on a timely basis. Also, projections of any evaluation of the effectiveness of the internal control over financial reporting to future periods are subject to the risk that the controls may become inadequate because of changes in conditions, or that the degree of compliance with the policies or procedures may deteriorate.

In our opinion, the Company maintained, in all material respects, effective internal control over financial reporting as of December 31, 2010, based on the criteria established in Internal Control—Integrated Framework issued by the Committee of Sponsoring Organizations of the Treadway Commission.

We have also audited, in accordance with the standards of the Public Company Accounting Oversight Board (United States), the consolidated financial statements and the financial statement schedule at Item 15(a)(2) of this annual report as of and for the year ended December 31, 2010 of the Company and our report dated March 14, 2011 expressed an unqualified opinion on those financial statements and the financial statement schedule and included an explanatory paragraph relating to the adoption of Accounting Standards Codification Topic 805, Business Combinations (formerly SFAS 141R).

/s/ DELOITTE & TOUCHE LLP

San Francisco, CA

March 14, 2011

52

(c) Changes in Internal Control over Financial Reporting

There was no change in internal control over financial reporting that occurred during the fourth quarter of 2010 that has materially affected, or is reasonably likely to materially affect, our internal control over financial reporting.

53

PART III

This Part incorporates certain information from our definitive Proxy Statement for our 2011 Annual Meeting of Stockholders that is to be filed with the Securities and Exchange Commission not later than 120 days after the end of our fiscal year covered by this Report on Form 10-K.

ITEM 10. Directors, Executive Officers, and Corporate Governance

The information required by this Item concerning our directors is incorporated by reference to our Proxy Statement including but not necessarily limited to the section entitled Election of Directors. Certain information required by this item concerning executive officers is set forth in Part I of this Report in Business—Executive Officers. The information required by this item concerning compliance with Section 16(a) of the Exchange Act of 1934, as amended (the “Exchange Act”), is incorporated by reference to the Proxy Statement including but not necessarily limited to the section entitled Section 16(a) Beneficial Ownership Reporting Compliance.

Audit Committee and Audit Committee Financial Expert

The members of the Audit Committee of our Board of Directors are Ken Ludlum, Robert A. Gunst, and Mark D. Michael. Our Board of Directors has determined that Ken Ludlum is an audit committee financial expert as defined in Item 407(d) of Regulation S-K. All of the members of our audit committee are considered “independent” as the term is used in Item 7(d)(3)(iv) of Schedule 14A under the Exchange Act.

Code of Conduct and Ethics

We have a code of conduct and ethics that applies to all of our employees, including our principal executive officer, principal financial officer, and principal accounting officer or controller. This code of conduct and ethics is posted on our internet website. The internet address for our website is www.natus.com, and the code of conduct and ethics may be found in the “Governance” section of our “Investor” webpage.

We intend to satisfy the disclosure requirement under Item 10 of Form 8-K regarding certain amendments to, or waivers from, provisions of this code of conduct and ethics by posting such information on our website, at the address and location specified above, or as otherwise required by The Nasdaq Stock Market.

The information required by this Item concerning our corporate governance is incorporated by reference to our Proxy Statement including but not necessarily limited to the section entitled Corporate Governance.

ITEM 11. Executive Compensation

The information required by this Item is incorporated by reference to our 2011 Proxy Statement including but not necessarily limited to the section entitled Executive Compensation.

ITEM 12. Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters

Equity Compensation Plan Information

The following table provides information as of December 31, 2010 about our common stock that may be issued upon the exercise of options, warrants, awards, and rights under all of our existing equity compensation plans, including the 1991 Stock Option Plan, 2000 Stock Awards Plan, 2000 Supplemental Stock Option Plan, 2000 Director Option Plan, and 2000 Employee Stock Purchase Plan, each as amended.

54

Plan Category	Number of Securities to be Issued upon Exercise of Outstanding Options, Warrants, Awards and Rights		Weighted-Average Exercise Price of Outstanding Options, Warrants Awards and Rights		Number of Securities Remaining Available for Future Issuance under Equity Compensation Plans (excluding securities reflected in the first column)
Equity compensation plans approved by security holders		3,710,257	$	10.94		7,581,417
Equity compensation plans not approved by security holders		—		—		—
Total		3,710,257	$	10.94		7,581,417

Of the shares of common stock to be issued upon exercise of outstanding options, warrants, awards and rights, 3,000,000 shares related to outstanding options under our 1991 Stock Option Plan, 3,330,957 shares related to outstanding options under our 2000 Stock Awards Plan, and 305,000 shares related to outstanding options under our 2000 Director Option Plan.

Of the shares of common stock remaining available for future issuance under equity compensation plans, 2,857,888 shares remained available for future issuance under our 2000 Stock Awards Plan, 4,212,387 shares remained available for future issuance under our 2000 Employee Stock Purchase Plan and 511,142 remained available for future issuance under the Director Option Plan. The 1991 Stock Option Plan and 2000 Supplemental Stock Option Plan were terminated as to new grants in July 2001. The number of shares reserved for issuance pursuant to our 2000 Stock Awards Plan is subject to an automatic increase on the first day of our fiscal year in an amount equal to the lesser of (i) 1,500,000 shares of common stock; (ii) 7% of our outstanding shares of common stock on the last day of the prior fiscal year; or (iii) an amount determined by our board of directors. The number of shares reserved for issuance pursuant to our 2000 Director Option Plan is subject to an automatic increase on the first day of our fiscal year in an amount equal to the lesser of (i) 100,000 shares of common stock; (ii) one-half of one percent of our outstanding shares of common stock on the last day of the prior fiscal year; or (iii) an amount determined by our board of directors. The number of shares reserved for issuance pursuant to our 2000 Employee Stock Purchase Plan is subject to an automatic increase on the first day of our fiscal year in an amount equal to the lesser of (i) 650,000 shares of common stock; (ii) 4% of our outstanding shares of common stock on the last day of the prior fiscal year; or (iii) an amount determined by our board of directors. We are unable to ascertain with specificity the number of securities to be issued upon exercise of outstanding rights under, or the weighted average exercise price of outstanding rights under, the 2000 Employee Stock Purchase Plan.

Pursuant to their terms, the 2000 Stock Awards Plan, 2000 Director Plan, and 2000 Employee Stock Purchase Plan will terminate in July 2011.

Additional information required by this Item concerning ownership of our securities by certain beneficial owners and management is incorporated by reference to our 2011 Proxy Statement including but not necessarily limited to the section entitled Beneficial Ownership of Common Stock. Information concerning securities authorized for issuance under equity compensation plans is incorporated by reference to our 2011 Proxy Statement including but not necessarily limited to the section entitled Equity Compensation Plan Information.

ITEM 13. Certain Relationships and Related Transactions, and Director Independence

The information required by this Item is incorporated by reference to the 2011 Proxy Statement including but not necessarily limited to the section entitled Corporate Governance Principles and Board Matters—Certain Relationships and Policies on Related Party Transactions.

ITEM 14. Principal Accountant Fees and Services

The information required by this Item is incorporated by reference to the 2011 Proxy Statement including but not necessarily limited to the section entitled Audit Fees.

55

PART IV

ITEM 15. Exhibits, Financial Statement Schedules

(a)(1) Financial Statements

The following consolidated financial statements are filed as part of this Report:

	Page
Report of Independent Registered Public Accounting Firm		F-2
Consolidated Balance Sheets		F-3
Consolidated Statements of Operations		F-4
Consolidated Statements of Stockholders’ Equity and Comprehensive Income		F-5
Consolidated Statements of Cash Flows		F-6
Notes to Consolidated Financial Statements		F-7

(a)(2) Financial Statement Schedule

SCHEDULE II: VALUATION AND QUALIFYING ACCOUNTS

For the years ended December 31, 2010, 2009 and 2008

(in thousands)

	Balance at Beginning of Period		Assumed Through Acquisitions		Additions Charged to Expense		Deductions			Balance at End of Period
Year ended December 31, 2010
Allowance for doubtful accounts	$	1,515	$	—	$	592	$	(464	)	$	1,643
Accrued warranty costs	$	694	$	43	$	331	$	(372	)	$	696
Year ended December 31, 2009
Allowance for doubtful accounts	$	1,056	$	—	$	1,207	$	(748	)	$	1,515
Accrued warranty costs	$	1,076	$	44	$	542	$	(968	)	$	694
Year ended December 31, 2008
Allowance for doubtful accounts	$	993	$	—	$	304	$	(241	)	$	1,056
Accrued warranty costs	$	1,000	$	75	$	1,122	$	(1,121	)	$	1,076

(a)(3) Exhibits

		Incorporated By Reference
Exhibit No.	Exhibit	Filing		Exhibit No.	File No.		File Date
2.1	Share Purchase Agreement dated October 12, 2010 by and between Natus Medical Incorporated, and Medix I.C.S.A.
3.1	Natus Medical Incorporated Amended and Restated Certificate of Incorporation		S-1	3.1.1		333-44138		08/18/2000
3.2	Natus Medical Incorporated Certificate of Designation of Rights, Preferences and Privileges of Series A Participating Preferred Stock		8-A	3.1.2		000-33001		09/06/2002
3.3	Bylaws of Natus Medical Incorporated		8-K	3.1		000-33001		06/18/2008

56

		Incorporated By Reference
Exhibit No.	Exhibit	Filing		Exhibit No.	File No.		File Date
4.1	Amended and Restated Preferred Stock Rights Agreement, dated as of October 8, 2002, between Natus Medical Incorporated and Equiserve Trust Company, N.A., including the form of Rights Certificate and Summary of Rights attached thereto as Exhibits B and C, respectively		8-A	4.1		000-33001		10/08/2002
4.2	Amendment No. 1 to the Amended and Restated Preferred Stock Rights Agreement dated as of February 14, 2003 between Natus Medical Incorporated and Equiserve Trust Company, N.A.		8-A	4.2		000-33001		02/25/2003
4.3	Amendment No. 2 to the Amended and Restated Preferred Stock Rights Agreement dated as of March 15, 2005 between Natus Medical Incorporated and Equiserve Trust Company, N.A.		8-K	99.1		000-33001		03/15/2005
4.4	Amendment No. 3 to the Amended and Restated Preferred Stock Rights Agreement dated as of August 17, 2006 between Natus Medical Incorporated and Wells Fargo Bank, National Association		8-K	99.01		000-33001		08/17/2006
4.5	Registration Rights Agreement dated as of April 9, 2008 by and among Natus Medical Incorporated and D3 Family Funds		8-K	4.01		000-33001		04/09/2008
10.1	Form of Indemnification Agreement between Natus Medical Incorporated and each of its directors and officers		S-1	10.1		333-44138		08/18/2000
10.2*	Natus Medical Incorporated Amended and Restated 1991 Stock Option Plan		S-1	10.2		333-44138		08/18/2000
10.2.1*	Form of Option Agreement under the Amended and Restated 1991 Stock Option Plan		S-1	10.2.1		333-44138		08/18/2000
10.3*	Natus Medical Incorporated Amended and Restated 2000 Stock Awards Plan		8-K	10.1		000-33001		01/04/2006
10.3.1*	Form of Option Agreement under the Amended and Restated 2000 Stock Awards Plan		S-1	10.3.1		333-44138		08/18/2000
10.3.2*	Form of Restricted Stock Purchase Agreement under the Amended and Restated 2000 Stock Awards Plan		10-Q	10.2		000-33001		08/09/2006
10.3.3*	Form of Restricted Stock Unit Agreement under the Amended and Restated 2000 Stock Awards Plan		10-K	10.3.3		000-33001		03/14/2008
10.4*	Natus Medical Incorporated 2000 Director Option Plan		10-Q	10.02		000-33001		05/09/2008
10.4.1*	Form of Option Agreement under the 2000 Director Option Plan		S-1	10.4.1		333-44138		08/18/2000

57

		Incorporated By Reference
Exhibit No.	Exhibit	Filing		Exhibit No.	File No.		File Date
10.5*	Natus Medical Incorporated 2000 Employee Stock Purchase Plan and form of subscription agreement thereunder		8-K	10.2		000-33001		01/04/2006
10.6	Lease Agreement dated August 24, 1998 between Natus Medical Incorporated and San Carlos Co-Tenancy		S-1	10.8		333-44138		08/18/2000
10.7	Amendment to Lease Agreement dated August 24, 1998 between Natus Medical Incorporated and San Carlos Co-Tenancy		10-K	10.8.1		000-33001		03/27/2003
10.8	6th Amendment to Lease Agreement dated July 1, 2005 between Natus Medical Incorporated and San Carlos Co-Tenancy		10-K	10.10		000-33001		03/16/2006
10.9*	Natus Medical Incorporated 2000 Supplemental Stock Option Plan		S-1	10.15		333-44138		08/18/2000
10.9.1*	Form of Option Agreement for 2000 Supplemental Stock Option Plan		S-1	10.15.1		333-44138		08/18/2000
10.10*	Form of Employment Agreement between Natus Medical Incorporated and each of its executive officers		10-K	10.1		000-33001		03/10/2009
10.11*	Amended Employment Agreement between Natus Medical Incorporated and James B. Hawkins dated April 25, 2008		8-K	99.1		000-33001		04/29/2008
10.12	Amended and Restated Credit Agreement dated November 28, 2007 by and between Natus Medical Incorporated and Wells Fargo Bank, National Association		8-K	10.1		000-33001		12/03/2007
10.13	Security Agreement dated November 28, 2007 by Natus Medical Incorporated in favor of Wells Fargo Bank, National Association		8-K	10.2		000-33001		12/03/2007
10.14	First Amendment to Amended and Restated Credit Agreement between Natus Medical Incorporated and Wells Fargo Bank, National Association		8-K	10.1		000-33001		08/06/2008
10.15	Second Amendment to Amended and Restated Credit Agreement between Natus Medical Incorporated and Wells Fargo Bank, National Association		8-K	10.1		000-33001		09/05/2008
10.16	Third Amendment to Amended and Restated Credit Agreement between Natus Medical Incorporated and Wells Fargo Bank, National Association		10-K	10.16		000-33001		03/10/2009
10.17	Amended and Restated Security Agreement dated February 19, 2009 in favor of Wells Fargo Bank, National Association		10-K	10.17		000-33001		03/10/2009

58

		Incorporated By Reference
Exhibit No.	Exhibit	Filing		Exhibit No.	File No.		File Date
10.18	Fourth Amendment to Amended and Restated Credit Agreement between Natus Medical Incorporated and Wells Fargo Bank, National Association		10-Q	10.1		000-33001		08/07/2009
10.19	Fifth Amendment to Amended and Restated Credit Agreement between Natus Medical Incorporated and Wells Fargo Bank, National Association		10-Q	10.1		000-33001		09/11/2009
10.20	Sixth Amendment to Amended and Restated Credit Agreement between Natus Medical Incorporated and Wells Fargo Bank, National Association		10-Q	10.1		000-33001		11/23/2009
10.21	Seventh Amendment to Amended and Restated Credit Agreement between Natus Medical Incorporated and Wells Fargo Bank, National Association		10-K	10.21		000-33001		03/15/2010
10.22	Second Amended and Restated Credit Agreement dated as of April 22, 2010 between Natus Medical Incorporated and Wells Fargo Bank, National Association		8-K	10.1		000-33001		04/27/2010
21.1	Subsidiaries of the Registrant
23.1	Consent of Independent Registered Public Accounting Firm
24.1	Power of Attorney
31.1	Certification of Principal Executive Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002
31.2	Certification of Principal Financial Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002
32.1	Certification of Principal Executive Officer and Principal Financial Officer pursuant to 18 U.S.C. Section 1350 as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002

* Indicates a management contract or compensatory plan or arrangement

(b) Exhibits

See Item 15(a)(3) above.

(c) Financial Statement Schedules

See Item 15(a)(2) above.

59

SIGNATURES

Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, the registrant has duly caused this Annual Report on Form 10-K to be signed on its behalf by the undersigned thereunto duly authorized.

NATUS MEDICAL INCORPORATED
By	/s/    James B. Hawkins
	James B. Hawkins President and Chief Executive Officer
By	/s/    Steven J. Murphy
	Steven J. Murphy Vice President Finance and Chief Financial Officer

Dated: March 14, 2011

POWER OF ATTORNEY

KNOW ALL PERSONS BY THESE PRESENTS, that each person whose signature appears below hereby constitutes and appoints James B. Hawkins and Steven J. Murphy and each of them acting individually, as his or her attorney-in-fact, each with full power of substitution, for him or her in any and all capacities, to sign any and all amendments to this Report on Form 10-K, and to file the same, with all exhibits thereto and other documents in connection therewith, with the Securities and Exchange Commission.

Pursuant to the requirements of the Securities Exchange Act of 1934, this Annual Report on Form 10-K has been signed by the following persons on behalf of the registrant and in the capacity and dates indicated:

Signature	Title	Date
/s/    James B. Hawkins         (James B. Hawkins)	Chief Executive Officer and Director (Principal Executive Officer)	March 14, 2011
/s/    Steven J. Murphy         (Steven J. Murphy)	Vice President Finance & Chief Financial Officer (Principal Financial and Accounting Officer)	March 14, 2011
/s/    Robert A. Gunst         (Robert A. Gunst)	Chairman of the Board of Directors	March 14, 2011
/s/    Doris Engibous         (Doris Engibous)	Director	March 14, 2011
/s/    Ken Ludlum         (Ken Ludlum)	Director	March 14, 2011
/s/    Mark D. Michael         (Mark D. Michael)	Director	March 14, 2011
/s/    William M. Moore         (William M. Moore)	Director	March 14, 2011

60

NATUS MEDICAL INCORPORATED

INDEX TO CONSOLIDATED FINANCIAL STATEMENTS

	Page
Report of Independent Registered Public Accounting Firm		F-2
Consolidated Balance Sheets		F-3
Consolidated Statements of Operations		F-4
Consolidated Statements of Stockholders’ Equity and Comprehensive Income		F-5
Consolidated Statements of Cash Flows		F-6
Notes to Consolidated Financial Statements		F-7

F-1

REPORT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM

To the Board of Directors and Stockholders of Natus Medical Incorporated

San Carlos, California

We have audited the accompanying consolidated balance sheets of Natus Medical Incorporated and subsidiaries (the “Company”) as of December 31, 2010 and 2009, and the related consolidated statements of operations, stockholders’ equity and comprehensive income, and cash flows for each of the three years in the period ended December 31, 2010. Our audits also included the financial statement schedule listed in the Index at Item 15(a)(2). These financial statements and the financial statement schedule are the responsibility of the Company’s management. Our responsibility is to express an opinion on these financial statements based on our audits.

We conducted our audits in accordance with the standards of the Public Company Accounting Oversight Board (United States). Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial statements are free of material misstatement. An audit includes examining, on a test basis, evidence supporting the amounts and disclosures in the financial statements. An audit also includes assessing the accounting principles used and significant estimates made by management, as well as evaluating the overall financial statement presentation. We believe that our audits provide a reasonable basis for our opinion.

In our opinion, such consolidated financial statements present fairly, in all material respects, the financial position of Natus Medical Incorporated and subsidiaries at December 31, 2010 and 2009, and the results of their operations and their cash flows for each of the three years in the period ended December 31, 2010, in conformity with accounting principles generally accepted in the United States of America. Also, in our opinion such financial statement schedule, when considered in relation to the basic consolidated financial statements taken as a whole, present fairly, in all material respects, the information set forth therein.

As discussed in Note 1 to the consolidated financial statements, effective January 1, 2009, the Company adopted Accounting Standards Codification 805, Business Combinations (formerly SFAS 141R).

We have also audited, in accordance with the standards of the Public Company Accounting Oversight Board (United States), the Company’s internal control over financial reporting as of December 31, 2010, based on the criteria established in Internal Control—Integrated Framework issued by the Committee of Sponsoring Organizations of the Treadway Commission and our report dated March 14, 2011, expressed an unqualified opinion on the Company’s internal control over financial reporting.

/s/ Deloitte & Touche LLP

San Francisco, CA

March 14, 2011

F-2

NATUS MEDICAL INCORPORATED

CONSOLIDATED BALANCE SHEETS

(In thousands, except share amounts)

	December 31,
	2010			2009
ASSETS
Current assets:
Cash and cash equivalents	$	28,383		$	32,586
Short-term investments		1,005			965
Accounts receivable, net of allowance for doubtful accounts of $1,643 and $1,515		54,782			43,750
Inventories		37,627			23,089
Prepaid expenses and other current assets		4,954			3,825
Deferred income tax		2,192			4,166
Total current assets		128,943			108,381
Property and equipment, net		23,408			14,066
Intangible assets		69,428			70,144
Goodwill		96,819			92,258
Other assets		12,449			7,241
Total assets	$	331,047		$	292,090
LIABILITIES AND STOCKHOLDERS’ EQUITY
Current liabilities:
Accounts payable	$	21,684		$	13,982
Current portion of long-term debt		156			178
Accrued liabilities		18,437			14,513
Deferred revenue		4,744			4,501
Total current liabilities		45,021			33,174
Long-term liabilities
Other liabilities		8,076			7,575
Long-term debt		737			931
Deferred income tax		13,958			6,853
Total liabilities		67,792			48,533
Commitments and contingencies (Note 18)
Stockholders’ equity:
Common stock, $0.001 par value; 120,000,000 shares authorized; shares issued and outstanding: 28,922,667 in 2010 and 28,414,229 in 2009		258,872			250,374
Retained earnings		18,057			6,138
Accumulated other comprehensive (loss)		(13,674	)		(12,955	)
Total stockholders’ equity		263,255			243,557
Total liabilities and stockholders’ equity	$	331,047		$	292,090

The accompanying notes are an integral part of these consolidated financial statements.

F-3

NATUS MEDICAL INCORPORATED

CONSOLIDATED STATEMENTS OF OPERATIONS

(In thousands, except per share amounts)

	Years Ended December 31,
	2010			2009		2008
Revenue	$	218,655		$	166,425	$	161,831
Cost of revenue		88,698			66,077		61,332
Gross profit		129,957			100,348		100,499
Operating expenses:
Marketing and selling		54,857			45,304		39,998
Research and development		21,283			16,732		15,520
General and administrative		35,986			22,979		19,808
Total operating expenses		112,126			85,015		75,326
Income from operations		17,831			15,333		25,173
Other income (expense), net		(118	)		1,750		2,142
Income before provision for income tax		17,713			17,083		27,315
Provision for income tax		5,794			5,701		10,033
Net income	$	11,919		$	11,382	$	17,282
Net income per share:
Basic	$	0.42		$	0.41	$	0.68
Diluted	$	0.41		$	0.40	$	0.65
Weighted average shares used in the calculation of net income per share:
Basic		28,092			27,651		25,278
Diluted		29,217			28,476		26,557

The accompanying notes are an integral part of these consolidated financial statements.

F-4

NATUS MEDICAL INCORPORATED

CONSOLIDATED STATEMENTS OF STOCKHOLDERS’ EQUITY

AND COMPREHENSIVE INCOME

(In thousands, except share amounts)

	Common Stock					Retained Earnings / (Accumulated Deficit)			Accumulated Other Comprehensive Income (Loss)			Stockholders’ Equity			Comprehensive Income
	Shares		Amount
Balances, December 31, 2007		21,956,771	$	137,837		$	(22,526	)	$	696		$	116,007
Issuance of common stock		5,485,500		99,278									99,278
Tax benefit of option exercises				2,222									2,222
Issuance of restricted stock		143,334
Employee stock purchase plan		39,552		548									548
Compensation expense for stock options				2,995									2,995
Exercise of stock options		368,024		2,316									2,316
Foreign currency translation adjustment										(14,336	)		(14,436	)	$	(14,336	)
Net income							17,282						17,282			17,282
Comprehensive income															$	2,946
Balances, December 31, 2008		27,993,181		245,196			(5,244	)		(13,640	)		226,312
Tax expense of options exercise				(159	)								(159	)
Issuance of restricted stock		305,200
Employee stock purchase plan		81,624		729									729
Compensation expense for stock options				4,260									4,260
Exercise of stock options		34,224		348									348
Foreign currency translation adjustment										685			685		$	685
Net income							11,382						11,382			11,382
Comprehensive income															$	12,067
Balances, December 31, 2009		28,414,229		250,374			6,138			(12,955	)		243,557
Tax expense of options exercises				551									551
Vesting of restricted stock units		8,750		31									31
Issuance of restricted stock		209,600
Employee stock purchase plan		68,050		866									866
Compensation expense for stock options				5,399									5,399
Exercise of stock options		222,038		1,651									1,651
Foreign currency translation Adjustment										(719	)		(719	)	$	(719	)
Net income							11,919						11,919			11,919
Comprehensive income															$	11,200
Balances, December 31, 2010		28,922,667	$	258,872		$	18,057		$	(13,674	)	$	263,255

The accompanying notes are an integral part of these consolidated financial statements.

F-5

NATUS MEDICAL INCORPORATED

CONSOLIDATED STATEMENTS OF CASH FLOWS

(In thousands)

	Year Ended December 31,
	2010			2009			2008
Operating activities:
Net income	$	11,919		$	11,382		$	17,282
Adjustments to reconcile net income to net cash provided by operating activities:
Accounts receivable reserves		592			1,137			304
Excess tax (benefit)/expense on the exercise of stock options		(551	)		159			(2,222	)
Depreciation and amortization		9,156			7,884			6,764
Impairment of intangible assets		300			—			—
(Gain)/loss on disposal of property and equipment		452			(29	)		71
Warranty reserve		331			542			1,197
Change in fair value of contingent obligation		—			(600	)		—
Share-based compensation		5,399			4,260			2,995
Changes in operating assets and liabilities, net of assets and liabilities acquired in acquisitions:
Accounts receivable		(3,231	)		683			(8,336	)
Inventories		(8,181	)		25			(2,296	)
Other assets		(1,161	)		(34	)		1,734
Accounts payable		(5,478	)		457			(2,782	)
Accrued liabilities		(448	)		380			(2,657	)
Deferred revenue		723			(153	)		(1,296	)
Deferred taxes		1,704			495			1,044
Net cash provided by operating activities		11,526			26,588			11,802
Investing activities:
Acquisition of businesses, net of cash acquired		(13,415	)		(47,222	)		(28,996	)
Acquisition of property and equipment		(4,152	)		(2,609	)		(3,593	)
Acquisition of intangible assets		(344	)		(1,003	)		(1,451	)
Purchases of short-term investments		(975	)		(965	)		(12,120	)
Sales of short-term investments		975			—			12,120
Net cash used in investing activities		(17,911	)		(51,799	)		(34,040	)
Financing activities:
Proceeds from stock option exercises and ESPP		2,548			1,077			2,864
Proceeds from issuance of common stock, net of issuance cost		—			—			99,278
Excess tax benefit (expense) on the exercise of stock options		551			(159	)		2,222
Borrowing on credit facility		—			—			6,000
Payments on borrowings		(1,403	)		(429	)		(41,259	)
Net cash provided by financing activities		1,696			489			69,105
Exchange rate effect on cash and cash equivalents		486			393			(1,868	)
Net increase (decrease) in cash and equivalents		(4,203	)		(24,329	)		44,999
Cash and cash equivalents, beginning of year		32,586			56,915			11,916
Cash and cash equivalents, end of year	$	28,383		$	32,586		$	56,915
Supplemental disclosure of cash flow information:
Cash paid for interest	$	130		$	153		$	1,002
Cash paid for income taxes	$	5,050		$	957		$	5,519
Non-cash investing activities:
Acquisition-related earnout obligations included in accrued liabilities	$	—		$	—		$	1,347
Contingent earnout obligations classified as liabilities	$	2,000		$	—		$	—

The accompanying notes are an integral part of these consolidated financial statements.

F-6

NATUS MEDICAL INCORPORATED

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

Years Ended December 31, 2010, 2009 and 2008

1—ORGANIZATION AND SIGNIFICANT ACCOUNTING POLICIES

Organization

Natus Medical Incorporated (“Natus”, the “Company”, “we”, “our”) was incorporated in California in May 1987 and reincorporated in Delaware in August 2000. Natus is a leading provider of healthcare products used for the screening, detection, treatment, monitoring and tracking of common medical ailments in newborn care, hearing impairment, neurological dysfunction, epilepsy, sleep disorders, and balance and mobility disorders. Product offerings include computerized neurodiagnostic systems for audiology, neurology, polysomnography, and neonatology, as well as newborn care products such as hearing screening systems, phototherapy devices for the treatment of newborn jaundice, head-cooling products for the treatment of brain injury in newborns, incubators to control the newborn’s environment, and software systems for managing and tracking disorders and diseases for public health laboratories. The Company’s headquarters are in San Carlos, California.

We have completed a number of acquisitions since 2003, consisting of either the purchase of a company, substantially all of the assets of a company or individual products or product lines. Our significant acquisitions are as follows: Neometrics in 2003; Fischer-Zoth in 2004; Bio-logic, Deltamed, and Olympic in 2006; Xltek in 2007; Sonamed, Schwarzer Neurology, and Neurocom in 2008; Hawaii Medical and Alpine Biomed in 2009; and Medix in 2010.

Principles of Consolidation— The accompanying consolidated financial statements include the accounts of the Company and its wholly-owned subsidiaries. All intercompany accounts and transactions have been eliminated in consolidation.

Use of Estimates—The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America (U.S. GAAP) requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities in the consolidated financial statements and the reported amount of revenue and expenses during the reporting period. Such estimates include allowances for potentially uncollectible accounts receivable, valuation of inventory, intangible assets, goodwill, share-based compensation, deferred income taxes, reserves for warranty obligations, and the provision for income taxes. Actual results could differ from those estimates.

Revenue Recognition—Revenue, net of discounts, is recognized from sales of medical devices and supplies, including sales to distributors, when the following conditions have been met: a purchase order has been received, title has transferred, the selling price is fixed or determinable, and collection of the resulting receivable is reasonably assured. Terms of sale for most domestic sales are FOB origin, reflecting that title and risk of loss are assumed by the purchaser at the shipping point; however, terms of sale for some neurology, sleep-diagnostic, and head cooling systems are FOB destination, reflecting that title and risk of loss are assumed by the purchaser upon delivery. Terms of sales to international distributors are generally EXW, reflecting that goods are shipped “ex works,” in which title and risk of loss are assumed by the distributor at the shipping point.

We have historically applied the software revenue recognition rules as prescribed by Accounting Standards Codification (“ASC”) Subtopic 985-605 to sales of certain of our diagnostic neurology and hearing systems (“products containing embedded software”). In October 2009, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update No. (“ASU”) 2009-14, Certain Revenue Arrangements That Include Software Elements, which amended ASC Subtopic 985-605. This ASU removes tangible products containing software components and non-software components that function together to deliver the product’s essential functionality from the scope of the software revenue recognition rules. We adopted the provisions of ASU 2009-14 prospectively on January 1, 2010 for new or significantly modified revenue arrangements. The

F-7

NATUS MEDICAL INCORPORATED

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS—(Continued)

Years Ended December 31, 2010, 2009 and 2008

adoption did not have a significant impact on our revenue or results of operations for the year ended December 31, 2010. In the case of the Company’s products containing embedded software, we have determined that the hardware and software components function together to deliver the products’ essential functionality, and therefore, the revenue from the sale of these products no longer falls within the scope of the software revenue recognition rules. Our revenue recognition policies for sales of these products are now substantially the same as for our other tangible products.

Revenue from sales of certain of our products that remain within the scope of the software revenue recognition rules under ASC Subtopic 985-605 is not significant.

We previously accounted for arrangements with multiple deliverables under ASC Topic 605, where revenue was allocated to the deliverables based on vendor specific objective evidence (“VSOE”). In October 2009 the FASB issued ASU 2009-13, Multiple Deliverable Revenue Arrangements, which amends ASC Topic 605. We adopted the provisions of ASU 2009-13 prospectively on January 1, 2010 for new or significantly modified revenue arrangements. The adoption did not have a significant impact on our revenue or results of operations for the year ended December 31, 2010. Under the revenue recognition rules for tangible products as amended by ASU 2009-13, we now allocate revenue from arrangements with multiple deliverables to each of the deliverables based upon their relative selling prices as determined by a selling-price hierarchy. A deliverable in an arrangement qualifies as a separate unit of accounting if the delivered item has value to the customer on a stand-alone basis. The principal deliverables in our multiple deliverable arrangements that qualify as separate units of accounting consist of (i) sales of medical devices and supplies, (ii) installation services, (iii) extended service and maintenance agreements, and (iv) upgrades to embedded software.

The new rules establish a hierarchy to determine the selling price to be used for allocating revenue to deliverables as follows: (i) vendor-specific objective evidence of fair value (“VSOE”), (ii) third-party evidence of selling price (“TPE”), and (iii) best estimate of the selling price (“ESP”). VSOE of fair value is defined as the price charged when the same element is sold separately, or if the element has not yet been sold separately, the price for the element established by management having the relevant authority when it is probable that the price will not change before the introduction of the element into the marketplace. VSOE generally exists only when we sell the deliverable separately and is the price actually charged for that deliverable. We have previously established VSOE for substantially all of the deliverables in our multiple element arrangements; however, in the future we may rely on ESPs, reflecting our best estimates of what the selling prices of elements would be if they were sold regularly on a stand-alone basis, to establish the amount of revenue to allocate to the deliverable. TPE generally does not exist for our products because of their uniqueness.

For products shipped under FOB origin or EXW terms, delivery is generally considered to have occurred when shipped. Undelivered elements in our sales arrangements, which are not considered to be essential to the functionality of a product, generally include installation or training services that are performed after the related products have been delivered. Revenue related to undelivered installation services is deferred until such time as installation is complete at the customer’s site. Revenue related to training services is recognized when the service is provided. Fair value for installation or training services is based on the price charged when the service is sold separately. The fair value of installation and training services is based upon billable hourly rates and the estimated time to complete the service.

Revenue from extended service and maintenance agreements, for both medical devices and data management systems, is recognized ratably over the service period. Freight charges billed to customers are included in revenue and freight-related expenses are charged to cost of revenue. Advance payments from customers are recorded as deferred revenue and recognized as revenue as otherwise described above. We

F-8

NATUS MEDICAL INCORPORATED

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS—(Continued)

Years Ended December 31, 2010, 2009 and 2008

generally do not provide rights of return on products. We accept trade-ins of our own and competitive medical devices. Trade-ins are recorded as a reduction of the replacement medical device sale. Provisions are made for initial standard warranty obligations that are generally one year in length.

More than 90% of the hospitals in the U.S. are members of Group Purchasing Organizations (“GPO”s), which negotiate volume purchase prices for member hospitals, group practices, and other clinics. Our agreements with GPOs typically contain preferential terms for the GPO and its members, including provisions for some, if not all, of the following:

• Negotiated pricing for all group members;

• Volume discounts and other preferential terms on their member’s direct purchases from us;

• Promotion of Natus’ products by the GPO to its members;

• Payment of marketing fees by Natus to the GPO, usually based on purchasing experience of group members; and

• Non-recourse cancellation provisions.

We do not sell products to GPOs. Hospitals, group practices, and other clinics that are members of a GPO purchase products directly from the Company under the terms negotiated by the GPO. Negotiated pricing and discounts are recognized as a reduction of the selling price of products at the time of the sale. Revenue from sales to members of GPOs is otherwise consistent with general revenue recognition policies as previously described.

Cash and Cash Equivalents—All highly liquid debt instruments purchased with an original maturity of three months or less are classified as cash equivalents.

Short-Term Investments—Fixed-rate guaranteed investment contracts with a commercial bank with a maturity of one year, valued at cost plus accrued interest that approximates fair value are classified as short-term investments.

Allowance for Doubtful Accounts—We assess the sufficiency of the allowance for estimated uncollectible accounts receivable. Estimates are based on historical collection experience within the markets in which we operate and other customer-specific information, such as bankruptcy filings or liquidity problems of customers. When it is determined that an account receivable is uncollectible, it is written off and relieved from the reserve. Any future determination that the allowance for estimated uncollectible accounts receivable is not properly stated could result in changes in operating expense and results of operations.

Fair Value of Financial Instruments—Financial instruments include cash and cash equivalents, short-term investments, accounts receivable, and accounts payable. Cash and cash equivalents are reported at their respective fair values on the balance sheet dates. The recorded carrying amount of accounts receivable and accounts payable approximates their fair value due to their short-term maturities.

Inventories—Inventories are stated at the lower of standard cost, which approximates actual cost on a first-in, first-out basis, or market. We may be exposed to a number of factors that could result in portions of our inventory becoming either obsolete or in excess of anticipated usage. These factors include, but are not limited to, technological changes, competitive pressures in products and prices, and the introduction of new product lines. We regularly evaluate our ability to realize the value of inventory based on a combination of factors, including historical usage rates, forecasted sales, product life cycles, and market acceptance of new products.

F-9

NATUS MEDICAL INCORPORATED

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS—(Continued)

Years Ended December 31, 2010, 2009 and 2008

When inventory that is obsolete or in excess of anticipated usage is identified, it is written down to realizable salvage value or an inventory valuation reserve is established.

Property and Equipment—Property and equipment are stated at cost less accumulated depreciation. Depreciation expense is computed using the straight-line method over estimated useful lives of the respective assets, which are three to five years for office furniture and equipment, three to five years for computer software and hardware, three to six years for demonstration and loaned equipment, and 40 years for buildings. Leasehold improvements are amortized over the shorter of the lease term or the estimated useful life. Land is not depreciated. Costs associated with acquiring and installing software to be used for internal purposes are capitalized.

Long-Lived Assets and Goodwill—Intangible assets with finite lives are amortized over their useful lives; any future changes that would limit their useful lives or any determination that these assets are carried at amounts greater than their estimated fair value could result in impairment charges. Goodwill and any other intangible assets with indefinite lives are recorded at original cost and are not amortized. Any future determination that these assets are carried at amounts greater than their estimated fair value could result in additional charges, which could impact operating results.

Definite-lived intangible assets are tested for impairment whenever changes in circumstances indicate the carrying value of these assets may be impaired. Impairment indicators include, but are not limited to, net book value as compared to market capitalization, significant negative industry and economic trends, and significant underperformance relative to historical and projected future operating results. Impairment is considered to have occurred when the estimated undiscounted future cash flows related to the asset are less than its carrying value. Estimates of future cash flows involve consideration of many factors including the marketability of new products, product acceptance and lifecycle, competition, appropriate discount rates, and operating margins.

Intangible assets with definite lives are amortizing using the straight-line and graded methods over periods ranging from seven to 20 years.

Goodwill and indefinite-lived intangible assets are tested for impairment at least annually as of October 1st; this assessment is also performed whenever there is a change in circumstances that indicates the carrying value of these assets may be impaired. The determination of whether any potential impairment of goodwill exists is based upon a two step process. In the first analysis, the fair value of the reporting unit is compared to the unit’s carrying value, including goodwill, to determine if there is a potential impairment. If the fair value exceeds the carrying amount, the goodwill of the reporting unit is considered not impaired and no further analysis or action is required. If the first analysis indicates that the carrying value exceeds the fair value, a second analysis is performed to determine the amount of the goodwill impairment loss, if any.

In step two of the impairment test, the implied fair value of a reporting unit’s goodwill is compared to the carrying amount of that goodwill. The implied fair value of the goodwill shall be determined in the same manner as the amount of goodwill recognized in a business combination is determined. That is, the entity shall allocate the fair value of a reporting unit to all the assets and liabilities of that reporting unit, including unrecognized intangible assets as if the reporting unit had been acquired in a business combination and the fair value of the reporting unit was the price paid to acquire the reporting unit. The excess of the fair value of the reporting unit over the amounts assigned to its assets and liabilities is the implied fair value of that goodwill.

To determine the estimated fair value of reporting units, three valuation methodologies are utilized: (i) discounted cash flow analyses, (ii) market multiples, and (iii) comparative transactions. The valuations

F-10

NATUS MEDICAL INCORPORATED

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS—(Continued)

Years Ended December 31, 2010, 2009 and 2008

indicated by these three methodologies are averaged, with the greatest weight placed on discounted cash flow analyses. Discounted cash flow analyses are dependent upon a number of quantitative and qualitative factors including estimates of forecasted revenue, profitability, earnings before interest, taxes, depreciation and amortization (i.e. EBITDA) and exit values. The discount rates applied in the discounted cash flow analyses also have an impact on the estimates of fair value, as use of a higher rate will result in a lower estimate of fair value. The estimated total fair value of reporting units is reconciled to the Company’s market capitalization.

Our discontinuance in 2010 of the Sonamed Clarity hearing screening line resulted in a write-off of the Sonamed Clarity tradename in the amount of $300,000.

Research & Development and Capitalized Software Development Costs—Costs incurred in research and development are charged to operations as incurred. Some of our products include imbedded software which is essential to the product’s functionality. In accordance with FASB ASC 985-20, Costs of Software to be Sold, Leased or Marketed, costs incurred in the research and development of new software components and enhancements to existing software components are expensed as incurred until technological feasibility has been established. We capitalize software development costs when the project reaches technological feasibility and cease capitalization when the project is ready for release. Software development costs are amortized on a straight-line basis over the estimated useful life of the product. Amortization begins when the product is available for general release to the customer.

Internal Use Software Development Costs—We account for internal use software development costs in accordance with ASC 350-40-15, Internal Use Software. In accordance with ASC 350-40-15, costs to develop internal use computer software during the application development stage are capitalized and reported as a component of intangible assets and amortized on a straight-line basis over the estimated useful lives of the related software applications.

Share-Based Compensation—We amortize share-based compensation expense associated with employee stock options under the single-option straight line method over the requisite service period, which is generally a four-year vesting period pursuant to ASC Topic 718, Compensation-Stock Compensation. See Note 11.

For employee stock options, the value of each option is estimated on the date of grant using the Black-Scholes option pricing model, which was developed for use in estimating the value of freely traded options. Our employee stock options have characteristics significantly different from those of traded options. Similar to other option pricing models, the Black-Scholes method requires the input of highly subjective assumptions, including stock price volatility. Changes in the subjective input assumptions can materially affect the estimated fair value of our employee stock options.

Forfeitures of employee stock options are estimated at the time of grant and revised, if necessary, in subsequent periods if actual forfeitures differ from initial estimates. Share-based compensation expense is recorded net of estimated forfeitures, such that expense is recorded only for those share-based awards that are expected to vest.

The cash flow resulting from the tax benefits resulting from tax deductions in excess of the compensation cost recognized for those options (excess tax benefits) is classified as a cash inflow from financing activities and a cash outflow from operating activities in our Statements of Cash Flows. We treat tax deductions from certain stock option exercises as being realized when they reduce taxes payable in accordance with relevant tax law.

We also recognize share-based compensation associated with Restricted Stock Awards and Restricted Stock Units in accordance with ASC Topic 718, Compensation-Stock Compensation.

F-11

NATUS MEDICAL INCORPORATED

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS—(Continued)

Years Ended December 31, 2010, 2009 and 2008

Uncertain Tax Positions—We recognize the tax benefit of uncertain tax positions in the financial statements in accordance with ASC Topic 740, Income Tax. When the tax position is deemed more likely than not of being sustained, we recognize the largest amount of tax benefit that is greater than 50 percent likely of being ultimately realized upon settlement, in accordance with ASC 740-10-05.

Foreign Currency—The functional currency of our foreign subsidiaries is generally the local currency of the country where the subsidiary is located. Accordingly, foreign currency translation exchange adjustments relating to the translation of foreign subsidiary financial statements are included as a component of accumulated other comprehensive income (loss). We recorded $(719,000), $685,000, and $(14.3) million of foreign currency translation adjustments for the years ended December 31, 2010, 2009 and 2008, respectively. We changed the functional currency of Xltek from the Canadian dollar to the U.S. Dollar on January 1, 2009.

Gains and losses from transactions denominated in currencies other than the functional currencies of the Company and its subsidiaries are included in other income and expense. In 2010, 2009 and 2008, net foreign currency transactions gains and (losses) were $(521,000), $520,000 and $1,620,000, respectively. Foreign currency gains and losses result primarily from fluctuations in the exchange rate between the US Dollar, Canadian Dollar, Euro, Argentine Peso and Danish Kroner.

Comprehensive Income—We report by major components and as a single total the change in our net assets during the period from non-owner sources in accordance with ASC Topic 220, Comprehensive Income. The consolidated statement of comprehensive income (loss) has been included with the consolidated statement of stockholders’ equity. Accumulated other comprehensive income (loss) consists of net unrealized gains and losses on available-for-sale securities and translation gains and losses on foreign subsidiary financial statements.

Basic and Diluted Net Income per Share—We compute net income per share in accordance with ASC Topic 260, Earnings per Share. Basic net income per share is based upon the weighted average number of common shares outstanding during the period. Diluted net income per share is based upon the weighted average number of common shares outstanding and dilutive common stock equivalents outstanding during the period. Common stock equivalents are options granted and shares of restricted stock issued under our stock awards plans and are calculated under the treasury stock method. Common equivalent shares from unexercised stock options and restricted stock are excluded from the computation when there is a loss as their effect is anti-dilutive, or if the exercise price of such options is greater than the average market price of the stock for the period.

For the year ended December 31, 2010, common stock equivalents of 1,125,006 were included in the weighted average shares outstanding used to calculate diluted income per share, while 1,090,401 shares were excluded from the calculation because of their anti-dilutive effect. For the year ended December 31, 2009, common stock equivalents of 824,516 were included in the weighted average shares outstanding used to calculate diluted income per share, while 1,168,704 shares were excluded from the calculation because of their anti-dilutive effect. For the year ended December 31, 2008, common stock equivalents of 1,206,000 were included in the weighted average shares outstanding used to calculate diluted income per share, while 525,000 shares were excluded from the calculation because of their anti-dilutive effect.

Certain Significant Risks and Uncertainties—Financial instruments that potentially subject us to credit risk consist principally of cash and cash equivalents, short-term investments, and accounts receivable. Cash and cash equivalents consist primarily of cash in bank accounts and investments in money market funds. To minimize our exposure to credit risk, our short-term investments consists exclusively of highly liquid, investment-grade financial instruments.

F-12

NATUS MEDICAL INCORPORATED

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS—(Continued)

Years Ended December 31, 2010, 2009 and 2008

We sell our products primarily to hospitals and medical institutions. Customers are generally not required to provide collateral or other security to support accounts receivable. Allowances for estimated potential bad debt losses are maintained. No single customer or distributor accounted for more than 10% of accounts receivable at December 31, 2010, 2009 or 2008.

Recent Accounting Pronouncements

In December 2010, the FASB issued Accounting Standards Update (“ASU”) 2010-28, Intangibles—Goodwill and Other (Topic 350): When to Perform Step 2 of the Goodwill Impairment Test for Reporting Units with Zero or Negative Carrying Amounts. ASU 2010-28 modifies Step 1 of the goodwill impairment test so that for reporting units with zero or negative carrying amounts, an entity is required to perform Step 2 of the goodwill impairment test if it is more likely than not based on an assessment of qualitative indicators that goodwill impairment exists. In determining whether it is more likely than not that goodwill impairment exists, an entity should consider whether there are any adverse qualitative factors indicating that impairment may exist. ASU 2010-28 is effective for fiscal years, and interim periods within those years, beginning after December 15, 2010. Early adoption is not permitted. We do not expect adoption of this standard to have a material impact on our financial position, results of operations, or cash flows.

In February 2010, the FASB issued ASU 2010-09, Subsequent Events (Topic 855) which updates the guidance in ASC Topic 855, Subsequent Events, to no longer require companies that file with the SEC to indicate the date through which they have analyzed subsequent events. This updated guidance became effective immediately upon issuance.

In January 2010, the FASB issued ASU 2010-06, Improving Disclosures about Fair Value Measurements (Topic 820): Fair Value Measurement. ASU 2010-06 requires new disclosures on the amount of and reason for transfers in and out of Level 1 and 2 fair value measurements, disclosure of activities, including purchases, sales, issuances, and settlements within Level 3 fair value measurements, and clarifies existing disclosure requirements on levels of disaggregation and disclosures about inputs and valuation techniques. The Company adopted ASU 2010-06 on January 1, 2010. The adoption of ASU 2010-06 did not impact our financial position, results of operations, and cash flows.

In December 2007, the FASB issued ASC Topic 805, Business Combinations, which expands the definition of a business combination and requires the fair value of the purchase price of an acquisition, including the issuance of equity securities, to be determined on the acquisition date. ASC Topic 805 also requires that all assets, liabilities, contingent consideration and contingencies of an acquired business be recorded at fair value at the acquisition date. In addition acquisition costs are generally expensed as incurred and restructuring costs generally are expensed in periods subsequent to the acquisition date. Changes in accounting for deferred tax asset valuation allowances and acquired income tax uncertainties resulting from new information obtained during the measurement period about facts and circumstances that existed as of the acquisition date will result in an adjustment to goodwill, while all other changes in these items are recognized as adjustments to income tax expense. We adopted ASC Topic 805 on January 1, 2009.

2— BUSINESS COMBINATIONS

Medix—We acquired Medix Industrial y Commercial S.A. (“Medix”) on October 12, 2010 pursuant to an Agreement and Plan of Merger. Medix is a leader in the development, manufacturing, and sales of devices for newborn care in Latin America. Medix, based in Argentina, manufactures incubators for use in hospital nurseries and NICU’s, transport incubators for use in ambulances and other emergency vehicles, infant warmers, and LED based phototherapy devices.

F-13

NATUS MEDICAL INCORPORATED

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS—(Continued)

Years Ended December 31, 2010, 2009 and 2008

The Company acquired all of the capital stock of Medix for $14.1 million in cash, excluding direct costs of the acquisition, with the potential for additional purchase consideration if certain revenue targets are met in 2011 and 2012. A total of $297,000 of direct costs associated with the acquisition was expensed as incurred and reported as a component of general and administrative expenses.

In accordance with ASC 805-10, the acquisition has been accounted for as a purchase business combination. Under the purchase method of accounting, the assets acquired and liabilities assumed from Medix at the date of acquisition are recorded in the consolidated financial statements at their respective fair values as of the acquisition date. The excess of the purchase price over the fair value of the acquired net assets has been recorded as goodwill in the amount of $4.8 million. Medix’s results of operations are included in the consolidated financial statements from the date of the acquisition.

The determination of estimated fair value of acquired assets and liabilities requires management to make significant estimates and assumptions. We determined the fair value by applying established valuation techniques, based on information that management believed to be relevant to this determination. The Company also hired independent third parties to assist in the valuation of real estate, intangible assets, goodwill, and additional purchase consideration.

The following table summarizes the purchase price allocation of the fair value of the assets acquired and liabilities assumed at the date of acquisition, (in thousands):

Cash	$	700
Accounts receivable		9,104
Inventories		8,283
Prepaid and other assets		128
Deferred income tax		152
Identifiable intangible assets:
Technology		1,600
Customer-related		2,300
Tradenames		1,000
Land and building		7,160
Other property and equipment		359
Goodwill		4,834
Accounts payable		(13,485	)
Accrued expenses		(1,861	)
Other liabilities		(1,736	)
Contingent earnout obligation-short-term		(1,252	)
Deferred income tax		(2,446	)
Contingent earnout obligation-long-term		(748	)
Total purchase price	$	14,092

Valuing certain components of the acquisition, including primarily accounts receivable, inventory, identifiable intangible assets, real estate, deferred taxes, accrued warranty costs, accounts payable, other accrued expenses, and contingent earnout obligation required us to make estimates that may be adjusted in the future; consequently the purchase price allocation is considered preliminary. Final determination of these estimates could result in an adjustment to the preliminary purchase price allocation, with an offsetting adjustment to Goodwill. In addition, the purchase consideration paid to the sellers is subject to adjustment pursuant to a minimum working capital provision of the purchase agreement.

F-14

NATUS MEDICAL INCORPORATED

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS—(Continued)

Years Ended December 31, 2010, 2009 and 2008

Identifiable intangible assets.    Intangible assets included in the purchase price allocation consist of: (i) technology of $1.6 million assigned an average economic life of 20 years being amortized on the straight line method, (ii) customer-related intangible assets of $2.3 million assigned an economic life of nine years being amortized on the straight line method, and (iii) tradenames of $1.0 million that have an indefinite life and are not being amortized.

Goodwill.    Approximately $4.8 million has been allocated to goodwill. Goodwill represents the excess of the purchase price over the fair value of the underlying net tangible and intangible assets. This goodwill is expected to be non-deductible for tax purposes. In accordance with ASC 350-20, goodwill will not be amortized but instead will be tested for impairment at least annually (more frequently if certain indicators are present). In the event that management determines that the value of goodwill has become impaired, we will incur an accounting charge for the amount of impairment during the fiscal quarter in which the determination is made.

Deferred income tax.    A preliminary estimate of $152,000 has been allocated to non-current deferred tax assets and $2.4 million has been allocated to non-current deferred tax liabilities, which results primarily from the fair market value assigned to various assets including intangibles, land, and building.

Contingent Earnout Obligation.    The Company is obligated to pay additional purchase consideration to the former shareholder of Medix if certain revenue targets are met in 2011 and 2012. We have recorded an estimate of the fair value of the contingent earnout obligation based on future revenue projections of the Medix business under various potential scenarios applying weighted probability assumptions of their outcomes. Actual amounts paid may differ from the obligation recorded.

Alpine Biomed Holdings Corp.—We acquired Alpine Biomed Holdings Corp. (“Alpine Biomed”) on September 14, 2009 for $43.2 million in cash pursuant to an Agreement and Plan of Merger. Alpine Biomed, with corporate headquarters in Fountain Valley, California and manufacturing facilities in Montreal, Canada, and Copenhagen, Denmark, is a leader in the development, manufacturing, and sales of devices for the diagnosis of neurological disorders. Alpine Biomed’s broad range of products includes advanced electromyography systems for the diagnoses of peripheral nervous system dysfunctions as well as devices for routine EEG and long term epilepsy monitoring. The acquisition broadened our product offerings, primarily in electromyography and allows us to further leverage our existing sales channels both in the United States and internationally.

During 2010 we substantially completed a reorganization plan adopted in January 2010 that was designed to eliminate redundant costs resulting from our acquisition of Alpine Biomed and to improve efficiencies in operations. Under the plan, Alpine operations in Fountain Valley were moved to our corporate headquarters in San Carlos, California, Alpine’s sales organization was merged into the Company’s global sales organization, and Alpine operations in Montreal, Canada were transitioned to our existing Xltek facility in Oakville, Ontario, Canada,.

We acquired all outstanding shares of Alpine Biomed capital stock for $43.2 million in cash. A total of $345,000 of direct costs associated with the acquisition was expensed as incurred and reported as a component of general and administrative expenses.

In accordance with ASC 805-10, the acquisition has been accounted for as a purchase business combination. Under the purchase method of accounting, the assets acquired and liabilities assumed from Alpine Biomed at the date of acquisition are recorded in the consolidated financial statements at their respective fair values as of the acquisition date. The excess of the purchase price over the fair value of the acquired net assets has been recorded as goodwill in the amount of $28.8 million. This goodwill is expected to be non-deductible for tax purposes. Alpine Biomed’s results of operations are included in the consolidated financial statements from the date of the acquisition.

F-15

NATUS MEDICAL INCORPORATED

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS—(Continued)

Years Ended December 31, 2010, 2009 and 2008

The Agreement and Plan of Merger also included an earnout provision based on the achievement of a certain revenue target as of December 31, 2009, however, the revenue target was not achieved and no additional cash consideration was paid.

In finalizing the purchase price allocation during 2010, we recorded adjustments to the original estimate of the purchase price allocation of the fair value of the assets acquired and liabilities assumed that decreased the carrying amount of goodwill by $34,000, due to adjustments to inventories, accounts payable, deferred taxes, and accrued expenses.

The following unaudited pro forma combined results of operations of Natus for the twelve months ended December 31, 2010 and 2009 are presented as if the acquisitions of Medix and Alpine Biomed had occurred on the first day of the periods presented:

Unaudited Pro Forma Financial Information

(in thousands)

	December 31,
	2010		2009
Revenue	$	236,452	$	227,723
Income from operations	$	20,436	$	15,644

The unaudited pro forma financial information is provided for comparative purposes only and is not necessarily indicative of what actual results would have been had the acquisitions occurred on the dates indicated, nor do they give effect to synergies, cost savings, and other changes expected to result from the acquisitions. Accordingly, the pro forma financial results do not purport to be indicative of results of operations as of the date hereof, for any period ended on the date hereof, or for any other future date or period. For purposes of preparing the Medix unaudited pro forma financial information for the years ended December 31, 2010. Medix’s Statement of Income for the period January 1, 2010 through October 12, 2010 was combined with the Company’s Consolidated Statement of Operations for the year ended December 31, 2010, which includes the results of Medix from the date of the acquisition. For the year ended December 31, 2009, Medix’s Statement of Income for the period January 1, 2009 through October 31, 2009 was combined with Medix’s Statement of Income for period November 1, 2009 through December 31, 2009. Alpine Biomed is included in the Company’s Consolidated Statement of Operations for the year ended December 31, 2010. For purposes of preparing the Alpine unaudited pro forma financial information for the year ended December 31, 2009, Alpine’s neurology business unaudited Statement of Sales and Direct Operating Expenses for the period January 1, 2009 through September 13, 2009 was combined with the Company’s consolidated Statement of Operations for the year ended December 31, 2009, which includes the results of Alpine from the date of the acquisition.

Hawaii Medical—We acquired Hawaii Medical, LLC (“Hawaii Medical”) on July 2, 2009 pursuant to an Agreement and Plan of Merger. Massachusetts based Hawaii Medical manufactures and markets single-use disposable products sold into the NICU and nursery in hospitals. During the third quarter 2009 we transitioned substantially all of the operations of Hawaii Medical to our Olympic facility in Seattle, Washington.

We acquired all outstanding units of Hawaii Medical for $2.9 million in cash. In addition to the purchase price paid at closing, an earnout provision of the purchase agreement may result in additional cash consideration depending upon the achievement of certain revenue targets over a 36 month period. Although there is no limit to the additional consideration that will be paid if the revenue targets are exceeded, no contingent obligation was

F-16

NATUS MEDICAL INCORPORATED

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS—(Continued)

Years Ended December 31, 2010, 2009 and 2008

recorded as there is significant uncertainty that the revenue targets will be achieved. As of December 31, 2010, the revenue targets were not achieved. We also incurred $115,000 of direct costs associated with the acquisition that were expensed as a component of general and administrative expense in the third quarter 2009.

The acquisition has been accounted for as a purchase business combination. Under the purchase method of accounting, the assets acquired and liabilities assumed from Hawaii Medical at the date of acquisition are recorded in the consolidated financial statements at their respective fair values as of the acquisition date. The excess of the purchase price over the fair value of the acquired net assets has been recorded as goodwill in the amount of $2.4 million. This goodwill is expected to be non-deductible for tax purposes. Hawaii Medical’s results of operations are included in the consolidated financial statements from the date of the acquisition.

3— INVENTORIES

Inventories consist of (in thousands):

	December 31,
	2010			2009
Raw materials and subassemblies	$	14,924		$	12,187
Finished goods		26,375			14,994
Total Inventories		41,299			27,181
Less: Non-current Inventories		(3,672	)		(4,092	)
Inventories	$	37,627		$	23,089

At December 31, 2010, the Company has classified $3.7 million of inventories as non-current. This inventory consists primarily of service components used to repair products held by our customers pursuant to warranty obligations and extended service contracts, including service components for products we are not currently selling. Management believes that these inventories will be utilized for their intended purpose.

Work in process represents an immaterial amount in all periods presented.

4— PROPERTY AND EQUIPMENT

Property and equipment consist of (in thousands):

	December 31,
	2010			2009
Land	$	4,903		$	3,403
Buildings		10,904			4,691
Leasehold improvements		2,523			1,479
Office furniture and equipment		9,067			7,898
Computer software and hardware		6,084			5,091
Demonstration and loaned equipment		7,571			6,286
		41,052			28,848
Accumulated depreciation		(17,644	)		(14,782	)
Total	$	23,408		$	14,066

F-17

NATUS MEDICAL INCORPORATED

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS—(Continued)

Years Ended December 31, 2010, 2009 and 2008

Depreciation expense of property and equipment was $3.7 million, $3.1 million and $3.2 million in the years ending December 31, 2010, 2009 and 2008, respectively.

5—GOODWILL

The carrying amount of goodwill and the changes in those balances are as follows (in thousands):

	Year Ended December 31,
	2010			2009
Balance, beginning of period	$	92,258		$	60,858
Goodwill as a result of acquisitions		4,834			28,856
Purchase accounting adjustments		(14	)		2,486
Foreign currency translation adjustment		(259	)		58
Total changes in goodwill		4,561			31,400
Balance, end of period	$	96,819		$	92,258

6—INTANGIBLE ASSETS

The following table summarizes the components of gross and net intangible asset balances (in thousands):

	December 31, 2010							December 31, 2009
	Gross Carrying Amount		Accumulated Amortization			Net Book Value		Gross Carrying Amount		Accumulated Amortization			Net Book Value
Intangible assets with definite lives:
Technology	$	50,301	$	(14,520	)	$	35,781	$	48,207	$	(10,970	)	$	37,237
Customer related		15,299		(3,016	)		12,283		13,448		(2,090	)		11,358
Internally developed software		3,831		(1,392	)		2,439		3,244		(565	)		2,679
Patents		2,571		(1,746	)		825		3,455		(1,595	)		1,860
Definite lived intangible assets		72,002		(20,674	)		51,328		68,354		(15,220	)		53,134
Intangible assets with indefinite lives:
Tradenames		18,100		—			18,100		17,010		—			17,010
Total intangibles assets	$	90,102	$	(20,674	)	$	69,428	$	85,364	$	(15,220	)	$	70,144

Definite lived intangible assets are amortized over their weighted average lives of 14 years for patents, 15 years for technology, 10 years for customer-related intangibles and 5 years for internally developed software. Intangible assets with indefinite lives are not subject to amortization.

Internally developed software consists of $2.9 million relating to costs incurred for development of internal use computer software and $943,000 for development of software to be sold.

F-18

NATUS MEDICAL INCORPORATED

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS—(Continued)

Years Ended December 31, 2010, 2009 and 2008

Amortization expense related to intangible assets with definite lives was as follows (in thousands):

	Years Ended December 31,
	2010		2009		2008
Technology	$	3,550	$	3,382	$	2,105
Customer Related		926		631		582
Software		827		474		91
Patents		151		280		827
Total amortization	$	5,454	$	4,767	$	3,605

Expected annual amortization expense related to amortizable intangible assets is as follows (in thousands):

2011	$	5,398
2012		5,398
2013		5,273
2014		4,959
2015		4,119
Thereafter		26,181
Total expected annual amortization expense	$	51,328

7— ACCRUED LIABILITIES

Accrued liabilities consist of (in thousands):

	December 31,
	2010		2009
Compensation and related benefits	$	8,530	$	7,155
Accrued contingent consideration		1,252		—
Accrued federal, state, and local taxes		1,697		2,050
Warranty reserve		696		694
Accrued professional fees		272		1,002
Other		5,990		3,612
Total	$	18,437	$	14,513

8— LONG-TERM OTHER LIABILITIES

Long-term other liabilities consist of (in thousands):

	December 31,
	2010		2009
Contingent tax obligations	$	6,383	$	6,037
Non-current deferred revenue		945		837
Accrued contingent consideration		748		—
Contractual obligations		—		670
Other		—		31
Total	$	8,076	$	7,575

F-19

NATUS MEDICAL INCORPORATED

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS—(Continued)

Years Ended December 31, 2010, 2009 and 2008

9— RESERVE FOR PRODUCT WARRANTIES

We provide a warranty on all medical device products that is generally one year in length. We also sell extended service agreements on our medical device products. Service for domestic customers is provided by Company-owned service centers that perform all service, repair and calibration services. Service for international customers is provided by a combination of Company-owned facilities and third-party vendors on a contract basis.

We have accrued a warranty reserve, included in accrued liabilities on the accompanying balance sheets, for the expected future costs of servicing products during the initial warranty period. We base the liability on actual warranty costs incurred to service those products. On new products, additions to the reserve are based on a combination of factors including the percentage of service department labor applied to warranty repairs, as well as actual service department costs, and other judgments, such as the degree to which the product incorporates new technology. The reserve is reduced as costs are incurred to honor existing warranty obligations or when current facts indicate that the original estimates of expected future costs of servicing products were overstated.

Detail of activity in product warranty reserve is as follows, (in thousands):

	Balance at Beginning of Period		Assumed Through Acquisitions		Additions Charged to Expense		Reductions			Balance at End of Period
Year ended December 31, 2010
Accrued warranty costs	$	694	$	43	$	331	$	(372	)	$	696

The estimates we use in projecting future product warranty costs may prove to be incorrect. Any future determination that our product warranty reserves are understated could result in increases to our cost of sales and reductions in our operating profits and results of operations.

10— STOCKHOLDERS’ EQUITY

Common Stock—We have 120,000,000 shares of common stock authorized at a par value or $0.001 per share. We issued 885,500 shares of our common stock in a registered offering in April 2008 at an offering price of $18.27 per share, raising approximately $15.2 million, net of underwriting fees and other costs. In May 2008, we issued 4,600,000 shares of our common stock in a registered offering at an offering price of $19.50 per share, raising approximately $84.1 million, net of underwriting fees and other costs of the offering.

Preferred Stock—We have 10,000,000 shares of preferred stock authorized at a par value of $0.001 per share. In accordance with the terms of the amended and restated certificate of incorporation, the Board of Directors is authorized to provide for the issuance of one or more series of preferred stock, including increases or decreases to the series. The Board of Directors has the authority to set the rights, preferences, and terms of such shares. As of December 31, 2010, no shares of preferred stock were issued and outstanding.

Stockholder Rights Plan—We adopted a Stockholder Rights Plan in September 2002 (the “Rights Plan”) that was amended most recently in September 2006. Pursuant to the Rights Plan, we declared a dividend of one Preferred Stock Purchase Right per share of common stock (the “Rights”) and each such Right has an exercise price of $23.00. The Rights become exercisable, unless redeemed by the Company, upon the occurrence of certain events, including the announcement of a tender offer or exchange offer for our common stock or the acquisition of a specified percentage of the our common stock by a third party.

F-20

NATUS MEDICAL INCORPORATED

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS—(Continued)

Years Ended December 31, 2010, 2009 and 2008

11— SHARE-BASED COMPENSATION

Share-Based Compensation Expense—We account for share-based compensation in accordance with ASC Topic 718, Compensation—Stock Compensation. Share-based compensation was recognized as follows in the consolidated statement of operations, (in thousands, except per share):

	December 31,
	2010			2009			2008
Cost of revenue	$	177		$	331		$	333
Marketing and sales		1,432			1,103			707
Research and development		425			314			321
General and administrative		3,365			2,512			1,634
Total expense		5,399			4,260			2,995
Income tax effect		(1,776	)		(1,423	)		(1,100	)
Decrease in net income	$	3,623		$	2,837		$	1,895

As of December 31, 2010, unrecognized compensation related to the unvested portion of our stock options and other stock awards was approximately $8.5 million, which is expected to be recognized over a weighted average period of 2.6 years.

Stock Awards Plans—Our Amended and Restated 2000 Stock Awards Plan (the “Plan”) provides for the granting of the following:

• Incentive stock options to employees;

• Non-statutory stock options to employees, directors and consultants;

• Restricted stock awards and restricted stock units;

• Stock bonuses; and

• Stock appreciation rights.

As of December 31, 2010, there were 2,857,888 shares available for future awards under the Restated Plan.

Under the Plan, stock options may be issued at not less than the fair market value of the common stock on the date of grant, as determined by the Board of Directors. Options issued under the Plan become exercisable as determined by the Board of Directors and expire no more than six years after the date of grant. Most options vest ratably over four years. Since 2005, our option awards have consisted solely of non-statutory stock options. Stock awards are typically granted to existing employees once a year at the time of the Company’s annual shareholder meeting.

We also provide for grants of options to our nonemployee directors from the 2000 Director Stock Option Plan (the “Director Plan”) that have similar terms to those options granted from the Plan, except that such options vest ratably over a twelve month period. As of December 31, 2010 there were 511,142 shares available for future awards under the Director Plan.

We also have the 1991 Stock Option Plan and the 2000 Supplemental Stock Option Plan (the “Inactive Plans”) that have been closed to new grants since July 20, 2001. Options outstanding under the Inactive Plans were generally governed by the same terms as those under the 2000 Plan, except that the options expired no more than ten years after the date of grant. Options still outstanding under the Inactive Plans remain outstanding pursuant to their original terms.

F-21

NATUS MEDICAL INCORPORATED

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS—(Continued)

Years Ended December 31, 2010, 2009 and 2008

Stock Option Activity—Stock option activity under our stock awards plans for the year ended December 31, 2010 is summarized as follows:

	Number of Shares			Weighted Average Exercise Price
Outstanding, December 31, 2008 (2,134,604 shares exercisable at a weighted average exercise price of $7.76 per share)		2,876,072		$	9.97
Granted (weighted average fair value of $3.67 per share)		676,600		$	10.71
Exercised		(34,224	)	$	10.16
Cancelled		(83,054	)	$	14.90
Outstanding, December 31, 2009 (2,494,821 shares exercisable at a weighted average exercise price of $8.70 per share)		3,435,394		$	10.00
Granted (weighted average fair value of $5.49 per share)		484,100		$	16.48
Exercised		(222,038	)	$	7.44
Cancelled		(58,499	)	$	14.75
Outstanding, December 31, 2010 (2,683,816 shares exercisable at a weighted average exercise price of $9.66 per share)		3,638,957		$	10.94

The following table summarizes information concerning outstanding and exercisable options outstanding at December 31, 2010:

	Options Outstanding						Options Exercisable
Range of Exercise Price	Number Outstanding as of 12/31/10		Weighted Average Exercise Price		Weighted  Average Remaining Contractual Life (Years)		Number Exercisable as of 12/31/10		Weighted Average Exercise Price
$3.15 - $4.07		582,334	$	3.81		2.72		582,334	$	3.81
$4.11 - $5.69		372,830	$	4.49		2.84		372,830	$	4.49
$ 5.77 - $8.51		138,330	$	7.08		3.73		130,205	$	7.02
$10.03 - $10.03		426,750	$	10.03		4.44		426,750	$	10.03
$10.73 - $10.73		591,233	$	10.73		4.33		227,858	$	10.73
$10.78 - $12.98		387,904	$	11.51		1.95		343,773	$	11.37
$13.16 - $16.15		347,601	$	15.69		2.87		298,963	$	15.73
$16.78 - $16.78		433,100	$	16.78		5.30		63,520	$	16.78
$16.89 - $18.74		40,500	$	17.91		3.24		29,416	$	17.96
$20.09 - $20.09		318,375	$	20.09		3.33		208,167	$	20.09
$3.15 - $20.09		3,638,957	$	10.94		3.53		2,683,816	$	9.66

The intrinsic value of options exercised, representing the difference between the closing stock price of Company’s common stock on the date of the exercise and the exercise price, in the years ended December 31, 2010, 2009 and 2008, was $1.5 million, $165,000, and $2.0 million, respectively.

As of December 31, 2010, there were: (i) 3,501,443 options vested and expected to vest with a weighted average exercise price of $10.80, an intrinsic value of $15.8 million, and a weighted average remaining contractual term of 3.5 years; and (ii) 2,683,816 options exercisable with a weighted average exercise price of $9.66, an intrinsic value of $14.5 million, and a weighted average remaining contractual term of 3.2 years.

F-22

NATUS MEDICAL INCORPORATED

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS—(Continued)

Years Ended December 31, 2010, 2009 and 2008

Cash received from option exercises for the years ended December 31, 2010 and 2009 was $1.7 million and $348,000, respectively.

Black-Scholes Inputs—The fair value of option grants was estimated using the Black-Scholes option pricing model with the following weighted average assumptions:

	Years Ended December 31,
	2010			2009			2008
Expected life in years		4.2			4.2			4.2
Risk free interest rate		1.5	%		2.2	%		2.8	%
Expected volatility		38	%		40	%		37	%
Expected forfeiture rate		11.5	%		13.2	%		13.4	%
Dividend yield		None			None			None

We have no history or expectation of paying dividends on our common stock. All options are treated as a single group in the determination of expected life, as we do not currently expect substantially different exercise or post-vesting termination behavior among our employee population. Prior to June 2006 we granted options that had a contractual term of 10 years. Subsequent to June 15, 2006, all options granted by the Company have a contractual life of six years. Through December 31, 2007 we used the simplified method allowed under Staff Accounting Bulletin No. 107 in determining the expected life of options. Beginning January 1, 2008 we adopted a method of determining the expected life of options based exclusively on historical share option exercise experience of our employees for options granted by the Company after June 15, 2006.

The risk-free interest rate is based on the U.S. Treasury yield for a term consistent with the expected life of the awards in effect at the time of grant. Expected volatility is based exclusively on historical volatility data of our common stock.

Share-based compensation expense associated with options is based on awards ultimately expected to vest. At the time of an option grant, we estimate the expected future rate of forfeitures based on historical experience. These estimates are revised, if necessary, in subsequent periods if actual forfeiture rates differ from those estimates. If the actual forfeiture rate is lower than estimated we will record additional expense and if the actual forfeiture is higher than estimated we will record a recovery of prior expense.

Restricted Stock Awards Activity—The following table summarizes the activity for restricted stock awards during the years ended December 31, 2010 and 2009:

	Shares			Weighted Average Grant Date Fair Value
Unvested at December 31, 2008		338,518		$	17.50
Forfeited		(16,800	)	$	16.77
Vested		(88,634	)	$	16.06
Granted		314,700		$	10.71
Unvested at December 31, 2009		547,784		$	13.87
Forfeited		(4,250	)	$	13.34
Vested		(165,584	)	$	15.96
Granted		212,100		$	16.68
Unvested at December 31, 2010		590,050		$	14.30

F-23

NATUS MEDICAL INCORPORATED

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS—(Continued)

Years Ended December 31, 2010, 2009 and 2008

The fair market value of outstanding restricted stock awards at December 31, 2010 was $8.5 million. The weighted average remaining recognition period for unvested restricted stock awards at December 31, 2010 was 2.6 years.

Restricted Stock Units Activity—The following table summarizes restricted stock units activity for the years ended December 31, 2010 and 2009:

	2010			2009
Beginning outstanding balance		66,500			35,500
Awarded		32,450			51,100
Released		(8,750	)		(8,500	)
Forfeited		(18,900	)		(11,600	)
Ending outstanding balance		71,300			66,500

The aggregate intrinsic value of outstanding restricted stock units at December 31, 2010 was $1.0 million. The weighted average remaining recognition period for unvested restricted stock units at December 31, 2010 was 2.9 years.

Employee Stock Purchase Plan—The 2000 Employee Stock Purchase Plan (the “ESPP”) was adopted effective upon the closing of our initial public offering. Under the ESPP, eligible employees can elect to have salary withholdings of up to 15% of the sum of their W-2 cash compensation and 401(k) contributions to a maximum of $12,500 per offering period, to purchase shares of common stock on April 30 and October 31 of each year. The purchase price for shares acquired under the ESPP is 85% of the fair market value on the last day of the offering period. As of December 31, 2010, there were 4,212,387 shares reserved for future issuance under the ESPP.

Because the ESPP does not have a “look back” feature, the compensation expense associated with the Plan is not measured by the use of the Black-Scholes pricing model, but rather by measuring the difference between the fair market value of our common stock on the last day of the offering period and the purchase price for the offering period, which is 85% of the fair market value. Compensation expense associated with the ESPP for the years ended December 31, 2010, 2009 and 2008, respectively, was $133,000, $108,000 and $87,000.

Cash received from purchases under the ESPP for the years ended December 31, 2010, 2009 and 2008, respectively, was approximately $866,000, $729,000 and $548,000.

12— RESTRUCTURING RESERVE

In January 2010, we adopted a reorganization plan (the “Restructuring Plan”) that is designed to eliminate redundant costs resulting from our acquisition of Alpine Biomed and to improve efficiencies in operations. Under the plan, which was substantially completed in the first half of 2010, Alpine operations in Montreal, Canada were transitioned to our existing Xltek facility in Oakville, Ontario, Canada, and Alpine’s sales organization was merged into our global sales organization.

The Restructuring Plan resulted in a staff reduction of approximately 70 employees for which we recorded a restructuring charge for severance benefits of approximately $3.0 million during the first fiscal quarter of 2010, which was reduced by $268,000 during the second fiscal quarter. In addition, during the second fiscal quarter of 2010 we recorded a $300,000 charge for a lease termination fee. We also recorded a $44,000 charge to write off property and equipment.

F-24

NATUS MEDICAL INCORPORATED

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS—(Continued)

Years Ended December 31, 2010, 2009 and 2008

We account for restructuring costs in accordance with ASC Topic 420, Exit or Disposal Cost Obligations. The balance of the reserve is included in accrued liabilities on the accompanying balance sheets. Substantially all of the costs associated with the Restructuring Plan will result in cash expenditures.

Detail of activity in the restructuring reserve is as follows, (in thousands):

	Balance January 1, 2010		Charged To Expense		Accrual Reversal			Amounts Paid			Balance December 31, 2010
Employee termination benefits	$	—	$	3,030	$	(268	)	$	(2,675	)	$	87
Lease termination fee		—		300		—			(300	)		—
Totals	$	—	$	3,330	$	(268	)	$	(2,975	)	$	87

In addition to the above charges, during 2010 we incurred approximately $131,000 of other costs directly associated with the Restructuring Plan that did not qualify for accrual and reporting under ASC Topic 420 and were charged to expense as incurred.

13— OTHER INCOME (EXPENSE), NET

Other income (expense), net consisted of (in thousands):

	Years Ended December 31,
	2010			2009			2008
Investment income	$	36		$	228		$	1,029
Interest expense		(128	)		(153	)		(735	)
Foreign currency exchange gain (loss)		(521	)		520			1,620
Change in fair value of contingent obligation		—			600			—
Other		495			555			228
Total other income (expense), net	$	(118	)	$	1,750		$	2,142

14— INCOME TAXES

We account for income taxes under the asset and liability method, which requires the recognition of deferred tax assets and liabilities for the expected future tax consequences of events that have been included in the financial statements. Under this method, deferred tax assets and liabilities are determined based on the differences between the financial statements and tax basis of assets and liabilities using enacted tax rates in effect for the year in which the differences are expected to reverse. The effect of a change in tax rates on deferred tax assets and liabilities is recognized in income in the period that includes the enactment date.

We record net deferred tax assets to the extent we believe these assets will more likely than not be realized. In making such determination, we consider all available positive and negative evidence, including future reversals of existing taxable temporary differences, projected future taxable income, tax planning strategies and recent financial operations. In the event we were to determine that we would be able to realize our deferred income tax assets in the future in excess of their net recorded amount, we would make an adjustment to the valuation allowance which would reduce the provision for income taxes.

F-25

NATUS MEDICAL INCORPORATED

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS—(Continued)

Years Ended December 31, 2010, 2009 and 2008

The components of our income tax expense for the years ended December 31, 2010, 2009 and 2008 consisted of the following (in thousands):

	Years Ended December 31,
	2010			2009			2008
Current
U.S. Federal	$	1,997		$	3,284		$	4,322
U.S. State and local		779			543			(150	)
Non-U.S.		1,366			640			1,647
Total current tax expense		4,142			4,467			5,819
Deferred
U.S. Federal		(574	)		(896	)		1,430
U.S. State and local		(89	)		(141	)		294
Non-U.S.		2,315			2,271			2,490
Total deferred tax benefit		1,652			1,234			4,214
Total income tax expense	$	5,794		$	5,701		$	10,033

Deferred income taxes reflect the net tax effects of temporary differences between the carrying amounts of assets and liabilities for financial reporting purposes and the amounts used for income tax purposes. Significant components of our deferred tax assets and liabilities as of December 31, 2010 and 2009 are as follows (in thousands):

	December 31,
	2010			2009
Deferred tax assets:
Net operating loss carryforwards	$	6,016		$	6,769
Credit carryforwards		3,966			3,297
Accruals deductible in different periods		8,414			9,001
Basis difference in fixed and intangible assets		—			285
Employee benefits		2,838			1,012
Total deferred tax assets		21,234			20,364
Valuation allowance		(5,739	)		(5,768	)
Total net deferred tax assets	$	15,495		$	14,596
Deferred tax liabilities:
Dividends from foreign subsidiaries	$	(369	)	$	(369	)
Basis difference in fixed and intangible assets		(18,479	)		(14,255	)
Total deferred tax liabilities		(18,848	)		(14,624	)
Total net deferred tax assets ( liabilities)	$	(3,353	)	$	(28	)

F-26

NATUS MEDICAL INCORPORATED

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS—(Continued)

Years Ended December 31, 2010, 2009 and 2008

The amount of income tax recorded by us differs from the amount using the federal statutory rate of 34% for 2010 and 35% for 2009 and 2008, respectively, as follows (in thousands):

	Years Ended December 31,
	2010			2009			2008
Federal statutory tax expense	$	6,022		$	5,979		$	9,560
State tax expense		532			299			494
Difference in US and foreign rates		(875	)		(473	)		(354	)
Stock compensation expense on incentive stock options		123			176			138
Valuation allowance		—			—			838
Other		(8	)		(280	)		(643	)
Total expense	$	5,794		$	5,701		$	10,033

At December 31, 2010 we had total U.S. federal net operating loss carryforwards of approximately $4.6 million and state net operating loss carryforwards of approximately $2.0 million, available to reduce future taxable income. The federal and state net operating loss carryforwards, if not utilized to offset taxable income in future periods, will expire in various amounts beginning in 2021 and 2015, respectively.

At December 31, 2010, we had foreign net operating losses of $3.7 million and $8.1 million from Deltamed and Alpine Biomed, respectively. Alpine Biomed’s net operating loss carryforwards, if not utilized to offset taxable income in future periods, will expire in various amounts beginning in 2028. In addition, Alpine has investment tax credits of approximately $147,000 which will expire in various amounts beginning in 2022. At December 31, 2010, Xltek has investment tax credits of approximately $549,000 which will expire in various amounts beginning in 2012.

The extent to which the federal operating loss and tax credit carryforwards can be used to offset future taxable income may be limited, depending on the extent of ownership changes within any three-year period, as provided in the Tax Reform Act of 1986. Such a limitation could result in the expiration of carryforwards before they are utilized.

A valuation allowance is provided when it is more likely than not that some portion or all of the deferred tax assets will not be realized. Accordingly, valuation allowances of $5.7 million and $5.8 million were recorded during the years ended December 31, 2010 and 2009, respectively.

We receive tax deductions from the gains realized by employees on the exercise of certain non-qualified stock options for which the benefit is recognized as a component of stockholders’ equity. In 2010 we recorded approximately $551,000 of additional paid in capital related to exercises of non-qualified stock options by employees.

We have not provided for U.S. federal income and foreign withholding taxes on undistributed earnings from non-U.S. operations as of December 31, 2010 because such earnings are intended to be reinvested indefinitely. As of December 31, 2010, the amount of undistributed earnings from non-U.S. operations has not been estimated as the determination is not practicable.

Uncertain Tax Positions—We account for uncertain tax positions in accordance with ASC 740-10-05, Accounting for Income Taxes – an interpretation of FASB Statement 109. This interpretation establishes the criteria that must be met prior to recognition of the financial statement benefit of a position taken in a tax return

F-27

NATUS MEDICAL INCORPORATED

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS—(Continued)

Years Ended December 31, 2010, 2009 and 2008

and is based on a benefit-recognition model. Provided that the tax position is deemed more likely than not of being sustained, we recognize the largest amount of tax benefit that is greater than 50 percent likely of being ultimately realized upon settlement. The tax position is derecognized when it is no longer more likely than not of being sustained.

A reconciliation of the beginning and ending amount of unrecognized tax benefits (excluding interest and penalties) is as follows (in thousands):

Balance at January 1, 2008	$	3,300
Additions for tax positions related to the current year		1,046
Lapse of statutes of limitations		(17	)
Balance at January 1, 2009		4,329
Additions for tax positions related to the current year		1,109
Lapse of statutes of limitations		(48	)
Balance at January 1, 2010		5,390
Additions for tax positions related to the current year		241
Lapse of statutes of limitations		(145	)
Balance at December 31, 2010	$	5,486

The unrecognized tax benefits of $5.5 million include $2.5 million of uncertain tax positions that would impact our effective tax rate if recognized.

At December 31, 2010 and 2009, we had cumulatively accrued approximately $932,000 and $647,000 for estimated interest and penalties related to uncertain tax positions. We record interest and penalties related to unrecognized tax positions as a component of income tax expense, which totaled approximately $285,000 and $161,000 for the 12 months ended December 31, 2009 and 2008, respectively.

We are currently unaware of any uncertain tax positions that could result in significant additional payments, accruals, or other material deviation in this estimate over the next 12 months.

Our tax returns remain open to examination as follows: U.S. federal, 2006 through 2010; U.S. states, generally 2005 through 2010; significant foreign jurisdictions, generally 2007 through 2010.

15— EMPLOYEE BENEFIT PLAN

We have a 401(k) tax-deferred savings plan under which eligible U.S. employees may elect to have a portion of their salary deferred and contributed to the plan. Employer matching contributions are determined by management and are discretionary. Employer matching contributions were approximately $492,000, $455,000 and $467,000, respectively, in the years ended December 31, 2010, 2009, and 2008. For new hires, employer contributions vest ratably over the first two years of employment.

16— SEGMENT, CUSTOMER, AND GEOGRAPHIC INFORMATION

We operate in one reportable segment in which we provide healthcare products used for the screening, detection, treatment, monitoring and tracking of common medical ailments in newborn care, hearing impairment, neurological dysfunction, epilepsy, sleep disorders, and balance and mobility disorders.

F-28

NATUS MEDICAL INCORPORATED

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS—(Continued)

Years Ended December 31, 2010, 2009 and 2008

Our end-user customer base includes hospitals, clinics, laboratories, physicians, nurses, audiologists, and governmental agencies. Most of our international sales are to distributors who resell our products to end users or sub-distributors.

Revenue and long-lived asset information by geographic region is as follows (in thousands):

	Years Ended December 31,
	2010		2009		2008
Revenue:
United States	$	126,680	$	109,721	$	112,589
Foreign countries		91,975		56,704		49,242
	$	218,655	$	166,425	$	161,831
Long-lived assets:
United States	$	7,852	$	6,297	$	7,579
Foreign countries		15,546		7,769		6,423
	$	23,408	$	14,066	$	14,002

Long-lived assets consist principally of property and equipment (net). During the years ended December 31, 2010, 2009 and 2008, no single customer or foreign country contributed to more than 10% of revenue, and revenue from services was less than 10% of revenue.

During the years ended December 31, 2010, 2009 and 2008, respectively, revenue from devices and systems was $134.8 million, $96.2 million and $102.5 million, while revenue from supplies and services was $80.1 million, $67.1 million and $56.7 million, respectively.

17— DEBT AND CREDIT ARRANGEMENTS

Long-term borrowings are composed of the following (2010 and 2009 columns in thousands):

	December 31,
	2010			2009
Term loan $2.9 million Canadian (“CAD”), interest at cost of funds plus 2.5%, due September 15, 2014 with principle repayable in monthly installments of $16,000 until August 15, 2014, and one final payment of $404,000 collateralized by a first lien on the land and building owned by Xltek	$	893		$	1,062
Term loan CAD $300,000, interest at cost of funds plus 2.5%, due November 15, 2010 with principle repayable in monthly installments of $2,000 until October 10, 2010 and one final payment of $36,000 collateralized by various assets of Xltek		—			47
Total long-term debt (including current portion)		893			1,109
Less: current portion of long-term debt		(156	)		(178	)
Total long-term debt	$	737		$	931

We have a $50 million revolving credit facility with Wells Fargo Bank, National Association (“Wells Fargo”). The revolving credit facility contains covenants, including covenants relating to liquidity and other

F-29

NATUS MEDICAL INCORPORATED

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS—(Continued)

Years Ended December 31, 2010, 2009 and 2008

financial measurements, and provides for events of default, including failure to pay any interest when due, failure to perform or observe covenants, bankruptcy or insolvency events and the occurrence of a material adverse effect. We have granted Wells Fargo a security interest in all of the assets of the Company. The credit facility contains covenants including minimum EBITDA, quick ratio, and a leverage ratio. We did not draw on the facility during 2010. We have no other significant credit facilities.

18— COMMITMENTS AND CONTINGENCIES

Leases – We have entered into noncancelable operating leases for some of our facilities located in the U.S. and Europe through October 2016. Minimum lease payments under noncancelable operating leases as of December 31, 2010 are as follows (in thousands):

	Operating Leases
Year Ending December 31,
2011	$	1,795
2012		938
2013		818
2014		744
2015		696
Thereafter		92
Total minimum lease payments	$	5,083

Rent expense, which is recorded on the straight-line method from commencement over the period of the lease, totaled $1,971,000, $2,140,000 and $1,805,000 in 2010, 2009 and 2008, respectively.

Purchase commitments—We had various firm purchase commitments for inventory totaling $15.7 million at December 31, 2010.

Indemnifications—Under our bylaws, we have agreed to indemnify our officers and directors for certain events or occurrences arising as a result of the officer or director serving in such capacity. We have a director and officer liability insurance policy that limits our exposure under these indemnifications and enables us to recover a portion of any future loss arising out of them. In addition, we enter into indemnification agreements with other parties in the ordinary course of business. We have determined that these agreements fall within the scope of ASC 460, Guarantees. In some cases we have obtained liability insurance providing coverage that limits its exposure for these other indemnified matters. We have not incurred material costs to defend lawsuits or settle claims related to these indemnification agreements. We believe the estimated fair value of these indemnification agreements is minimal and have not recorded a liability for these agreements as of December 31, 2010.

Legal matters—We may from time to time become a party to various legal proceedings or claims that arise in the ordinary course of business. We do not believe that any current legal or administrative proceedings are likely to have a materially adverse effect on our business, financial condition, or results of operations.

F-30

NATUS MEDICAL INCORPORATED

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS—(Continued)

Years Ended December 31, 2010, 2009 and 2008

19— FAIR VALUE OF FINANCIAL INSTRUMENTS

The fair value of our assets and liabilities subject to fair value measurements are as follows (in thousands):

	Fair Value as of 12/31/10		Fair Value Measurements as of 12/31/10 Using Fair Value Hierarchy
			Level 1		Level 2		Level 3
Bank money market investments	$	3,146		—	$	3,146		—
Fixed rate term deposits		1,005		—		1,005		—
Total	$	4,151		—	$	4,151		—

	Fair Value as of 12/31/09		Fair Value Measurements as of 12/31/09 Using Fair Value Hierarchy
			Level 1		Level 2		Level 3
Bank money market investments	$	3,142		—	$	3,142		—
Fixed rate term deposits		965		—		965		—
Total	$	4,107		—	$	4,107		—

In accordance with ASC Topic 820, Fair Value Measurements and Disclosures, Level 1 evaluations are based on quoted prices in active markets for identical assets or liabilities that the Company has the ability to access. Level 2 valuations are based on quoted prices in markets that are not active or for which all significant inputs are observable, either directly or indirectly. Bank money market accounts have a net asset value of $1.00 per share and consist principally of commercial paper with a rating of A-1/A-1+. Level 3 valuations are based on inputs that are not unobservable and significant to the overall fair value measurement.

20— IMMATERIAL CORRECTIONS TO PRIOR PERIOD FINANCIAL STATEMENTS

Subsequent to the issuance of our consolidated financial statements for the year ended December 31, 2009 we discovered certain errors relating primarily to the amount of manufacturing labor and overhead applied to inventory. As a result, certain previously reported amounts included in the accompanying consolidated financial statements have been restated to reflect the correction of the errors. We believe the effects of the errors are not material to our consolidated financial statements. In addition, certain other corrections previously identified that are not material individually or in the aggregate have also been corrected related to accrued sales commissions, the amount of revenue deferred under multiple deliverable revenue arrangements, and reclassification from accrued liabilities to accounts payable.

F-31

NATUS MEDICAL INCORPORATED

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS—(Continued)

Years Ended December 31, 2010, 2009 and 2008

A summary of the effects of the correction of these errors on our consolidated financial statements as of and for the years ended December 31, 2009 and 2008 are presented in the table below (in thousands, except per share data):

	2009
	As Previously Reported		As Corrected
Balance Sheet
Inventories	$	22,408	$	23,089
Prepaid expenses		4,213		3,825
Deferred income tax		4,248		4,166
Total current assets		108,170		108,381
Other assets		6,853		7,241
Total assets		291,491		292,090
Accounts payable		11,074		13,982
Accrued liabilities		17,245		14,513
Deferred revenue		4,705		4,501
Total current liabilities		33,202		33,174
Other liabilities		7,186		7,575
Deferred income tax		7,016		6,853
Total liabilities		48,335		48,533
Retained earnings		5,737		6,138
Total liabilities and stockholders’ equity		291,491		292,090

	2009						2008
	As Previously Reported			As Corrected			As Previously Reported			As Corrected
Statements of Operations
Revenue	$	166,505		$	166,425		$	161,831		$	161,831
Cost of revenue		66,670			66,077			60,933			61,332
Gross profit		99,835			100,348			100,898			100,499
Income from operations		14,817			15,333			25,483			25,173
Income before provision for income tax		16,567			17,083			27,625			27,315
Net income		11,079			11,382			17,473			17,282
Net income per share, diluted	$	0.39		$	0.40		$	0.66		$	0.65
Statements of Cash Flows
Net income	$	11,079		$	11,382		$	17,473		$	17,282
Share based compensation		3,980			4,260			3,275			2,995
Change in operating assets and liabilities, net of assets and liabilities acquired in acquisitions:
Accounts receivable		(78	)		683			(7,575	)		(8,336	)
Inventories		740			25			(2,726	)		(2,296	)
Other assets		727			(34	)		973			1,734
Accrued liabilities		(142	)		380			(2,698	)		(2,657	)
Deferred revenue		237			(153	)		—			—
Net cash provided by operating activities		26,588			26,588			11,802			11,802
Retained Earnings (Accumulated Deficit)
Beginning of year	$	(5,342	)	$	(5,244	)	$	(22,815	)	$	(22,526	)
End of year		5,737			6,138			(5,342	)		(5,244	)

F-32

EXHIBIT INDEX

		Incorporated By Reference
Exhibit No.	Exhibit	Filing		Exhibit No.	File No.		File Date
2.1	Share Purchase Agreement dated October 12, 2010 by and between Natus Medical Incorporated, and Medix I.C.S.A.
3.1	Natus Medical Incorporated Amended and Restated Certificate of Incorporation		S-1	3.1.1		333-44138		08/18/2000
3.2	Natus Medical Incorporated Certificate of Designation of Rights, Preferences and Privileges of Series A Participating Preferred Stock		8-A	3.1.2		000-33001		09/06/2002
3.3	Bylaws of Natus Medical Incorporated		8-K	3.1		000-33001		06/18/2008
4.1	Amended and Restated Preferred Stock Rights Agreement, dated as of October 8, 2002, between Natus Medical Incorporated and Equiserve Trust Company, N.A., including the form of Rights Certificate and Summary of Rights attached thereto as Exhibits B and C, respectively		8-A	4.1		000-33001		10/08/2002
4.2	Amendment No. 1 to the Amended and Restated Preferred Stock Rights Agreement dated as of February 14, 2003 between Natus Medical Incorporated and Equiserve Trust Company, N.A.		8-A	4.2		000-33001		02/25/2003
4.3	Amendment No. 2 to the Amended and Restated Preferred Stock Rights Agreement dated as of March 15, 2005 between Natus Medical Incorporated and Equiserve Trust Company, N.A.		8-K	99.1		000-33001		03/15/2005
4.4	Amendment No. 3 to the Amended and Restated Preferred Stock Rights Agreement dated as of August 17, 2006 between Natus Medical Incorporated and Wells Fargo Bank, National Association		8-K	99.01		000-33001		08/17/2006
4.5	Registration Rights Agreement dated as of April 9, 2008 by and among Natus Medical Incorporated and D3 Family Funds		8-K	4.01		000-33001		04/09/2008
10.1	Form of Indemnification Agreement between Natus Medical Incorporated and each of its directors and officers		S-1	10.1		333-44138		08/18/2000
10.2*	Natus Medical Incorporated Amended and Restated 1991 Stock Option Plan		S-1	10.2		333-44138		08/18/2000
10.2.1*	Form of Option Agreement under the Amended and Restated 1991 Stock Option Plan		S-1	10.2.1		333-44138		08/18/2000
10.3*	Natus Medical Incorporated Amended and Restated 2000 Stock Awards Plan		8-K	10.1		000-33001		01/04/2006
10.3.1*	Form of Option Agreement under the Amended and Restated 2000 Stock Awards Plan		S-1	10.3.1		333-44138		08/18/2000

		Incorporated By Reference
Exhibit No.	Exhibit	Filing		Exhibit No.	File No.		File Date
10.3.2*	Form of Restricted Stock Purchase Agreement under the Amended and Restated 2000 Stock Awards Plan		10-Q	10.2		000-33001		08/09/2006
10.3.3*	Form of Restricted Stock Unit Agreement under the Amended and Restated 2000 Stock Awards Plan		10-K	10.3.3		000-33001		03/14/2008
10.4*	Natus Medical Incorporated 2000 Director Option Plan		10-Q	10.02		000-33001		05/09/2008
10.4.1*	Form of Option Agreement under the 2000 Director Option Plan		S-1	10.4.1		333-44138		08/18/2000
10.5*	Natus Medical Incorporated 2000 Employee Stock Purchase Plan and form of subscription agreement thereunder		8-K	10.2		000-33001		01/04/2006
10.6	Lease Agreement dated August 24, 1998 between Natus Medical Incorporated and San Carlos Co-Tenancy		S-1	10.8		333-44138		08/18/2000
10.7	Amendment to Lease Agreement dated August 24, 1998 between Natus Medical Incorporated and San Carlos Co-Tenancy		10-K	10.8.1		000-33001		03/27/2003
10.8	6th Amendment to Lease Agreement dated July 1, 2005 between Natus Medical Incorporated and San Carlos Co-Tenancy		10-K	10.10		000-33001		03/16/2006
10.9*	Natus Medical Incorporated 2000 Supplemental Stock Option Plan		S-1	10.15		333-44138		08/18/2000
10.9.1*	Form of Option Agreement for 2000 Supplemental Stock Option Plan		S-1	10.15.1		333-44138		08/18/2000
10.10*	Form of Employment Agreement between Natus Medical Incorporated and each of its executive officers		10-K	10.1		000-33001		03/10/2009
10.11*	Amended Employment Agreement between Natus Medical Incorporated and James B. Hawkins dated April 25, 2008		8-K	99.1		000-33001		04/29/2008
10.12	Amended and Restated Credit Agreement dated November 28, 2007 by and between Natus Medical Incorporated and Wells Fargo Bank, National Association		8-K	10.1		000-33001		12/03/2007
10.13	Security Agreement dated November 28, 2007 by Natus Medical Incorporated in favor of Wells Fargo Bank, National Association		8-K	10.2		000-33001		12/03/2007
10.14	First Amendment to Amended and Restated Credit Agreement between Natus Medical Incorporated and Wells Fargo Bank, National Association		8-K	10.1		000-33001		08/06/2008

		Incorporated By Reference
Exhibit No.	Exhibit	Filing		Exhibit No.	File No.		File Date
10.15	Second Amendment to Amended and Restated Credit Agreement between Natus Medical Incorporated and Wells Fargo Bank, National Association		8-K	10.1		000-33001		09/05/2008
10.16	Third Amendment to Amended and Restated Credit Agreement between Natus Medical Incorporated and Wells Fargo Bank, National Association		10-K	10.16		000-33001		03/10/2009
10.17	Amended and Restated Security Agreement dated February 19, 2009 in favor of Wells Fargo Bank, National Association		10-K	10.17		000-33001		03/10/2009
10.18	Fourth Amendment to Amended and Restated Credit Agreement between Natus Medical Incorporated and Wells Fargo Bank, National Association		10-Q	10.1		000-33001		08/07/2009
10.19	Fifth Amendment to Amended and Restated Credit Agreement between Natus Medical Incorporated and Wells Fargo Bank, National Association		10-Q	10.1		000-33001		09/11/2009
10.20	Sixth Amendment to Amended and Restated Credit Agreement between Natus Medical Incorporated and Wells Fargo Bank, National Association		10-Q	10.1		000-33001		11/23/2009
10.21	Seventh Amendment to Amended and Restated Credit Agreement between Natus Medical Incorporated and Wells Fargo Bank, National Association		10-K	10.21		000-33001		03/15/2010
10.22	Second Amended and Restated Credit Agreement dated as of April 22, 2010 between Natus Medical Incorporated and Wells Fargo Bank, National Association		8-K	10.1		000-33001		04/27/2010
21.1	Subsidiaries of the Registrant
23.1	Consent of Independent Registered Public Accounting Firm
24.1	Power of Attorney
31.1	Certification of Principal Executive Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002
31.2	Certification of Principal Financial Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002
32.1	Certification of Principal Executive Officer and Principal Financial Officer pursuant to 18 U.S.C. Section 1350 as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002

* Indicates a management contract or compensatory plan or arrangement

EX-2.1

Exhibit 2.1

CONFIDENTIAL

SHARE PURCHASE AGREEMENT

by and among

NATUS MEDICAL INCORPORATED

and

THE PERSONS LISTED ON THE SIGNATURE PAGES HERETO

AS SELLING SHAREHOLDERS

Dated as of October 12, 2010

This SHARE PURCHASE AGREEMENT (this “Agreement”) is made and entered into as of October 12, 2010 (the “Agreement Date”) by and among Natus Medical Incorporated, a Delaware corporation (“Natus”), and each of the persons listed on the signature pages hereto as shareholders (the “Selling Shareholders”) of Medix I.C.S.A., a company incorporated and existing under the laws of the Republic of Argentina (the “Company”).

A. The Selling Shareholders are the registered owners of all of the issued and outstanding shares of the Company.

B. The Selling Shareholders desire to sell all of the shares of the Company to Natus, and Natus desires to purchase all of the shares of the Company from the Selling Shareholders, on the terms and subject to the conditions set forth in this Agreement (sometimes hereinafter referred to as the “Share Purchase” or the “Transaction”).

C. Natus and each of the Selling Shareholders desire to make certain representations, warranties, covenants and agreements in connection with the Transaction and to prescribe various conditions to the Transaction.

D. Concurrently with the execution of this Agreement and as a material inducement to the willingness of Natus to enter into this Agreement, each of those Selling Shareholders and certain employees of the Company listed on Exhibit A-1 (each, a “Key Employee,” and together, the “Key Employees”) is executing and delivering to the Company an employment agreement (including Natus’ standard form of confidentiality, non-competition and non-solicitation agreement, and invention assignment agreement) substantially in the form attached hereto as Exhibit A-2 (the “Employment Agreement”) to become effective upon the Closing.

NOW, THEREFORE, in consideration of the foregoing and the mutual covenants and agreements herein contained, and intending to be legally bound hereby, Natus and each of the Selling Shareholders hereby agree as follows:

ARTICLE I

DEFINITIONS

SECTION 1.01 Definitions.

(a) For purposes of this Agreement:

“affiliate” of a specified person means a person who, directly or indirectly through one or more intermediaries, controls, is controlled by, or is under common control with, such specified person.

“Argentine pesos” and “P$” means the lawful currency of the Republic of Argentina.

“Business Day” means a day (a) other than Saturday or Sunday and (b) on which commercial banks are open for business in Buenos Aires, Argentina.

“Company Balance Sheet” means the Company’s unaudited balance sheet as of July 31, 2010 included in the Company Financial Statements.

“Company Financial Statements” means the audited financial statements of the Company for the fiscal years ended on October 31, 2008 and October 31, 2009, and the unaudited financial statements of the Company for the 9-month fiscal period ended July 31, 2010, including the Company Balance Sheet, and any notes to such financial statements.

2

“Company IT Systems” means all IT Systems used in or held for use in connection with the business of the Company.

“Control” (including the terms “controlled by” and “under “common control with”) means the possession, directly or indirectly, or as trustee or executor, of the power to direct or cause the direction of the management and policies of a person, whether through the ownership of voting securities, as trustee or executor, by contract or credit arrangement or otherwise.

“Drawback” means reimbursement applied to exports of industrial products made in Argentina, including, without limitation, drawback as per Argentine Federal Decree No. 1011/91, as amended.

“Environmental Laws” means any national, federal, state or local Argentine laws, statutes, ordinances, regulations, rules, codes, orders, other requirements of law and common law relating to (i) releases or threatened releases of Hazardous Substances or materials containing Hazardous Substances; (ii) exposure or alleged exposure to Hazardous Substances; (iii) the manufacture, handling, transport, recycling, reclamation, use, treatment, storage or disposal of Hazardous Substances or materials containing Hazardous Substances; or (iv) pollution, natural resource damages or protection of the environment, health or safety.

“Fiscal Bonus” means fiscal benefit destined to Argentine manufacturers of industrial products, including, without limitation, fiscal bonus as per Argentine Federal Decree No. 379/2001 as amended by Argentine Federal Decree No. 2316/2008, as amended.

“GAAP” means generally accepted accounting principles in Argentina.

“Hazardous Substances” means (i) any toxic, poisonous or hazardous substance, material or waste; (ii) natural gas, synthetic gas, and any mixtures thereof; (iii) polychlorinated biphenyls, asbestos, mold and radon; and (iv) any other pollutant, contaminant, infectious or radioactive substance, material or waste regulated by any Governmental Authority pursuant to any Environmental Law.

“Healthcare Law” means the Laws or regulations relating to the regulation of the healthcare industry (as such laws are currently enforced or as interpreted on the Closing Date by existing, publicly available judicial and administrative decisions and regulations) which are applicable to the Company: (i) issued by the Administración Nacional de Medicamentos, Alimentos y Tecnología Médica (ANMAT) or any other Argentine Governmental Authority; (ii) issued by the United States Food and Drug Administration (“FDA”) set forh in the FDA Permits attached to the Disclosure Schedule; (iii) including (a) the licensure, certification or registration requirements of healthcare facilities, services, equipment or product; (b) any state certificate of need or similar law governing the establishment of healthcare facilities or services or the making of healthcare capital expenditures; (c) any state law relating to fee-splitting or the corporate practice of medicine; (d) any state physician self-referral prohibition or state anti-kickback law; (e) any criminal offense relating to the delivery of, or claim for payment for, a healthcare item or service under any federal or state healthcare program; and (f) any federal or state law relating to the interference with or obstruction of any investigation into any criminal offense.

“Intellectual Property” means, collectively, all of the following worldwide legal rights, whether or not filed, perfected, registered or recorded, that may exist under the laws of any jurisdiction to and under all: (i) patents, patent applications, statutory invention registrations, patent rights, including all continuations, continuations-in-part, divisions, reissues, reexaminations or extensions thereof, whether

3

now existing or hereafter filed, issued or acquired, and all inventions, whether or not patentable, (ii) trademarks, service marks, domain names, (including, but not limited to Internet domain names, Internet and World Wide Web URLs, and domain name registrations and pending applications therefor) trade dress, logos, trade names, corporate names, and other identifiers of source or goodwill, including registrations and applications for registration thereof, (iii) rights associated with works of authorship (including audiovisual works) including mask works and copyrights, including copyrights in Software, and registrations and applications for registration thereof, (iv) rights relating to the protection of trade secrets, know-how, invention rights, and other confidential or proprietary technical, business and other information, including manufacturing and production processes and techniques, research and development information, technology, drawings, specifications, designs, plans, proposals, technical data, financial, marketing and business data, pricing and cost information, business and marketing plans, customer and supplier lists and information, and all rights in any jurisdiction to limit the use or disclosure thereof, and (v) licenses involving the items listed in (i) to (iv) above.

“IT Systems” means computer systems, programs, networks, hardware, Software, databases, operating systems, Internet websites, website content and links and equipment used to process, store, maintain and operate data, information and functions.

“knowledge of the Selling Shareholders”, means what the Selling Shareholders actually know or should have known in the understanding that the Selling Shareholders are, in addition to shareholders of the Company, members of the board of directors of the Company involved in the day-to-day business.

“Liens” means with respect to the Shares (as defined herein) and to any property or asset of the Company, all mortgages, pledges, liens, security interests, conditional and installment sale agreements, encumbrances, charges or other claims of third parties of any kind with respect to such property or asset, including, without limitation, any easement, right of way or other encumbrance to title, or any option, right of first refusal, or right of first offer, but excluding in all cases Permitted Encumbrances.

“MASA” means a company under the laws of the Republic of Argentina controlled by the Selling Shareholders to be denominated “Medix Argentina S.A.”, “Medix Latinoamericana S.A.”, “Medix America S.A.” or “Medix Americana S.A.” or with any similar or other denomination at the option of the Selling Shareholders.

“Material Adverse Effect” means, when used in connection with the Company, any event, circumstance, change or effect that, individually or in the aggregate with any other events, circumstances, changes and effects, is or is reasonably likely to be or become materially adverse to (i) the business, condition (financial or otherwise), assets, liabilities, results of operations or prospects of the Company or (ii) the ability of the Company to consummate the Transaction.

“Material Contract” means any written plan, contract or agreement required to be listed on Section 3.10(a) or Section 3.16(a) of the Disclosure Schedule pursuant to Section 3.10(a) or Section 3.16(a) hereof.

“owned Intellectual Property” means any Intellectual Property that is owned or purportedly owned by or exclusively licensed to the Company.

“Permitted Encumbrances” means (A) liens for current Taxes and assessments not yet past due, (B) inchoate mechanics’ and materialmen’s liens for construction in progress, (C) workmen’s, repairmen’s, warehousemen’s and carriers’ liens arising in the ordinary course of business of the Company consistent with past practice, and (D) all matters of record, liens and other imperfections of title and encumbrances that, would not, individually or in the aggregate, have a Material Adverse Effect on the Company’s ability to occupy and utilize such property.

4

“person” means an individual, corporation, partnership, limited partnership, limited liability company, private company limited by shares or any similar legal entity, syndicate, person, trust, association or entity or government, political subdivision, agency or instrumentality of a government.

“Software” means computer software, programs and databases in any form, including Internet web sites, web content and links, all versions, updates, corrections, enhancements, and modifications thereof, and all related documentation.

“Taxes” shall mean any and all taxes, fees, levies, duties, tariffs, imposts and other similar charges of any kind (together with any and all interest, penalties, additions to tax and additional amounts imposed with respect thereto) imposed by any Governmental Authority or taxing authority, including, without limitation: taxes or other charges on or with respect to income, franchise, windfall or other profits, gross receipts, property, sales, use, share capital, payroll, employment, social security, workers’ compensation, unemployment compensation or net worth; taxes or other charges in the nature of excise, withholding, ad valorem, stamp, transfer, value-added or gains taxes; license, registration and documentation fees; and customers’ duties, tariffs and similar charges.

“Tax Return” means any return, report, declaration, estimate, claim for refund, or information return or statement relating to Taxes, including any schedule or attachment thereto, and including any amendment thereof, filed or to be filed with any taxing authority in connection with the determination, assessment, collection or administration of any Taxes.

“Transaction Expenses” means any fees, costs, expenses, payments and expenditures of legal counsel, accountants, financial advisors or in general brokers or finders of the Company or the Selling Shareholders in connection with the Share Purchase and this Agreement and the transactions contemplated hereby.

“U.S. $” or “US$” means the lawful currency of the United States of America.

ARTICLE II

THE STOCK PURCHASE

SECTION 2.01 The Transaction; Purchase Price; Earnout Amounts.

(a) Subject to the terms and conditions of this Agreement, the Selling Shareholders will sell to Natus, and Natus will purchase from the Selling Shareholders, an aggregate of 1,118,273 shares of the Company, par value P$ 1 per share, representing all issued and outstanding shares of the Company together with all financial and voting rights vested therein, including, without limitation, rights to stock dividends, dividends in kind or cash dividends (excluding the Dividends and Director Fees indicated in Section 6.07), that have not been distributed as of the Closing Date (as defined hereinafter), as well as all rights and causes of action derived from the capitalization of reserves, revaluations, capital adjustments and contributions of all kinds that remain pending and all credit rights (excluding the credit rights indicated in Section 6.08) vested in the Selling Shareholders vis-a-vis the Company (the “Shares”). The breakdown of the Selling Shareholders respective shareholding in the Company is indicated in Schedule I – Part A.

5

(b) The purchase price for the Shares and any other obligations specifically referred to in this Agreement (the “Purchase Price”), shall be payable to the Selling Shareholders as follows:

(i) U.S. $ 12,100,000, on the Closing Date;

(ii) U.S. $ 1,900,000 on the Closing Date in Escrow as per Section 2.04 of this Agreement;

(iii) (A) U.S. $ 2,000,000 (the “First Earnout Amount”) on December 20, 2011 (the “First Earnout Payment Date”) contingent and subject to Section 2.01(c) of this Agreement; and

(B) U.S. $1,000,000 (the “Supplemental Earnout Amount”), on the First Earnout Payment Date, contingent and subject to Section 2.01 (c) of this Agreement; and

(iv) U.S. $ 2,000,000 (the “Second Earnout Amount”) and together with the First Earnout Amount and the Supplemental Earnout Amount, the “Earnout Amounts”) on December 20, 2012 (the “Second Earnout Payment Date”) contingent and subject to Section 2.01(c) of this Agreement.

Any payment under this Agreement shall be made to the Selling Shareholders according to their pro-rata share of the Purchase Price which is indicated in Schedule I – Part B to this Agreement (referred to as each Selling Shareholder’s “pro rata share”) and by wire transfer of immediately available same day funds to the bank accounts with banks indicated in Schedule I – Part C. Any portion of the Purchase Price due to the Selling Shareholders under this Agreement which is not paid when due as set forth in Section 2.01(b), shall bear default interest (“Default Interest”) at a monthly rate of 1%.

(c) Natus shall pay to the Selling Shareholders the Earnout Amounts as determined by and contingent upon future Forecasted Sales (as defined below) or Company Gross Revenue (as defined below) for the Earnout Periods described below and on the following terms.

(i) Earnout Periods. The first earnout period shall begin on November 1, 2010 and shall end on October 31, 2011 (the “First Earnout Period”); and the second earnout period shall begin on November 1, 2011 and shall end on October 31, 2012 (the “Second Earnout Period,” and together with the First Earnout Period, hereinafter referred to individually as an “Earnout Period” and collectively as the “Earnout Periods”).

(ii) Thresholds for Forecasted Sales. The threshold amount for payment of the Earnout Amounts (except for the Supplemental Earnout Amount) based on Forecasted Sales shall be U.S. $9,150,000 for the First Earnout Period and U.S. $ 11,895,000 for the Second Earnout Period (referred to herein, respectively, as “First Forecasted Sales Threshold” and “Second Forecasted Sales Threshold”, and together, the “Forecasted Sales Thresholds”). Forecasted Sales shall not be taken into account for payment of the Supplemental Earnount Amount.

(iii) Thresholds for Company Gross Revenue. The threshold amount for payment of the Earnout Amounts (except for the Supplemental Earnout Amount) based on Company Gross Revenue shall be U.S. $37,772,000 for the First Earnout Period (the “First Company Gross Revenue Threshold”) and U.S. $38,976,000 for the Second Earnout Period (the “Second Company Gross Revenue Threshold”, and together with the First Company Gross Revenue Threshold, the “Company Gross Revenue Thresholds”). The threshold amount for payment of the Supplemental Earnout Amount based on Company Gross Revenue shall be U.S. $30,000,000 for the First Earnout Period (the “Supplemental Earnout Threshold”).

(iv) (A) Earnout Amount for the First Earnout Period. Natus shall pay the First Earnout Amount to the Selling Shareholders in accordance with their respective pro rata share if (i) the amount of Forecasted Sales for the First Earnout Period is equal to or greater than the First Forecasted Sales Threshold or (ii) the amount of Company Gross Revenue for the First Earnout Period is equal to or

6

greater than the First Company Gross Revenue Threshold. Such payment shall be made on the First Earnout Payment Date, unless Natus delivers on or before the First Earnout Payment Date an Earnout Certificate (as defined in clause (vi) of this Section 2.01(c)) to the Shareholders’ Agent containing amounts of Forecasted Sales and Company Gross Revenue that do not equal or exceed the thresholds set forth in clauses (ii) or (iii) of this Section 2.01(c), as applicable, for the First Earnout Period, in which case payment shall be made within three Business Days of the parties’ resolution of any objection of the Shareholders’ Agent to the amounts of Forecasted Sales and/or Company Gross Revenue as set forth in the Earnout Certificate pursuant to the procedures set forth in Section 2.01(c)(vi) and (xii) below if such resolution concludes that Forecasted Sales and/or Company Gross Revenue equals or exceeds the thresholds set forth in clauses (ii) or (iii) of this Section 2.01(c), as applicable, for the First Earnout Period. For the avoidance of any doubt, if for whatever reason Natus fails to deliver the Earnout Certificate for the First Earnout Period on or before December 20, 2011, the Shareholders’ Agent shall deliver to Natus in writing a default notice, providing Natus an additional 15-day term to deliver the Earnout Certificate. If such additional 15-day term expires without Natus delivering the Earnout Certificate, Natus shall forthwith pay the First Earnout Amount to the Selling Shareholders in accordance with their respective pro rata share irrespective of the achievement or not of the thresholds set forth in clauses (ii) or (iii) of this Section 2.01(c), as applicable, for the First Earnout Period. Any portion of the First Earnout Amount due to the Selling Shareholders under this Agreement which is not paid when due shall bear the Default Interest.

(B) Payment of the Supplemental Earnout Amount. Natus shall pay the Supplemental Earnout Amount to the Selling Shareholders in accordance with their respective pro rata share if the amount of Company Gross Revenue for the First Earnout Period is equal to or greater than the Supplemental Earnout Threshold. Such payment shall be made on the First Earnout Payment Date, unless Natus delivers on or before the First Earnout Payment Date an Earnout Certificate to the Shareholders’ Agent containing amounts of Company Gross Revenues that do not equal or exceed the Supplemental Earnout Threshold, in which case payment shall be made within three Business Days of the parties’ resolution of any objection of the Shareholders’ Agent to the amounts of Company Gross Revenue as set forth in the Earnout Certificate pursuant to the procedures set forth in Section 2.01(c)(vi) and (xii) if such resolution concludes that the Company Gross Revenue equals or exceeds the Supplemental Earnout Threshold. For the avoidance of any doubt, if for whatever reason Natus fails to deliver the Earnout Certificate for the First Earnout Period on or before December 20, 2011, the Shareholders’ Agent shall deliver to Natus in writing a default notice, providing Natus an additional 15-day term to deliver the Earnout Certificate. If such additional 15-day term expires without Natus delivering the Earnout Certificate, Natus shall forthwith pay the Supplemental Earnout Amount to the Selling Shareholders in accordance with their respective pro rata share irrespective of the achievement or not of the Supplemental Earnout Threshold. Any portion of the Supplemental Earnout Amount due to the Selling Shareholders under this Agreement which is not paid when due shall bear the Default Interest.

(v) Earnout Amount for the Second Earnout Period. Natus shall pay the Second Earnout Amount to the Selling Shareholders in accordance with their respective pro rata share if (i) the amount of Forecasted Sales for the Second Earnout Period is equal to or greater than the Second Forecasted Sales Threshold or (ii) the amount of Company Gross Revenue for the Second Earnout Period is equal to or greater than the Second Company Gross Revenue Threshold. Such payment shall be made on the Second Earnout Payment Date, unless Natus delivers on or before the Second Earnout Payment Date an Earnout Certificate (as defined in clause (vi) of this Section 2.01(c)) to the Shareholders’ Agent containing an amount of either Forecasted Sales or Company Gross Revenue that does not equal or exceeds the thresholds set forth in clauses (ii) or (iii) of this Section 2.01(c), as applicable, for the Second Earnout Period, in which case payment shall be made within three Business Days of the parties’ resolution of any objection of the Shareholders’ Agent to the amounts of Forecasted Sales or Company Gross Revenue as set forth in the Earnout Certificate pursuant to the procedures set forth in Section

7

2.01(c)(vi) and (xii) below if such resolution concludes that either Forecasted Sales or Company Gross Revenue equals or exceeds the thresholds set forth in clauses (ii) or (iii) of this Section 2.01(c), as applicable, for the Second Earnout Period. For the avoidance of any doubt, if for whatever reason Natus fails to deliver the Earnout Certificate for the Second Earnout Period on or before December 20, 2012, the Shareholders’ Agent shall deliver to Natus in writing a default notice, providing Natus an additional 15-day term to deliver the Earnout Certificate. If such additional 15-day term expires without Natus delivering the Earnout Certificate, Natus shall forthwith pay the Second Earnout Amount to the Selling Shareholders in accordance with their respective pro rata share irrespective of the achievement or not of the thresholds set forth in clauses (ii) or (iii) of this Section 2.01(c), as applicable, for the Second Earnout Period. Any portion of the Second Earnout Amount due to the Selling Shareholders under this Agreement which is not paid when due shall bear the Default Interest.

(vi) Payments; Review of Books and Records. For any payments due to the Selling Shareholders pursuant to clauses (iv) and (v) above, Natus shall pay each Selling Shareholder its pro rata share of the applicable Earnout Amount, if any, as indicated in Schedule I – Part B, by wire transfer of immediately available same day funds to the bank accounts with U.S. banks as indicated in Schedule I – Part C. On or before the First Earnout Payment Date, with respect to the First Earnout Period, or on or before the Second Earnout Payment Date, with respect to the Second Earnout Period, Natus shall deliver, or shall cause the Company to deliver, to the Shareholders’ Agent on behalf of the Selling Shareholders a certificate of the Chief Financial Officer, Treasurer or Controller of Natus or a duly authorized officer of the Company certifying in reasonable detail the amount of Forecasted Sales and Company Gross Revenue for the applicable Earnout Period and, if applicable, any adjustments to the thresholds set forth in clauses (ii) or (iii) of this Section 2.01(c) as per clause (xi) of this Section 2.01(c) (the “Earnout Certificate”). The Earnout Certificate shall contain a description of the Forecasted Sales for each client of the Company detailing the amount and date of each sale. If the Earnout Certificate indicates that no Earnout Amount is payable for the applicable Earnout Period, then the Shareholders’ Agent shall have the right to review the relevant books and records of the Company to verify or challenge the Forecasted Sales and Company Gross Revenue set forth in the applicable Earnout Certificate for the applicable Earnout Period and, if applicable, any adjustments to the thresholds set forth in clauses (ii) or (iii) of this Section 2.01(c) as per clause (xi) of this Section 2.01(c), provided that the Shareholders’ Agent shall provide written notice to Natus of its intent to exercise such right within 30 days of the receipt of the Earnout Certificate for such applicable Earnout Period. If the Shareholders’ Agent provides such notice, Natus shall, and shall cause the Company to, grant the Shareholders’ Agent (together with a reasonable number of its appointed advisors) access to the Company’s books and records of the Company during normal business hours and with 3-day advance notice as requested by the Shareholders’ Agent for the purpose of such review, and such review shall be completed within 60 days from the date of the Shareholders’ Agent’s notice of the intent to conduct such review. If following such review the Shareholders’ Agent disagrees with Natus on behalf of the Selling Shareholders as to the amount of either Forecasted Sales or Company Gross Revenue

8

for the applicable Earnout Period and, if applicable, any adjustments to the thresholds set forth in clauses (ii) or (iii) of this Section 2.01(c) as per clause (xi) of this Section 2.01(c), the Shareholders’ Agent shall provide written notice in reasonable detail to Natus of its objections to the calculations of such amounts, which must be delivered not later than 65 days from the date of the Shareholders’ Agent’s notice to Natus of the intent to conduct the review of Forecasted Sales or Company Gross Revenue for the applicable Earnout Period and, if applicable, any adjustments to the thresholds set forth in clauses (ii) or (iii) of this Section 2.01(c) as per clause (xi) of this Section 2.01(c) (the “Earnout Objection Deadline Date”), then such disagreement or dispute shall be determined in accordance with Section 2.01(c)(xii) of this Agreement. The parties intend, for tax purposes, that the payments set forth in clauses (iv) and (v) above qualify for installment sale treatment under applicable Tax Law. Such payments shall be treated as imputed interest to the extent required by applicable Tax Law. If upon resolution of objections of the Shareholders’ Agent in accordance with Section 2.01(c)(xii), Natus and Shareholders’ Agent agree, or the Earnout Expert Accountant determines, that the amount of Forecasted Sales or Company Gross Revenue for the applicable Earnout Period equals or exceeds the applicable Forecasted Sales Threshold or Company Gross Revenue Threshold or Supplemental Earnout Threshold (taking into consideration, if applicable, any adjustments to the thresholds set forth in clauses (ii) or (iii) of this Section 2.01(c) as per clause (xi) of this Section 2.01(c)), then within three (3) Business Days of such agreement or determination Natus shall pay each Selling Shareholder its pro rata share of the applicable Earnout Amount, as indicated in Schedule I – Part B, by wire transfer of immediately available same day funds to the bank accounts with U.S. banks as indicated in Schedule I – Part C. Any portion of the applicable Earnout Amount due to the Selling Shareholders under this Agreement which is not paid when due shall bear the Default Interest.

(vii) No Carry-over. Subject to Section 2.01(c)(xi), if no Earnout Amount is paid for the First Earnout Period because the amount of Forecasted Sales for such Earnout Period did not equal or exceeded the First Forecasted Sales Threshold and the amount of Company Gross Revenue for such Earnout Period did not equal or exceeded the First Company Gross Revenue Threshold (taking into consideration, if applicable, any adjustments to such thresholds as per clause (xi) of this Section 2.01(c)), then the Selling Shareholders shall have no right to carry-over and apply any amount of Forecasted Sales or Company Gross Revenue from the First Earnout Period to the Second Earnout Period in order to earn payment of the Second Earnout Amount.

(viii) Forecasted Sales. For purposes of this Agreement, “Forecasted Sales” for any Earnout Period shall be the aggregate amount of sales (including, without limitation, Drawback and Fiscal Bonus applicable (including retroactively) to the relevant Earnout Period), as determined in accordance with GAAP as consistently applied by the Company in its audited annual financial statements for the fiscal years ended on October 31, 2008 and October 31, 2009, from sales of the Earnout Products and Services by the Company for the Venezuelan market in the applicable Earnout Period. For purposes of calculating Forecasted Sales to be expressed in US$ in determining whether the Forecasted Sales Thresholds for the applicable Earnout Period have been met, any amount of sales which is not already recorded in US$ by the Company shall be converted and translated from the corresponding currency into US$ as follows: (A) using the average of the closing spot exchange rates published by Banco de la Nación Argentina for the corresponding currency into US$ for each Business Day of each particular month, calculate the average exchange rate of the corresponding currency into US$ in effect for such particular month, and (B) convert monthly revenue in the corresponding currency into US$ using the average monthly exchange rate in effect for that month (hereinafter referred to as the “Exchange Rate Convention”). For the sake of clarity, the parties acknowledge that sales of Earnout Products and Services by the Company do not include any royalties received by the Company from MASA under the MASA Distribution Agreement (as defined in Section 2.03).

(ix) Company Gross Revenue. For purposes of this Agreement, “Company Gross Revenue” for any Earnout Period shall be the aggregate amount of gross revenue (including, without limitation, Drawback and Fiscal Bonus applicable (including retroactively) to the relevant Earnout Period), as determined in accordance with GAAP as consistently applied by the Company in its audited annual financial statements for the fiscal years ended on October 31, 2008 and October 31, 2009, from sales of the Earnout Products and Services by the Company in the applicable Earnout Period, including, without limitation, sales to the Argentine market and any and all foreign markets. For purposes of calculating Company Gross Revenue to be expressed in US$ in determining whether the Company

9

Gross Revenue Thresholds for the applicable Earnout Period have been met, the amount of sales which is not already recorded in US$ by the Company shall be converted and translated into US$ in accordance with the Exchange Rate Convention. For the sake of clarity, the parties acknowledge that sales of Earnout Products and Services by the Company do not include any royalties received by the Company from MASA under the MASA Distribution Agreement (as defined in Section 2.03).

(x) Earnout Products and Services. For purposes of this Agreement, “Earnout Product and Services” shall mean any of the products and services at any time produced, manufactured, marketed, licensed, sold, distributed or otherwise commercialized by the Company (including, for the sake of clarification, from and after the Closing Date) (“Products and Services”).

(xi) Management of Business. Natus and each of the Selling Shareholders acknowledges and agrees that Natus shall have sole and absolute discretion in the ordinary course of its business and consistent with its past practice over all matters relating to any Earnout Product and Services from and after the Closing Date, including, but not limited to, any matter relating to the development, testing, regulatory submission or regulatory approval, if applicable, manufacturing, marketing, sales, distribution, pricing, service or maintenance thereof, and that Natus has no duty to take any action with regard to the sales of Earnout Product and Services from and after the Closing Date; provided, however, that Natus acknowledges and agrees that (x) it shall not take any action or omit to take an action with the primary purpose of seeking to avoid the payment of any Earnout Amount and (y) the thresholds set forth in clauses (ii) or (iii) of this Section 2.01(c) shall be proportionally reduced to neutralize the negative impact, if any such actions of Natus affects the payment of any Earnout Amount.

(xii) Disagreements over Calculation of Earnout Amount. If the Shareholders’ Agent on behalf of the Selling Shareholders has provided notice to Natus on or before the Earnout Objection Deadline Date of its disagreement with the calculation of the amount of Forecasted Sales or Company Gross Revenue for an Earnout Period as set forth in the relevant Earnout Certificate, such disagreement shall be resolved as follows:

(A) Natus and the Shareholders’ Agent shall first use reasonable efforts to resolve the Shareholders Agent’s objections to Natus’ calculations of the Forecasted Sales or Company Gross Revenue for the relevant period.

(B) If Natus and the Shareholders’ Agent do not reach a resolution of all objections set forth on the Shareholders’ Agent’s statement of objections within 30 days after the delivery of such statement of objections as provided in clause (vi) of this Section 2.01(c), the Shareholders’ Agent shall, within 30 days following the expiration of such 30-day period, submit the dispute to an Earnout Expert Accountant (as defined below) to resolve any remaining objections set forth on the Shareholders’ Agent’s statement of objections (the “Earnout Unresolved Objections”), and always in accordance with GAAP, as consistently applied by the Company in its audited annual financial statements for the fiscal years ended on October 31, 2008 and October 31, 2009. “Earnout Expert Accountant” shall mean an Argentine accounting firm designated by the Shareholders’ Agent among: Ernst & Young, PriceWaterhouse Coopers, or KPMG, or if for any reason they are not able to act, the Earnout Expert Accountant shall be an Argentine accounting firm agreed between the parties, in the understanding that any such accountant (and its affiliates) (other than Deloitte & Touche and the three expressly named in this paragraph) so selected has not performed services for Natus, the Company, the Shareholders’ Agent or any of the Selling Shareholders in the previous five years.

(C) Each of Natus and the Shareholders’ Agent shall submit to the Earnout Expert Accountant, within 15 days after the date of the engagement of the Earnout Expert

10

Accountant (as evidenced by the date of the engagement agreement), a copy of the Earnout Certificate for the applicable Earnout Period, a copy of the statement of objections delivered by the Shareholders’ Agent to Natus, and a statement setting forth the resolution of any objections agreed to by Natus and the Shareholders’ Agent. Each of Natus and the Shareholders’ Agent shall submit to the Earnout Expert Accountant (with a copy delivered to the other party on the same day), within 45 days after the date of the engagement of the Earnout Expert Accountant, a memorandum (which may include supporting exhibits) setting forth their respective positions on the Earnout Unresolved Objections. Each of Natus and the Shareholders’ Agent may (but shall not be required to) submit to the Earnout Expert Accountant (with a copy delivered to the other party on the same day), within 60 days after the date of the engagement of the Earnout Expert Accountant, a memorandum responding to the initial memorandum submitted to the Earnout Expert Accountant by the other party. Unless expressly requested in writing by the Earnout Expert Accountant in a request made known to both Natus and the Shareholders’ Agent, neither party may present any additional information or arguments to the Earnout Expert Accountant, either orally or in writing.

(D) Within 90 days after the date of its engagement hereunder, the Earnout Expert Accountant shall issue an opinion which shall include a determination of the Forecasted Sales and Company Gross Revenue for the applicable Earnout Period, giving effect to any resolutions to objections agreed upon by Natus and the Shareholders’ Agent and to the Earnout Expert Accountant’s opinion on the Earnout Unresolved Objections. Such determination of Forecasted Sales or Company Gross Revenue for such Earnout Period shall be deemed to be final.

(E) The opinion by the Earnout Expert Accountant of the Earnout Unresolved Objections shall be conclusive and binding upon Natus and the Shareholders’ Agent. Natus and the Shareholders’ Agent agree that the procedure set forth in this Section 2.01(c)(xii) for resolving disputes with respect to the payout of any Earnout Amounts for the relevant Earnout Period shall be the sole and exclusive method for resolving any such disputes; provided that this provision shall not prohibit either party from (i) instituting litigation to enforce the opinion of the Earnout Expert Accountant or (ii) submitting the matter to arbitration as per Article IX of this Agreement in case the Earnout Expert Accountant rejects to consider whether the thresholds set forth in clauses (ii) or (iii) of this Section 2.01(c) have been reduced as per Section 2.01(c)(xi).

(F) The fees and expenses of the Earnout Expert Accountant shall be borne by the non prevailing party (and to the extent that the Selling Shareholders are the non prevailing party, Natus and the Shareholders’ Agent at Natus request may cause the Escrow Agent to deduct such fees and expenses of the Earnout Expert Accountant from the Escrow Cash and to pay such amount to Natus). For such purpose, the written decision of the Earnout Expert Accountant shall set forth which was the prevailing party.

SECTION 2.02 Purchase Price Adjustment. (a) The Purchase Price shall be subject to adjustment on the following terms and conditions:

Within 90 days after the Closing Date, Natus shall prepare and deliver to the Shareholders’ Agent the Draft Closing Balance Sheet, which shall set forth the proposed Final Net Working Capital amount.

(ii) The Shareholders’ Agent shall deliver to Natus, within sixty (60) days after the date of delivery by Natus to the Shareholders’ Agent of the Draft Closing Balance Sheet (the “Objection Deadline Date”), either a notice indicating that the Shareholders’ Agent accepts the Draft Closing Balance Sheet or a statement describing in reasonable detail its objections (if any) to the Draft Closing Balance Sheet. For the purpuses of allowing the Shareholders’ Agent to

11

prepare such detailed statement, Natus shall grant, and shall cause the Company to grant, at the Shareholders’ Agent reasonably request, access to the Company’s accounting books and records by the Shareholders’ Agent (together with a reasonable number of appointed advisors). If the Shareholders’ Agent delivers to Natus a notice accepting the Draft Closing Balance Sheet, or the Shareholders’ Agent does not deliver a written objection to the Draft Closing Balance Sheet by the Objection Deadline Date, then, effective as of either the date of delivery of such notice of acceptance or as of the close of business (6 p.m. Buenos Aires time) on the Objection Deadline Date, the Draft Closing Balance Sheet shall be deemed to be the Final Closing Balance Sheet. If the Shareholders’ Agent timely objects to the Draft Closing Balance Sheet, such objections shall be resolved as follows:

(A) Natus and the Shareholders’ Agent shall first use reasonable efforts to resolve such objections.

(B) If Natus and the Shareholders’ Agent do not reach a resolution of all objections set forth on the Shareholders’ Agent’s statement of objections within 30 days after delivery of such statement of objections, the Shareholders’ Agent shall, within 30 days following the expiration of such 30-day period, submit the dispute to an Arbitrating Accountant (as defined below) to resolve any remaining objections set forth on the Shareholders’ Agent’s statement of objections (the “Unresolved Objections”), and always in accordance with GAAP, as consistently applied by the Company in its audited annual financial statements for the fiscal years ended on October 31, 2008 and October 31, 2009. “Arbitrating Accountant” shall mean an Argentine accounting firm designated by Natus among Ernst & Young, PriceWaterhouse Coopers, or KPMG, or if for any reason they are not able to act, the Arbitrating Accountant shall be an Argentine accounting firm agreed between the parties, with the understanding that any such accountant (and its affiliates) (other than Deloitte & Touche the three expressly named in this paragraph) so selected has not performed services for Natus, the Company, the Shareholders’ Agent or any of the Selling Shareholders in the previous five years.

(C) Each of Natus and the Shareholders’ Agent shall submit to the Arbitrating Accountant, within 10 days after the date of the engagement of the Arbitrating Accountant (as evidenced by the date of the engagement agreement), a copy of the Preliminary Balance Sheet and the Draft Closing Balance Sheet, a copy of the statement of objections delivered by the Shareholders’ Agent to Natus, and a statement setting forth the resolution of any objections agreed to by Natus and the Shareholders’ Agent. Each of Natus and the Shareholders’ Agent shall submit to the Arbitrating Accountant (with a copy delivered to the other party on the same day), within 45 days after the date of the engagement of the Arbitrating Accountant, a memorandum (which may include supporting exhibits) setting forth their respective positions on the Unresolved Objections. Each of Natus and the Shareholders’ Agent may (but shall not be required to) submit to the Arbitrating Accountant (with a copy delivered to the other party on the same day), within 15 days after the date of filing of the initial memorandum of the other party, a memorandum responding to the initial memorandum submitted to the Arbitrating Accountant by the other party. Unless expressly requested in writing by the Arbitrating Accountant in a request made known to both Natus and the Shareholders’ Agent, neither party may present any additional information or arguments to the Arbitrating Accountant, either orally or in writing.

(D) Within 90 days after the date of its engagement hereunder, the Arbitrating Accountant shall issue an opinion which shall include a balance sheet,

12

comprised of the Draft Closing Balance Sheet as adjusted pursuant to any resolutions to objections agreed upon by Natus and the Shareholders’ Agent and pursuant to the Arbitrating Accountant’s opinion on the Unresolved Objections. Such balance sheet shall be deemed to be the Final Closing Balance Sheet.

(E) The opinion by the Arbitrating Accountant of the Unresolved Objections shall be conclusive and binding upon Natus and the Shareholders’ Agent. Natus and the Shareholders’ Agent agree that the procedure set forth in this Section 2.02 for resolving disputes with respect to the Draft Closing Balance Sheet shall be the sole and exclusive method for resolving any such disputes; provided that this provision shall not prohibit either party from instituting litigation to enforce the opinion of the Arbitrating Accountant.

(F) The fees and expenses of the Arbitrating Accountant shall be borne by Natus or the Shareholders’ Agent depending on which party’s calculation of Final Net Working Capital as reflected in the Unresolved Objections is furthest away from the amount of Final Net Working Capital ultimately determined by the Arbitrating Accountant to be final pursuant to the provisions of this Section 2.02(a)(ii); provided, however, that if the amount calculated by a party which is furthest away from such final amount as determined by the Arbitrating Accountant is equal to or less than five percent (5%) of the final amount determined by the Arbitrating Accountant, then Natus and the Shareholders’ Agent shall split such fees and expenses equally (and to the extent that the Shareholders’ Agent’s calculation of such amount is furthest away from such amount, or for its one-half share of such fees and expenses, as applicable, Natus and the Shareholders’ Agent may cause the Escrow Agent to deduct such fees and expenses of the Arbitrating Accountant from the Escrow Cash and to pay such amount to Natus). For such purpose, the Arbitraiting Accountant shall determine which party will be responsible for paying the fees in accordance with this paragraph. If Natus recovers cash from Escrow Cash as provided in this paragraph, the Selling Shareholders shall replenish the Escrow Cash being held by the Escrow Agent with cash in US$ equal to the amount of the fees and expenses, in the same way indicated hereinbelow.

(iii) (A) If Final Net Working Capital as shown on the Final Closing Balance Sheet is lower than US$ 4,969,400, and that deficiency exceeds the Deductible Amount (as defined in clause (B) of this Section 2.02(a)(iii)), then Natus may recover from Escrow Cash, within three Business Days after the date on which the Final Closing Balance Sheet is finally determined pursuant to this Section 2.02, an amount equal to the amoun in which such deficiency exceeds the Deductible Amount (such excess, the “Deficiency Amount”). If the Deficiency Amount is greater than the amount of Escrow Cash then held by the Escrow Agent, the Selling Shareholders shall pay to Natus, within seven Business Days after the amount of Final Net Working Capital shall have been determined, such excess amount by wire transfer in immediately available same day funds to an account designated by Natus in writing to the Shareholders’ Agent. If Natus recovers cash from Escrow Cash as provided in this paragraph, the Selling Shareholders shall replenish the Escrow Cash being held by the Escrow Agent with cash in US$ equal to the amount of the Deficiency Amount that has been withdrawn from the Escrow Cash by Natus, and shall pay to the Escrow Agent, within seven Business Days after the amount of Final Net Working Capital shall have been determined, such amount necessary to replenish the Escrow Cash by wire transfer in immediately available same day funds. No adjustment shall be made if the Final Net Working Capital as shown on the Final Closing Balance Sheet is higher than US$ 4,969,400,

13

(B) Notwithstanding anything to the contrary set forth in this Agreement or in this Section 2.02, no adjustment shall be made under clause (A) of this Section 2.02(a)(iii) if the Deficiency Amount reflected in such final determination of Final Net Working Capital as determined pursuant to this Section 2.02 is equal to or lower than U.S. $500,000 (such amount, the “Deductible Amount”).

(b) For purposes of this Agreement:

(i) “Draft Closing Balance Sheet” means a balance sheet prepared by Natus pursuant to Section 2.02(a)(i) as at the Closing Date reflecting only the assets and liabilities of the Company immediately prior to the Closing (but including and after giving pro forma effect to all legal fees and financial advisors fees incurred, or to be incurred, by the Company for legal and financial advisor of Selling Shareholders in connection with the closing of the transactions contemplated by this Agreement), prepared in accordance with GAAP consistently applied with the past practices of the Company as reflected in its annual financial statements for the fiscal years ended on October 31, 2008 and October 31, 2009.

(ii) “Final Closing Balance Sheet” means the balance sheet as at the Closing Date determined pursuant to the procedures of this Section 2.02 reflecting only the assets and liabilities of the Company immediately prior to the Closing (but including and after giving pro forma effect to all legal fees and financial advisors fees incurred, or to be incurred, by the Company for legal and financial advisor of Selling Shareholders in connection with the closing of the transactions contemplated by this Agreement), prepared in accordance with GAAP consistently applied with the past practices of the Company as reflected in its annual financial statements for the fiscal years ended on October 31, 2008 and October 31, 2009.

(iii) “Final Net Working Capital” means Net Working Capital as shown on the Final Closing Balance Sheet.

(iv) “Net Working Capital” means the Company’s total current assets as of the Closing Date (as defined by and determined in accordance with GAAP consistently applied with the past practices of the Company as reflected in its annual financial statements for the fiscal years ended on October 31, 2008 and October 31, 2009) less the Company’s total current liabilities as of the Closing Date (as defined by and determined in accordance with GAAP consistently applied with the past practices of the Company as reflected in its annual financial statements for the fiscal years ended on October 31, 2008 and October 31, 2009). For purposes of calculating Net Working Capital, the Company’s current assets shall include without limitation all VAT fiscal credits (IVA crédito fiscal). For purposes of calculating Net Working Capital, the Company’s current liabilities (1) shall include all indebtedness of the Company for borrowed money, whether or not classified as a current liability on the Company’s balance sheet, (2) shall include all liabilities for Taxes as of the Closing Date, whether or not classified as a current liability on the Company’s balance sheet (including the employer portion of employee social taxes, such as social security with respect to payments made or to be made in connection with options, if any), and (3) shall include all Transaction Expenses which remain unpaid as of the Closing Date.

SECTION 2.03 Closing.

The closing (“Closing”) of the Transaction shall take place on October 12, 2010 at 10:00 a.m. at the offices of Estudio Beccar Varela, Edificio Republica, Tucuman 1, Piso 3º (C1049AAA), Buenos Aires, Argentina or at such other time and place as the parties shall mutually agree in writing (the date on which the Closing occurs being defined herein as the “Closing Date”).

14

At the Closing,

(I) the Selling Shareholders shall deliver to Natus: (i) The certificates representing the Shares as per the detail attached hereto as Schedule I – Part A; (ii) Transfer letters addressed to the Board of Directors of the Company, duly signed by each of the Selling Shareholders (and their respective spouses consent, to the extent required by Section 1277 of the Argentine Civil Code); and (iii) the Company’s corporate and accounting books.

(II) Natus shall deliver to each of the Selling Shareholders, such Selling Shareholder’s pro rata share, as reflected in Schedule I – Part B to this Agreement, of the portion of the Purchase Price specified in Section 2.01(b)(i), by wire transfer of immediately available same day funds to the bank accounts for each such Selling Shareholders as indicated in Schedule I – Part C to this Agreement, and shall deliver to the Escrow Agent, the Escrow Cash as per Section 2.04.

(III) Natus shall receive from Allende & Brea, legal counsel to the Selling Shareholders, an opinion opining in the form of Exhibit 2.03(III) hereto;

(IV) The Selling Shareholders shall execute and deliver to Natus a release in form and substance reasonably satisfactory to Natus that acknowledges that no Selling Shareholder has any claim of any nature against the Company and that the Company has no liability to such Selling Shareholder except as otherwise expressly provided in this Agreement and in the Employment Agreements.

(V) Each of the Key Employees shall enter into an Employment Agreement with Natus in the form attached as Exhibit 2.03(V) hereto.

(VI) The Company and the Selling Shareholders shall initialize the distribution agreement and the additional agreement to be entered into by the parties thereto (both, the “MASA Distribution Agreement”) in the forms attached as Exhibit 2.03(VI) hereto.

(VIII) The Selling Shareholders shall deliver to Natus the public, pacific and uncontroverted property and possession (posesión and/or tenencia, as the case may be) of the assets of the Company.

SECTION 2.04 Escrow.

On or before the Closing, Natus, the Shareholders’ Agent and Banco Santander Río S.A. who shall be appointed as the escrow agent for the Transaction (“Escrow Agent”), shall enter into an Escrow Agreement substantially in the form of Exhibit 2.04 hereto (the “Escrow Agreement”), which will subject to Argentine law and the jurisdiction as per Section 9.06 and which will provide the terms and conditions for the release of the Escrow Cash to the Selling Shareholders on the one-year anniversary of the Closing Date subject to the terms of this Agreement and the Escrow Agreement. On the day of the Closing, Natus shall deposit by wire transfer of immediately available same day funds U.S. $1,900,000 (and together with any interest earned thereon, the “Escrow Cash”) with the Escrow Agent and the Escrow Agent shall deliver to the Selling Shareholders and Natus written evidence to the effect of attesting the holding by the Escrow Agent of the Escrow Cash. Any interest paid on the Escrow Cash shall at the one year anniversary entirely belong to the Selling Shareholders and shall be treated for tax purposes as owned by the Selling Shareholders. A portion of the Escrow Cash shall be treated as imputed interest to the extent required by applicable Tax Law.

15

ARTICLE III

REPRESENTATIONS AND WARRANTIES OF THE SELLING SHAREHOLDERS

As an inducement to Natus to enter into this Agreement, and subject to the disclosures set forth in the disclosure schedule prepared by the Selling Shareholders and delivered by the Selling Shareholders to Natus simultaneously with the execution and delivery of this Agreement (the “Disclosure Schedule”), each of the Selling Shareholders severally hereby represents and warrants to Natus, as of the date hereof, that:

SECTION 3.01 Organization and Qualification; Subsidiaries.

(a) The Company is a company duly organized, validly existing and in good standing under the laws of Argentina and has the requisite corporate power and authority and all necessary governmental approvals to own, lease and operate its properties and to carry on its business as it is now being conducted, except where the failure to be in good standing or to have such power, authority and governmental approvals, individually or in the aggregate, would not prevent or materially delay consummation of the Transaction or would or could not reasonably be expected to have a Material Adverse Effect on the Company.

(b) The Company does not have any subsidiaries and does not directly or indirectly own any equity or similar interest in, or any interest convertible into or exchangeable or exercisable for any equity or similar interest in, any corporation, partnership, joint venture or other business association or entity.

SECTION 3.02 Organizational Documents / Books and Records.

(a) The Company has made available to Natus a complete, updated (as amended) and correct copy of the Articles of Association of the Company. Such Articles of Association are in full force and effect. The Company is not in violation of any of the provisions of its Articles of Association.

(b) The accountings records, minute books, stock record books and other records of the Company are true and complete in all material respects and have been maintained in accordance with sound business practices.

SECTION 3.03 Capitalization.

The authorized share capital of the Company consists solely of the Shares.The Shares are the only issued and outstanding shares of share capital of the Company and all of the Shares are validly issued, fully paid and nonassessable. There are no options, warrants or other rights, agreements, arrangements or commitments of any character relating to the issued or unissued share capital of the Company or obligating the Company to issue or sell any shares of share capital of, or other equity interests in, the Company, except for the non capitalized profits indicated as a reserve in the Company financial statements as decided by the Shareholders´ Meeting dated February 2, 2000 which are included in this transaction by the Selling Shareholders for the Purchase Price. There are no outstanding contractual obligations of the Company to repurchase, redeem or otherwise acquire any Shares, or to capitalize any amounts, irrevocable capital contributions or results, profits or earnings, or to provide funds to, or make any investment (in the form of a loan, capital contribution or otherwise) in, any other person. The Shares have been issued in compliance with all applicable securities laws and other applicable Laws. Such Selling Shareholder is and on the Closing Date such Selling Shareholder will be the record and beneficial

16

owner of the Shares, free and clear of any charge, claim, community property interest, condition, equitable interest, Lien, option, pledge, security interest, right of first refusal or restriction of any kind, including any restriction on use, voting or transfer (any of the foregoing being an “Encumbrance”), and upon consummation of the Transaction in accordance with the terms hereof Natus will acquire title to the Shares free of any Encumbrance (other than any Encumbrance that may have been independently created by Natus).

SECTION 3.04 Authority Relative to This Agreement.

No corporate proceedings on the part of the Company are necessary for the Selling Shareholders’ execution of this Agreement or consummation of the Transaction. This Agreement has been duly and validly executed and delivered by the Selling Shareholders and, assuming the due authorization, execution and delivery by Natus, constitutes the legal, valid and binding obligation of the Selling Shareholders, enforceable against the Selling Shareholders in accordance with its terms.

SECTION 3.05 No Conflict; Required Filings and Consents.

(a) The execution and delivery of this Agreement by the Selling Shareholders do not, and the performance of this Agreement by the Selling Shareholders will not conflict with or violate in any material respect the Articles of Association, and, it will neither (i) conflict with or violate in any material respect any national, federal, state, provincial, municipal or local statute, law, ordinance, regulation, rule, code, executive order, injunction, judgment, decree or other order (“Law”) applicable to any Selling Shareholder or the Company or by which any property or asset of any Selling Shareholder or the Company is bound or affected, or (ii) result in any material breach of or constitute a material default (or an event which, with notice or lapse of time or both, would become a material default) under, or give to others any right of termination, amendment, acceleration or cancellation of, or result in the creation of a Lien or other encumbrance on any property or asset of the Company pursuant to, any note, bond, mortgage, indenture, contract, agreement, lease, license, permit, franchise or other instrument or obligation to which any Selling Shareholder or the Company is a party or by which any Selling Shareholder or the Company or any material property or asset of any Selling Shareholder or the Company is bound or affected.

(b) The execution and delivery of this Agreement by the Selling Shareholders does not, and the performance of this Agreement by the Selling Shareholders will not, require any consent, approval, authorization or permit of, or filing with or notification to, any competent national, federal, state, provincial, municipal or local government, governmental, regulatory or administrative authority, agency, instrumentality or commission or any competent court, tribunal, or judicial or arbitral body (a “Governmental Authority”). For the purposes of Article 8 of Law 25,156, the Selling Shareholders hereby declare that the Company’s turnover for its fiscal year ended on October 31, 2009 was P$ 164,884,157.

SECTION 3.06 Permits; Compliance.

(a) Section 3.06 of the Disclosure Schedule contains a complete list of all licenses, permits, certificates and approvals of any Governmental Authority (except for licenses, permits, certificates and approvals under Environmental Laws which are addressed in Section 3.15 hereof) which are in possession of the Company and which are necessary for the Company to own, lease and operate its properties or to carry on its business as it is now being conducted (the “Permits”). No suspension or cancellation of any of the Permits is pending or, to the knowledge of the Selling Shareholders, threatened. The Company is not, in any material respect, in conflict with, or in default, breach or violation of, (a) any Law applicable to the Company or by which any property or asset of the Company is bound or affected, including, without limitation, with respect to design, labeling, testing and inspection of the Company’s products, or

17

(b) any note, bond, mortgage, indenture, contract, agreement, lease, license, Permit, franchise or other instrument or obligation to which the Company is a party or by which the Company or any property or asset of the Company is bound.

(b) The Company has not received, at any time since January 1, 2006, any written notice from any Governmental Authority or any other person (and does not have reason to believe any such notice could be received in the future) regarding (A) any actual violation of or failure to comply with any term or requirement of any Permit, or (B) any actual revocation, withdrawal, suspension, cancellation, termination of, or modification to any Permit, and (ii) all applications required to have been filed for the renewal of any Permit have been filed with the appropriate Governmental Authority, and all other filings required to have been made with respect to any such Permit have been duly made on a timely basis with the appropriate Governmental Authority.

SECTION 3.07 Financial Statements.

(a) Section 3.07 of the Disclosure Schedule includes the Company Financial Statements. The Company Financial Statements: (a) are in all material respects derived from and in accordance with the books and records of the Company; (b) fairly present in all material respects the financial condition of the Company and the results of operations and cash flows of the Company at the dates therein indicated and for the periods therein specified (subject, in the case of interim period financial statements, to normal recurring year-end audit adjustments); and (c) have been prepared in all material respects in accordance with GAAP applied by the Company on a basis consistent with prior periods (except that the interim period financial statements do not have notes thereto).

(b) All accounts receivable of the Company reflected on the Company Balance Sheet have arisen from bona fide transactions in the ordinary course of business consistent with past practices and are reflected in accordance with GAAP as consistently applied by the Company in its audited annual financial statements for the fiscal years ended on October 31, 2008 and October 31, 2009 and are not subject to valid defenses, setoffs or counterclaims except for defenses, setoffs or counterclaims in the ordinary course of the business of the Company and consistent with past practice.

(c) Section 3.07 of the Disclosure Schedule sets forth the names and locations of all banks, trust companies, savings and loan associations and other financial institutions at which the Company maintains accounts of any nature and the names of all persons authorized to draw thereon or make withdrawals therefrom.

SECTION 3.08 Absence of Certain Changes or Events.

Since July 31, 2010, except as as expressly contemplated by this Agreement or any ancillary documents hereto, (a) the Company has in all material respects conducted its businesses in the ordinary course and in a manner substantially consistent with past practice, and (b) there has not been any material adverse change in the business of the Company, other than changes relating to the worldwide economy in general or the Company’s industry in general and not specifically relating to the Company, and (c) the Company has not taken any action that, if taken after the date of this Agreement, would constitute a breach of any of the covenants set forth in Section 5.01.

SECTION 3.09 Absence of Litigation.

Section 3.09 of the Disclosure Schedule sets forth all private or governmental litigation, suit, claim, action or proceeding (an “Action”) pending or, to the knowledge of the Selling Shareholders, threatened by or against the Company or any property or asset of the Company, or any manager, director or shareholder of the Company (in any such capacities), before any Governmental Authority.

18

SECTION 3.10 Employees and Employee Benefit Plans.

(a) Section 3.10(a) of the Disclosure Schedule lists all employees of the Company and their benefit plans and all incentive, deferred compensation, retiree medical or life insurance, supplemental retirement, severance or other benefit plans, programs or arrangements, and all employment, termination, severance or other contracts or agreements (including without limitation all employment terms and conditions such as holidays, salary, fringe benefits and other kinds of monetary and non-monetary compensation, seniority, and so forth), whether legally enforceable or not, to which the Company is a party, with respect to which the Company has any obligation or which are maintained, contributed to or sponsored by the Company for the benefit of any current employee, officer or director of, or any current consultant to, the Company, and any contracts (including loan agreements), arrangements, or understandings between the Company and any employee of the Company including without limitation any contracts, arrangements or understandings relating in any way to a sale of the Company (collectively, the “Plans”), which grant any such benefit in excess of the legal benefits granted as per Argentine law. Except for those compulsory under applicable law, the Company has no express or implied commitment, whether legally enforceable or not, (i) to create, incur liability with respect to or cause to exist any employee benefit plan, program or arrangement, (ii) to enter into any contract or agreement to provide compensation or benefits to any individual, or (iii) to modify, change or terminate any Plan.

(b) Except for those compulsory under applicable law, there is no Company severance plan (“Severance Plan”).

(c) Each Plan is now and always has been operated in accordance with its terms and the requirements of all applicable Laws, including any applicable Tax Law. The Company has performed all obligations required to be performed by it under, is not in any material respect in default under or in violation of, and has no knowledge of any default or violation by any party to, any Plan. Except as set forth in Section 3.11 of the disclosure Schedule, no Action is pending or, to the knowledge of the Selling Shareholders, threatened with respect to any Plan (other than claims for benefits in the ordinary course), and, to the knowledge of the Selling Shareholders, no fact or event exists that could reasonably be expected to give rise to any such Action.

(d) All contributions, premiums or payments required to be made with respect to any Plan have been made on or before their due dates. All such contributions have been fully deducted for income tax purposes and no such deduction has been challenged or disallowed by any Governmental Authority and, to the knowledge of the Selling Shareholders, no fact or event exists which could give rise to any such challenge or disallowance.

(e) All employees of the Company whose employment with the Company started on or after May 2009 have executed the form of confidentiality agreement set forth in Section 3.11 of the Disclosure Schedule.

(f) No benefit payable or that may become payable by the Company pursuant to any agreement or arrangement or as a result of, in connection with or arising under this Agreement shall constitute a “parachute payment” or similar payment that is subject to the imposition of an excise tax under applicable Tax Law or that would not be deductible by reason of any provision of applicable Tax Law. Except for the Employment Agreements and unless otherwise indicated in Section 3.16 of the Disclosure Schedule, the Company is not a party to any: (i) contract, agreement or arrangement with any person (A) the benefits of which are contingent, or the terms of which are materially altered, upon the occurrence of a

19

transaction involving the Company in the nature of the Share Purchase or any of the other transactions contemplated by this Agreement, (B) providing any term of employment or compensation guarantee, or (C) providing severance benefits or other benefits after the termination of employment of such employee regardless of the reason for such termination of employment; or (ii) benefit plan or arrangement, any of the benefits of which shall be increased, or the vesting of benefits of which shall be accelerated, by the occurrence of the Share Purchase or any of the other transactions contemplated by this Agreement, or any event subsequent to the Share Purchase such as the termination of employment of any person, or the value of any of the benefits of which shall be calculated on the basis of any of the transactions contemplated by this Agreement. To the knowledge of the Selling Shareholders, the Company has no obligation to pay any material amount or provide any material benefit to any former employee or officer.

SECTION 3.11 Labor and Employment Matters.

(a) Section 3.11of the Disclosure Schedule sets forth the controversies pending or, to the knowledge of the Selling Shareholders, threatened between the Company and any of their respective employees or any labor claim pending in which the Company is involved as employer or jointly liable with the employer and/or with respect to the collective bargaining agreement or other labor union contract applicable to persons employed by the Company.

(b) Except as set forth in Section 3.11 of the Disclosure Schedule the Company is in compliance with all applicable laws relating to the employment of labor, including those related to wages, hours, immigration and naturalization, collective bargaining, subcontractors and outsourcers, and the payment and withholding of taxes and other sums as required by the appropriate Union and Governmental Authority and has withheld and paid to the appropriate Governmental Authority or is holding for payment not yet due to such Union or Governmental Authority all amounts required to be withheld from employees of the Company and is not liable for any arrears of wages, taxes, penalties or other sums for failure to comply with any of the foregoing and the Company has paid in full to all employees or adequately accrued for in accordance with generally accepted accounting principles and standards in Argentina consistently applied all wages, salaries, commissions, bonuses, benefits and other compensation due to or on behalf of such employees and there is no claim with respect to payment of wages, salary or overtime pay that has been asserted or is now pending or, to the knowledge of the Selling Shareholders, threatened before any Governmental Authority with respect to any persons currently or formerly employed by the Company. The Company is not subject to any investigation by any Governmental Authority relating to employees or employment practices. There is no charge or proceeding with respect to a violation of any occupational safety or health standards that has been asserted or is now pending or to the knowledge of the Selling Shareholders threatened with respect to the Company. There is no charge of discrimination in employment or employment practices, for any reason, including, without limitation, age, gender, race, religion or other legally protected category, which has been asserted or is now pending or to the knowledge of the Selling Shareholders threatened before any Governmental Authority in any jurisdiction in which the Company has employed, employs or has been alleged to employ any person. The Company does not have any liability under labor or social security laws as a transferee or successor, and has not been (and, to the knowledge of the Selling Shareholders, there is no reason to believe that it will be) considered jointly liable for labor or social security liabilities corresponding to employees of third parties.

(c) To the knowledge of the Selling Shareholders no employee or consultant of the Company is in material violation of (i) any contract or agreement or (ii) any restrictive covenant relating to the right of any such employee or consultant to be employed by the Company or to use trade secrets or proprietary information of others.

20

(d) In the past two years, there has been no “mass layoff,” “employment loss,” or “plant closing” as defined by applicable Law requiring specified notice to affected employees or service providers in connection with such events.

(e) Section 3.11of the Disclosure Schedule lists as of the Agreement Date each employee of the Company who is not fully available to perform work because of disability or other leave and also lists, with respect to each such employee, the basis of such disability or leave and the anticipated date of return to full service.

(f) Section 3.11 of the Disclosure Schedule lists as of the Agreement Date each employee of the Company who is granted with a special protection because of Union Activity, Pregnancy, marriage, or by any other reason, and indicates the starting and ending dates of their special protection.

SECTION 3.12 Real and Personal Property; Title to Assets.

(a) Section 3.12 of the Disclosure Schedule lists all real and material personal property and interests therein owned by the Company (with all easements and other rights appurtenant to such property, the “owned Property”) and the agreements, documents or other instruments by which the Company acquired ownership of real estate property, including any mortgage, deed of trust or similar security instrument relating to any parcel of real property or interest therein, any real estate appraisals or site assessments of such owned Property if available, and any owner’s or lender’s title insurance policy in respect of such real estate property (collectively, the “owned Property Documents”). True, correct and complete copies of all owned Property Documents have been made available to Natus. No Selling Shareholder or affiliate of the same is a lessor of any parcel of owned Property or any portion thereof or interest therein.

(b) Section 3.12(b) of the Disclosure Schedule lists all real and material personal property and interests therein currently leased or subleased by the Company, with the name of the lessor and the date of the lease, sublease, assignment of the lease, any guaranty given or leasing commissions payable by the Company in connection therewith and each amendment to any of the foregoing (collectively, the “Lease Documents”). True, correct and complete copies of all Lease Documents have been made available to Natus. All such current leases and subleases are in full force and effect, are valid and effective in accordance with their respective terms, and there is not, under any of such leases, any existing material default or event of default (or event which, with notice or lapse of time, or both, would constitute a default) by the Company or, to the Selling Shareholders’ knowledge, by the other party to such lease or sublease, or person in the chain of title to such leased premises. No affiliate of the Company or any Selling Shareholder is a lessor of any parcel of leased property or any portion thereof or interest therein, except as set forth in Section 3.12(b) of the Disclosure Schedule.

(c) To the knowledge of the Selling Shareholders, there are no contractual or legal restrictions that preclude or restrict the ability to use any real and personal property owned or leased by the Company as presently being used. There are no material latent defects or material adverse physical conditions affecting the real property, and improvements thereon owned or leased by the Company.

(d) The Company has good and valid title to, or, in the case of leased properties and assets, valid leasehold or subleasehold interests in, all of its real properties and its personal property and assets, tangible or intangible, reflected on the Company Balance Sheet, used or held for use in its business, free and clear of any Liens, except for (i) mechanics’, carriers’, workmen’s, repairmen’s or other like Liens arising or incurred in the ordinary course of business, Liens arising under original purchase price conditional sales contracts and equipment leases with third parties entered into in the ordinary course of business and liens for Taxes that are not due and payable or that may thereafter be paid without penalty,

21

all of which are referred to in the notes to the Company Balance Sheet, (ii) Liens that secure obligations that are reflected as liabilities on the Company Balance Sheet or Liens the existence of which is referred to in the notes to the Company Balance Sheet, (iii) other imperfections of title or encumbrances, if any, that, individually or in the aggregate, do not materially impair, and could not reasonably be expected materially to impair, the continued used and operation of the assets to which they relate in the conduct of the business of the Company as presently conducted, (iv) leases, subleases and similar agreements set forth in Section 3.16 of the Disclosure Schedule, and (v) zoning, building and other similar restrictions.

(e) The Company has the public, pacific and uninterrupted possession of all of its material assets.

SECTION 3.13 Intellectual Property.

(a) Section 3.13 of the Disclosure Schedule sets forth a true and complete list of all material owned Intellectual Property and licensed Intellectual Property used, filed by or licensed to the Company, other than unregistered designs and copyrights that, individually and in the aggregate, are not material to the conduct of the business of the Company as presently conducted. All the owned Intellectual Property of the Company which is registered is constituted by the trademarks “Medix” (in Argentina and Turkey only), “Medix I.C.S.A.” (in Argentina only) and “Servocuna” (in Argentina only), under the classess and pursuant to the registration information indicated in Section 3.13 of the Disclosure Schedule. The filing for the registration of the trademarks “Medix”, “Medix I.C.S.A.” and “Servocuna” are the sole proceedings or actions before any Governmental Authority related to any of the owned Intellectual Property or licensed Intellectual Property. Except as set forth in Section 3.13 of the Disclosure Schedule, there are no opposition proceedings and proceedings against those three trademarks, or related to the Internet domain name www.medix.com.ar.

(b) To the knowledge of the Selling Shareholders, the conduct of the business of the Company as currently conducted, including the use of the owned Intellectual Property, the licensed Intellectual Property, and Company IT Systems in connection therewith, does not conflict with, infringe upon, misappropriate or otherwise violate the Intellectual Property rights of any third party. To the knowledge of the Selling Shareholders, no person is engaging in any activity that infringes upon, misappropriates or otherwise violates the owned Intellectual Property or licensed Intellectual Property of the Company.

(c) The Company owns and has good and exclusive title to each item of owned Intellectual Property, free and clear of any liens and encumbrances out of the ordinary course of business of the Company as presently conducted. The Company has the valid right to use the owned Intellectual Property, licensed Intellectual Property, and access and use the Company IT Systems, in the continued operation of its business as presently conducted.

(d) No owned Intellectual Property or, to the knowledge of the Selling Shareholders, no licensed Intellectual Property, is subject to any outstanding decree, order, injunction, judgment or ruling restricting the use of such Intellectual Property or that would impair the validity or enforceability of such Intellectual Property. The owned Intellectual Property and the licensed Intellectual Property, are subsisting, valid and enforceable, and have not been adjudged invalid or unenforceable in whole or part.

(e) The owned Intellectual Property and the licensed Intellectual Property include all of the Intellectual Property currently used in the operation of the business of the Company, and there are no other items of Intellectual Property that are material to the operation of the business of the Company as currently conducted. The Company IT Systems include all of the IT Systems currently used in the operation of the business of the Company (other than Shrink Wrap Software), and there are no other IT Systems that are material to the operation of the business of the Company as currently conducted.

22

(f) To the knowledge of the Selling Shareholders, (i) each License is valid and enforceable, is binding on all parties thereto, and is in full force and effect; (ii) no party to any License is in material breach thereof or default thereunder; and (iii) neither the execution of this Agreement nor the consummation of the Share Purchase shall (x) adversely affect any of the rights of the Company with respect to the owned Intellectual Property or licensed Intellectual Property, or (y) impair or interrupt the Company’s access and use of, or their right to access and use, the Company IT Systems or, to the extent applicable, their customers’ access and use of, or their right to access and use, the Company IT Systems.

(g) The Company has taken all commercially reasonable steps in accordance with normal industry practice to maintain the confidentiality of the trade secrets of the Company and other confidential or non-public information included in the owned Intellectual Property or licensed Intellectual Property.

(h) To the knowledge of the Selling Shareholders, the Company IT Systems are free of all viruses, worms, and other known contaminants, and do not contain any errors or problems, that would (i) materially disrupt the ordinary operation of such IT Systems in the conduct of the business of the Company as presently conducted, or (ii) have a material adverse impact on the operation of other Software or operating systems. To the knowledge of the Selling Shareholders, the Company IT Systems do not incorporate or use any software or other material that is distributed as “free software,” “open source software” or under a similar license or distribution terms. . The access and use of the Company IT Systems by the Company and, to the knowledge of the Selling Shareholders, any customer thereof (to the extent applicable) in connection with the operation of the business of the Company as currently conducted do not violate any applicable Laws in any material respect.

(i) Upon the consummation of the Share Purchase, the owned Intellectual Property of the Company, the licensed Intellectual Property of the Company and the other assets and intellectual property rights of the Company will be maintained and owned by it and will provide Natus with all Intellectual Property and IT Systems sufficient to conduct the business and operations of the Company as currently conducted.

(f) To the knowledge of the Selling Shareholders, all owned Intellectual Property, licensed Intellectual Property, and Company IT Systems, as applicable, have been duly registered, maintained and renewed where such registration, maintenance and renewal is necessary for the conduct of the business of the Company as presently conducted.

SECTION 3.14 Taxes.

Except as set forth in Section 3.14 of the Disclosure Schedule, this Agreement, the Company Financial Statements and the Company’s books and records that have been made available to Natus:

(a) The Company has timely filed all material Tax Returns required to be filed by applicable tax Law. All such Tax Returns are true, complete and correct in all material respects. The Company has paid when due all material Taxes due and payable as of the Closing Date. The Company has made available to Natus correct and complete copies of all federal income Tax Returns, examination reports, and statements of deficiencies assessed against or agreed to by the Company and filed or received since January 1, 2006.

(b) Section 3.14 of the Disclosure Schedule sets forth the adjustments actually conducted by Taxing agencies on the Company’s Tax Returns for the past year.

23

(c) Except as provided in Section 3.14 of the Disclosure Schedule no deficiencies for any Tax had been claimed, proposed or assessed against the Company that have been not settled and/or paid as of the Closing Date.

(d) Except as provided in Section of the Disclosure Schedule, the Company is not being audited by any Taxing agency or Governamental Authority in relation to Taxes as of the Closing Date.

(e) To the knowledge of the Selling Shareholders, no claim has ever been made by any Governmental Authority in a jurisdiction where the Company does not file Tax Returns that the Company is or may be subject to taxation by that jurisdiction.

(f) All the Company intercompany transactions with any affiliate have been properly documented with written intercompany agreements, and the intercompany royalties/interests/fees payable thereunder have been determined by applicable transfer pricing methodologies and supported by transfer pricing documentation.

(g) There is not in effect any waiver by the Company of any statute of limitations with respect to any Taxes or agreement to any extension of time for filing any Tax Return which has not been filed, and the Company has not consented to extend to a date later than the Agreement Date the period in which any Tax may be assessed or collected by any Tax authority. The Company is not a party to, and does not owe any amount under, any Tax-sharing or allocation agreement.

(h) The Company has withheld and paid (and until the Closing Date will withhold and pay) all Taxes required to have been withheld and paid in connection with any amounts paid or owing to any employee, independent contractor, creditor, shareholder or other third party, resident or not, and have timely filed all withholding Tax Returns. The Company does not have any liability for the Tax of any Person as a transferee or successor, by contract or otherwise.

(i) The Company has in its possession official receipts for any Taxes paid by it to any Tax Governmental Authorities for which receipts are ordinarily provided.

(j) The Company has not been and will not be required to include any item of income in, or exclude any item of deduction from, taxable income for any taxable period (or portion thereof) ending after the Closing Date as a result of any: (i) change in method of accounting for a taxable period ending on or prior to the Transaction; (ii) installment sale or open transaction disposition made on or prior to the Transaction; or (iii) prepaid amount received on or prior to the Transaction.

(k) There is no claim for Taxes being asserted against the Company that has resulted in a lien against the property of the Company other than liens for Taxes not yet due and payable.

(l) There is currently no limitation on the utilization of net operating losses, capital losses, built-in losses, tax credits or similar items of the Company.

(m) The Company has made available to Natus all documentation relating to any applicable Tax holidays or incentives.

(n) No equalization tax is applicable or pending to be paid for any amounts that were paid to the Selling Shareholders or has to be paid as a result of capitalizing the profits indicated in Section 3.03.

24

SECTION 3.15 Environmental Matters.

Except as described in Section 3.15 of the Disclosure Schedule, to the knowledge of the Selling Shareholders: (a) the Company has not received any written communication from a Governmental Authority that alleges that the Company is not in compliance with, or is subject to liability under, any Environmental Law, and there is no reason to believe that any such communication will be received in the future; (b) to the knowledge of the Selling Shareholders, none of the real properties (including associated soils and surface and ground waters and building materials) currently or formerly owned, leased, used, occupied or operated by the Company are contaminated; (c) the Company has not disposed Hazardous Substances against the applicable regulations; (d) the Company has all permits, licenses and other authorizations required for the Company to conduct its business in all material respects under any Environmental Law (“Environmental Permits”) as presently conducted; (e) the Company is in compliance with its Environmental Permits and applicable environmental laws, and (f) the Company has not contaminated or otherwise generated environmental damage, or acted or ceased to act in a way that may render it liable under applicable environmental regulations.

SECTION 3.16 Material Contracts.

(a) Subsections (i) through (xv) of Section 3.16 of the Disclosure Schedule lists the following types of written contracts and agreements currently in force to which the Company is a party, other than purchase orders in general and contracts and agreements which are not material to the Company and its business as presently conducted:

(i) each contract and agreement, whether or not made in the ordinary course of business, that contemplates an exchange of consideration with a value of more than U.S. $100,000, in the aggregate, over the term of such contract or agreement;

(ii) all contracts and agreements evidencing indebtedness in excess of U.S. $100,000;

(iii) all joint venture, partnership, strategic alliance and business acquisition or divestiture agreements (and all letters of intent and term sheets relating to any such pending transactions);

(iv) all agreements relating to issuances of securities of the Company (and all letters of intent and term sheets relating to any such pending transactions);

(v) all agreements between the Company, on the one hand, and any Selling Shareholder, any affiliate, any officer or director of the Company and any family member of any Selling Shareholder or any officer or director of the Company, on the other hand;

(vi) all exclusive distribution contracts to which the Company is a party;

(vii) all broker, distributor, dealer, manufacturer’s representative, franchise, agency, sales promotion, market research, marketing consulting and advertising contracts and agreements to which the Company is a party and any other contract that compensates any person based on any sales by the Company;

(viii) all management contracts (excluding contracts for employment, which are to be listed on Section 3.10 of the Disclosure Schedule) and contracts with other consultants, including any contracts involving the payment of royalties or other amounts calculated based upon the revenues or income of the Company or income or revenues related to any product of the Company to which the Company is a party;

25

(ix) all contracts and agreements with any Governmental Authority to which the Company is a party;

(x) all licenses;

(xi) all contracts and agreements that limit, or purport to limit, the ability of the Company to compete in any line of business or with any person or entity or in any geographic area or during any period of time;

(xii) all material contracts or arrangements that result in any person or entity holding a power of attorney from the Company that relates to the Company or its respective businesses;

(xiii) all agreements related to professional services rendered to the Company in connection with the Transaction and this Agreement;

(xiv) each warranty, guaranty or other similar undertaking with respect to any contractual performance extended by the Company;

(xv) all contracts containing a provision of the type commonly referred to as a “most favored nation” provision; and

(xvi) all other contracts and agreements, whether or not made in the ordinary course of business, which are material to the Company, taken as a whole.

(b) To the knowledge of the Selling Shareholders: (i) each Material Contract is a legal, valid and binding agreement; (ii) the Company has not received any claim of material default under or cancellation of any Material Contract and the Company is not, in any material respect, in breach or violation of, or default under, any Material Contract; (iii) to the knowledge of the Selling Shareholders no other party is, in any material respect, in breach or violation of, or default under, any Material Contract; and (iv) neither the execution of this Agreement nor the consummation of the Transaction shall constitute a material default under, give rise to cancellation rights under, or otherwise adversely affect any of the material rights of the Company under any Material Contract. The Company has made available to Natus true and complete copies of all Material Contracts, including any amendments thereto.

SECTION 3.17 Customers and Suppliers.

Section 3.17(a) of the Disclosure Schedule sets forth a true and complete list of the top ten customers of the Company (based on the revenue from such customer during the 12-month period ended October 31, 2009 and the 9-month period ended July 31, 2010). Schedule 3.17(b) of the Disclosure Schedule sets forth a true and complete list of the top ten suppliers of the Company (based on amounts paid or payable by the Company to such supplier during the 12-month period ended October 31, 2009 and the 9-month period ended July 31, 2010). As of the date of this Agreement, none of the customers listed in Section 3.17(a) of the Disclosure Schedule and none of the suppliers listed in Section 3.17(b) of the Disclosure Schedule, (i) has cancelled or otherwise terminated any contract with the Company prior to the expiration of the contract term, or (ii)has notified in writing to the Company its intention to cancel or otherwise terminate its relationship with the Company or to reduce substantially its purchase from or sale to the Company of any products, equipment, goods or services.

26

SECTION 3.18 Inventory.

Except as set forth in Section 3.18 of the Disclosure Schedule, the inventory of the Company is generally of a quality and quantity usable and saleable at customary gross margins and with customary markdowns consistent in all material respects with past practice in the ordinary course of business and is reflected on the Company Balance Sheet and in the books and records of the Company in accordance with GAAP consistently applied with past practices of the Company.

SECTION 3.19 Company Products and Services.

(a) During the past year, the Company has not received any written customer material complaint concerning its products and services, nor have it had any of its products returned by a purchaser thereof, other than complaints and returns in the ordinary course of business that, individually or in the aggregate, have not had and could not reasonably be expected to have a Material Adverse Effect on the Company.

(b) Section 3.19 of the Disclosure Schedule lists all Company Products by name and version number. “Company Products” means all products or services produced, marketed, licensed, sold, distributed or performed by or on behalf of the Company and all products or services currently under development by the Company. Each Company Product has been in conformity in all material respects with all applicable contractual commitments, any applicable Law and all express and implied warranties, and the Company has no material liabilities or obligations for replacement or repair thereof or other damages in connection therewith. The Company has not been required to file any notice or other report with, or provide information to, any product safety agency, commission, board or other Governmental Authority concerning actual or potential hazards with respect to any Company Product. The Company has not been notified of any material liabilities or obligations arising out of any injury to persons or property as a result of the ownership, possession or use of any Company Product.

(c) Since January 1, 2005 there have been no (i) recalls related to any product manufactured sold, leased or delivered by the Company, or (ii) withdrawals of any product manufactured sold, leased or delivered by the Company due to quality or safety issues.

SECTION 3.20 Insurance.

The Company maintains the policies of insurance set forth in Section 3.20 of the Disclosure Schedule. To the knowledge of the Selling Shareholders, there is no material claim pending under any of such policies as to which coverage has been questioned, denied or disputed by the underwriters of such policies. All premiums due and payable under all such policies have been timely paid (other than retroactive or retrospective premium adjustments still not in place/not enforceable), and the Company is otherwise in compliance with the terms of such policies and bonds. All such policies and bonds remain in full force and effect, and the Selling Shareholders have no knowledge of any threatened termination of, or material premium increase with respect to, any of such policies or bonds, except for premium increase suffered by the market in general.

SECTION 3.21 Certain Business Practices.

Neither the Company nor, to the Selling Shareholders’ knowledge, any directors or officers, employees of the Company, or agents of the Company, including without limitation any distributors or other persons engaged by the Company for the purpose of marketing or selling or assisting in the marketing or selling of any products, has (i) used any funds for unlawful contributions, gifts, entertainment or other unlawful expenses related to political activity; (ii) made any unlawful payment to

27

foreign or domestic government officials or employees or to foreign or domestic political parties or campaigns, (iii) made any payment to any government official of any country for the purpose of obtaining or retaining business or gaining any other advantage, it being understood that for this purpose that the term “payment” is construed broadly to include any actual payment or promise to pay money or the giving or promising to give anything of value, including without limitation such actions as making or promising to make charitable contributions or donations, employing or agreeing to employ a specified person or persons, providing the use of facilities or services or paying for or reimbursing a person for the use of commercial or recreational facilities or services ; or (iv) made any payment in the nature of criminal bribery. The Company has advised its directors, officers and employees of the prohibition of the practices described in clauses (i) – (iv) above, and reiterates this advice periodically, and undertakes its best efforts to advise its agents of the prohibition of any such practices on behalf of or for the benefit of the Company.

SECTION 3.22 Government Regulation.

(a) Neither the Company nor any of its managers or directors or employees have been notified in writing of, or have received a written notice of being investigated with respect to, any activity that materially contravenes or could contravene, or constitutes or could constitute, a material violation of any Healthcare Law.

(b) Neither the Company nor its managers or, to the knowledge of the Selling Shareholders, employees has engaged in any activity that contravenes or constitutes a violation of any Healthcare Law during their employment or association with the Company.

(c) The Company has not: (i) had a material civil monetary penalty assessed against it; or (ii) been convicted for: (A) criminal offenses relating to the delivery of an item or service under any state or federal healthcare program; (B) criminal offenses under federal or state law for misconduct in connection with the delivery of a healthcare item or service or with respect to any act or omission in a program operated by or financed in whole or in part by any federal, state or local government agency; or (C) federal or state laws relating to the interference with or obstruction of any investigation into any criminal offense described in this clause.

(d) Since January 1, 2006, the Company has not been notified in writing of: (i) any United States Food and Drug Administration (“FDA”) Form 483’s relating to any product manufactured, sold, leased or delivered by the Company; (ii) any FDA Notices of Adverse Findings relating to any product manufactured, sold, leased or delivered by the Company; or (iii) any warning letters or other written correspondence from the FDA or any other Governmental Authority or the ANMAT or Board of Health concerning any product manufactured, sold, leased or delivered by the Company in which the FDA or such other Governmental Authority or ANMAT or Board of Health asserted that the operations of the Company were not in compliance with applicable Law, regulations, rules or guidelines with respect to any product manufactured, sold, leased or delivered by the Company.

SECTION 3.23 Brokers.

Except for [REDACTED] (which will be born by the Selling Shareholders), no broker, finder or investment banker is entitled to any brokerage, finder’s or other fee or commission in connection with this Agreement or the Transaction based upon arrangements made by or on behalf of the Company or any Selling Shareholder.

28

SECTION 3.24 Powers of Attorney.

Schedule 3.24 of the Disclosure Schedule sets forth a list of all the powers of attorney granted by the Company.

SECTION 3.25 Guaranties.

Except as set forth in Section 3.22 of the Disclosure Schedule attached hereto and made a part hereof, the Company is not a guarantor for any liability or obligation (including indebtedness) of any third party.

SECTION 3.26 Bank Accounts; Safe Deposit Boxes.

Except as set forth in Section 3.07 of the Disclosure Schedule (identifying numbers or symbols thereof, and the name of each person authorized to draw thereon or to have access thereto) there are no bank accounts with any bank, trust company, securities broker or other financial institution with which the Company has any account nor any safe deposit boxes maintained by the Company.

SECTION 3.27 Representations Complete.

None of the representations or warranties made by the Selling Shareholders herein or in any exhibit or schedule hereto, including the Disclosure Schedule, or in any certificate furnished by any of the Selling Shareholders or the Shareholders’ Agent on their behalf pursuant to this Agreement, when all such documents are read together in their entirety, contains any untrue statement of a material fact, or omits to state any material fact necessary in order to make the statements contained herein or therein, in the light of the circumstances under which made, not misleading.

ARTICLE IV

REPRESENTATIONS AND WARRANTIES OF NATUS

As an inducement to the Selling Shareholders to enter into this Agreement, Natus hereby represents and warrants to the Selling Shareholders that:

SECTION 4.01 Corporate Organization.

Natus is a corporation duly incorporated, validly existing and in good standing under the laws of Delaware and has the requisite corporate power and authority and all necessary governmental approvals to own, lease and operate its properties and to carry on its business as it is now being conducted, except where the failure to be so organized, existing or in good standing or to have such power, authority and governmental approvals would not, individually or in the aggregate, prevent or materially delay consummation of the Transaction.

SECTION 4.02 Authority Relative to This Agreement.

Natus has all necessary corporate power and authority to execute and deliver this Agreement, to perform its obligations hereunder and to consummate the Transaction. The execution and delivery of this Agreement by Natus and the consummation by Natus of the Transaction have been duly and validly authorized by all necessary corporate action, and no other corporate proceedings are necessary to authorize this Agreement or to consummate the Transaction. This Agreement has been duly and validly executed and delivered by Natus and constitutes the legal, valid and binding obligation of Natus enforceable against Natus in accordance with its terms.

29

SECTION 4.03 No Conflict; Required Filings and Consents.

(a) The execution and delivery of this Agreement by Natus does not, and the performance of this Agreement by Natus will not, and the consummation of the Transaction by Natus will not, (i) conflict with or violate the Certificate of Incorporation or By-laws of Natus, (ii) assuming that all consents, approvals and other authorizations described in Section 4.03(b) have been obtained and that all filings and other actions described in Section 4.03(b) have been made or taken, conflict with or violate any Law applicable to Natus or by which any property or asset of Natus is bound or affected, or (iii) result in any breach of, or constitute a default (or an event which, with notice or lapse of time or both, would become a default) under, or give to others any rights of termination, amendment, acceleration or cancellation of, or result in the creation of a Lien or other encumbrance on any property or asset of Natus pursuant to, any note, bond, mortgage, indenture, contract, agreement, lease, license, permit, franchise or other instrument or obligation to which Natus is a party or by which Natus or any property or asset of Natus is bound or affected, except, with respect to clauses (ii) and (iii), for any such conflicts, violations, breaches, defaults or other occurrences which would not, individually or in the aggregate, prevent or materially delay consummation of the Transaction.

(b) The execution and delivery of this Agreement by Natus does not, and the performance of this Agreement by Natus will not, require any consent, approval, authorization or permit of, or filing with or notification to, any Governmental Authority, except for (i) applicable requirements, if any, of the Exchange Act, and (ii) where the failure to obtain such consents, approvals, authorizations or permits, or to make such filings or notifications, would not prevent or materially delay consummation of the Share Purchase. For the purposes of Article 8 of Law 25,156, Natus hereby declares that Natus’ group turnover in Argentina for its fiscal year ended on October 31, 2009 was US$ 17,642, furthermore, Natus hereby declares that Natus’ group has no assets or participation interests in Argentina as per Article 10(c) of Law 25,156.

SECTION 4.04 Financing.

Natus has sufficient cash available to consummate the Transaction, including to pay any amounts on account of Purchase Price due hereunder.

SECTION 4.05 Investment Intent.

Natus is an “accredited investor” as such term is defined in Rule 501 promulgated by the Securities and Exchange Commission as part of Regulation D. Natus will acquire the Shares hereunder for its own investment intent, with no view to the distribution of such Shares, except to any Natus affiliate company.

SECTION 4.06 No Additional Representations.

Natus acknowledges that it and its representatives have had access to the Company’s management for discussion. Natus acknowledges that (i) none of Selling Shareholders, the Company or any other person has made any representation or warranty, expressed or implied, as to the Company or the accuracy or completeness of any information regarding the Company furnished or made available to Natus and its representatives, except as expressly set forth in this Agreement, any ancillary agreements or the Schedules, (ii) Natus has not relied on any representation or warranty from the Selling Shareholders or any other person in determining to enter into this Agreement, except as expressly set forth in this Agreement, the ancillary agreements and the Schedules.

30

ARTICLE V

NONCOMPETITION

SECTION 5.01 Defined Terms. As used in this Article V, the term “engage in” means to carry on, participate in, provide finance or services, or otherwise be directly or indirectly involved as a shareholder, unitholder, director, consultant, adviser, contractor, principal, agent, manager, employee, beneficiary, partner, associate, trustee or financier; the term “Prohibited Person” means (a) each Selling Shareholder and (b) each affiliate of each Selling Shareholder; and the term “Business” means the business of developing, manufacturing, marketing and selling neonatal medical devices, and the business of acting as a distributor of neonatal medical devices developed or manufactured by third parties, except as provided in the last sentence of Section 5.02.

SECTION 5.02 Prohibited Activities. Each Selling Shareholder undertakes to Natus that the Prohibited Persons will not:

(a) engage in a business activity that is in competition with the Business or any material part of the Business;

(b) solicit, canvass, approach or accept an approach from a Person who was at any time during the twelve months ending on the Closing a customer of the Company with a view to obtaining their customers in a business that is in competition with the Business;

(c) interfere with the relationship between the Company or the Business and its customers, employees or suppliers; and

(d) induce or help to induce an employee of the Company to leave their employment.

Notwithstanding the foregoing, and as only exemption to the non-compete obligation, the Selling Shareholders shall be entitled to engage through MASA in the sale of neonatal medical devices to purchasers in Venezuela who acquire such devices for their own use or for further sale or distribution exclusively within Venezuela. This exemption will only be valid for as long as one or more of the Selling Shareholders owns a majority of the outstanding voting equity securities of MASA, all in the terms of the model of distribution agreement attached hereto as Exhibit 2.03(VII).

SECTION 5.03 Duration of Prohibition. The undertakings in Section 5.02(a), (b), (c) and (d) shall begin on the Closing Date and end of the third (3rd) anniversary of the Closing Date.

SECTION 5.04 Geographic Application of Prohibition. The undertakings in Section 5.02(a), (b), (c) and (d) apply if the activity prohibited by Section 5.02 occurs anywhere on earth.

SECTION 5.05 Interpretation. Sections 5.02, 5.03 and 5.04 have effect together as if they consisted of separate provisions, each being severable from the other. Each separate provision results from combining each undertaking in Section 5.02, with each period in Section 5.03, and combing each of those combinations with each area in Section 5.04. If any of those separate provisions is invalid or unenforceable for any reason, the invalidity or unenforceability does not affect the validity or enforceability of any of the other separate provisions or other combinations of the separate provisions of Sections 5.02, 5.03 and 5.04.

31

ARTICLE VI

COVENANTS

SECTION 6.01 Access to Information

No investigation by Natus of the Company or the Selling Shareholders, or by the Selling Shareholders of Natus and its subsidiaries, shall affect any representation or warranty in this Agreement of any party hereto or any condition to the obligations of the parties hereto.

SECTION 6.02 Further Action; Reasonable Best Efforts.

Upon the terms and subject to the conditions of this Agreement, each of the parties hereto shall use its reasonable best efforts to take, or cause to be taken, all appropriate action, and to do, or cause to be done, all things necessary, proper or advisable under applicable Laws to consummate and make effective the Transaction, including, without limitation, using its reasonable best efforts to obtain all Permits, consents, approvals, authorizations, qualifications and orders of Governmental Authorities and parties to contracts with the Company as are necessary for the consummation of the Transaction. In case, at any time after the Closing Date, any further action is necessary or desirable to carry out the purposes of this Agreement, the proper officers and directors of each party to this Agreement shall use their reasonable best efforts to take all such action.

SECTION 6.03 Confidentiality. Public Announcements.

(a) This Agreement and the information exchanged between the parties hereto by reason of the Transaction hereby shall be confidential and shall therefore not be disclosed to any person until the fifth anniversary of this Agreement, unless there exists the obligation to disclose said information under the Law or upon request of a competent judicial or administrative authority, in which case the party required to disclose information shall notify in writing to the other party of the disclosure made, provided that such disclosure shall not include the names of the Selling Shareholders or any member of the [REDACTED] familiy. The name of the Selling Shareholders or any member of the [REDACTED] family may only be disclosed in cases where such names are expressly requested by a competent Governmental Autority and expressly and undoubtfully required by Law.

(b) Natus and the Company shall be allowed to disclose the name of [REDACTED] in connection with his capacity as general manager (gerente general) of the Company (or in connection with other position that [REDACTED] may occupy in the Company in the future), provided that such disclosure is reasonably discreet and makes no reference to [REDACTED] in his capacity as ex shareholder of the Company.

(c) Natus and Selling Shareholder shall consult with each other before issuing any press release or otherwise making any public statements with respect to this Agreement or the Transaction and shall not issue any such press release or make any such public statement prior to such consultation and shall not include the name of any of the parties, the name of the Company, and Purchase Price, except as may be required by Law or the rules or regulations of any United States securities exchange. The parties shall agree upon the form of a joint press release announcing the execution of this Agreement.

SECTION 6.04 Tax Matters.

(a) Tax Periods Ending on or before Closing Date. Natus shall prepare or cause to be prepared and file or cause to be filed all Tax Returns for the Company for all periods ending on or prior to the Closing Date that are filed after the Closing Date. To the extent permitted by applicable law, Selling

32

Shareholder shall include any income, gain, loss, deduction or other tax items for such periods on their Tax Returns in a manner consistent with the records or schedules furnished by the Company to such Selling Shareholder for such periods.

(b) Certain Taxes. All stamp Taxes (including any penalties and interest) incurred in connection with this Agreement shall be paid by both parties by halves when due. To that effect, Natus shall remit the necessary funds to the Selling Shareholders, who will file or caused to be filed all necessary Tax Returns and other documentation with respect to all such stamp Taxes and shall provide Natus written evidence of such payment within 10 days from the date of this Agreement.

SECTION 6.05 Expenses. Whether or not the Share Purchase is consummated, all costs and expenses incurred in connection with this Agreement and the transactions contemplated hereby (including the Transaction Expenses) shall be paid by the party incurring such expense, whether directly or, in the case of the Selling Shareholders only (and provided the Transaction has been consummated), indirectly through the Company as reflected in the adjustment of the Purchase Price as per Section 2.02.

SECTION 6.06 Guaranty with Banco de la Pampa. Immediately after Closing and in any event no later than 60 days as from the Closing Date, Natus shall replace the guaranty (the “Guaranty”) granted by the Selling Shareholders to Banco de la Pampa S.E.M. as security for the loans granted by Banco de la Pampa S.E.M. to the Company as set forth in Section 3.16(ii) of the Disclosure Schedule, and have the Selling Shareholders released to the maximum extent available by law from any obligations guaranteed under the Guaranty. Natus shall hold harmless and indemnify the Selling Shareholders from any and all damages, costs and expenses (including reasonable attorney’s fees) suffered by the Selling Shareholders due to the Guaranty, including due to any failure or delay in the replacement thereof by Natus. If the Guaranty is not timely replaced, Natus shall pay as penalty until the effective replacement thereof, a monthly guaranty fee to the Selling Shareholders equal to 1% of the amount guaranteed under the Guaranty.

SECTION 6.07 Dividends and Director Fees. Natus acknowledges and agrees that, as of the Agreement Date and after Closing, the Company owes and will owe to the Selling Shareholders and its directors the following dividends and directors’ fees (the “Dividends and Director Fees”): (i) P$ 600,000 to the Selling Shareholders on account of dividends corresponding to the fiscal year ended on October 31, 2008; (ii) P$ 1,200,000 to the Selling Shareholders on account of dividends corresponding to the fiscal year ended on October 31, 2009; and (iii) P$ 1,315,706.36 to the Company’s directors on account of directors’ fees for the fiscal year ended on October 31, 2009, pursuant to the following breakdown: [REDACTED]: P$ 278,934.01; [REDACTED]: P$ 376,541.17; [REDACTED]: P$ 363,607.40; and [REDACTED]: P$ 296,623.78. Natus covenants and agrees to cause the Company to fully pay the Dividends and Director Fees to the Selling Shareholders and the Company’s directors indicated above not later than June 30, 2011, plus the Default Interest in case of late payment. Section 6.07 of the Disclosure Schedule details all moneys distributed by the Company to the Selling Shareholders, either as distributions, dividends, payments or otherwise, since January 1, 2010.

SECTION 6.08 Credit against the Ministerio de Salud. With respect to the Company’s P$ 1,520,405.72 (plus interest) credit (the “Contingent Credit”) claimed against the Ministerio de Salud de la Provincia de Buenos Aires, as detailed in Section 3.09 of the Disclosure Schedule, the parties agree that any amounts collected by the Company on account of such Contingent Credit shall adjust the Purchase Price and, therefore, immediately upon receipt by the Company of any amounts on account of Contingent Credit (and in any event within ten (10) Business Days thereafter), Natus shall pay to the Selling Shareholders on account of Purchase Price an amount equal to such amount collected by the Company on account of Contingent Credit less any taxes and expenses incurred by the Company in collecting, or paying to the Selling Shareholders, such Contingent Credit (including reasonable attorney’s fees). Any

33

payments to the Selling Shareholders under this paragraph shall be paid proportionally to their pro rata share as indicated in Schedule I – Part B and be wire transfer of same day available funds to the bank accounts indicated in writing by the Selling Shareholders reasonably in advance.

SECTION 6.09 Execution of the MASA Distribution Agreement. The parties shall cause the execution of the MASA Distribution Agreement by the parites thereto, in the form of Exhibit 2.03(VI), as promptly as possible.

ARTICLE VII

[HAS BEEN INTENTIONALLY OMITTED]]

ARTICLE VIII

SURVIVAL OF REPRESENTATIONS, INDEMNIFICATION

AND REMEDIES; CONTINUING COVENANTS

SECTION 8.01 Survival. If the Transaction is consummated, the representations and warranties of Selling Shareholders contained in this Agreement shall survive the Closing Date and remain in full force and effect, regardless of any investigation or disclosure made by or on behalf of any of the parties to this Agreement, until the one-year anniversary of the Closing Date; provided, however, that the representations and warranties contained in Sections 3.03, 3.04, 3.14 (with respect to representations and warranties in Section 3.14 pertaining to matters of Argentinean income Taxes only), 3.15 and 3.21 shall, only with respect to Third-Party Claims, survive the Closing Date and remain in full force and effect, regardless of any investigation or disclosure made by or on behalf of any of the parties to this Agreement, until the fifth anniversary of the Closing Date; provided further, that no right to indemnification pursuant to this Article VIII in respect of any claim subject to indemnification as per Section 8.02 that is set forth in a Notice of Claim delivered prior to the applicable expiration date of such representation or warranty shall be affected by the expiration of such representation or warranty. If the Transaction is consummated, all covenants of the parties shall expire and be of no further force or effect as of the Closing Date, except to the extent such covenants provide that they are to be performed after the Closing Date; provided, however, that no right to indemnification pursuant to Article VIII in respect of any claim based upon any breach of a covenant shall be affected by the expiration of such covenant.

SECTION 8.02 Agreement to Indemnify. If the Transaction is consummated, from and after the Closing, each of the Selling Shareholders, severally and proportionally to their pro rata share as indicated in Schedule I – Part B, shall indemnify and hold harmless Natus, and its officers, directors, agents, representatives, shareholders, employees, and affiliates (each a “Natus Indemnified Person” and collectively the “Natus Indemnified Persons”) from and against any and all losses, reductions in value, costs, damages, liabilities and expenses (including reasonable attorneys’ fees, other professionals’ and experts’ fees, costs of investigation and court costs), actually incurred and, as applicable, paid by the Natus Indemnified Persons, calculated net of actual recoveries under existing insurance policies (net of any applicable collection costs and reserves, deductibles, premium adjustments and retrospectively rated premiums) (hereinafter collectively referred to as “Damages”), arising out of, resulting from or in connection with: (a) any failure of any representation or warranty of the Selling Shareholders made in this Agreement to be true and correct as of the date of this Agreement and as of the Closing Date (as though such representation or warranty were made as of the Closing Date, except in the case of representations and warranties which by their terms speak only as of a specific date or dates); (b) any breach of or default in connection with any of the covenants or agreements made by the Selling Shareholders in this Agreement.

34

SECTION 8.03 Limitations.

(a) If the Transaction is consummated, recovery from the Escrow Cash shall be the sole and exclusive remedy under this Agreement for the matters listed in Section 8.02 (a), except in the case of Damages resulting from Third Party Claims in connection with any failure of any of the representations and warranties contained in Sections 3.03, 3.04, 3.14 (with respect to representations and warranties in Section 3.14 pertaining to matters of Argentinean income Taxes only), 3.15 and 3.21 to be true and correct. In the case of Damages resulting from Third Party Claims in connection with any failure of any of the representations and warranties contained in Sections 3.03, 3.04, 3.14 (with respect to representations and warranties in Section 3.14 pertaining to matters of Argentinean income Taxes only), 3.15 and 3.21 to be true and correct, or in the case of Section 8.02 (b), after Natus has exhausted all amounts of Escrow Cash (after taking into account all other claims for indemnification from the Escrow Cash made by Natus), the Selling Shareholders shall be liable, severally and proportionally to their pro rata share as indicated in Schedule I – Part B, for the amount of any Damages resulting therefrom; provided, however, that such liability shall be limited to the aggregate amount actually paid to the Selling Shareholders pursuant to Section 2.01.

(b) If the Transaction is consummated, the Natus Indemnified Persons may not receive any Escrow Cash in respect of any claim for indemnification under this Article VIII unless and until: (i) in case of Third-Party Claims, Damages in an aggregate amount greater than U.S. $100,000 have been incurred and, as applicable, paid by Natus Indemnified Persons; or (ii) in case of any other claim other than a Third-Party Claim, Damages in an aggregate amount greater than U.S. $500,000 have been incurred and, as applicable, paid by Natus Indemnified Persons. Whenever Damages greater than the above mentioned thresholds have been incurred and, as applicable, paid, the Natus Indemnified Persons shall be entitled to receive Escrow Cash in indemnification therefore without regard to such thresholds.

SECTION 8.04 Notice of Claim.

As used herein, the term “Claim” means a claim for indemnification of Natus or any other Natus Indemnified Person for Damages under this Article VIII. Natus may give notice of a Claim under this Agreement, whether for its own Damages or for Damages incurred by any other Natus Indemnified Person, and Natus shall give written notice of a Claim executed by an officer of Natus (a “Notice of Claim”) to the Shareholders’ Agent (with a copy to the Escrow Agent if the Claim involves recovery against the Escrow Cash) promptly after Natus becomes aware of the existence of any potential claim by an Natus Indemnified Person for indemnification from Selling Shareholder under this Article VIII, arising from or relating to:

(a) any matter specified in Section 8.02; or

(b) the assertion, whether orally or in writing, against Natus or any other Natus Indemnified Person of a claim, demand, suit, action, arbitration, investigation, inquiry or proceeding brought by a third party against Natus or such other Natus Indemnified Person (in each such case, a “Third-Party Claim”) that is based on, arises out of or relates to any matter specified in Section 8.02.

Natus acknowledges and agrees that no direct Claim (i.e., a Claim that does not derive from a Third-Party Claim based on, arising out or relationg to any matter specified in Section 8.02) shall be entitled to indemnification under this Agreement if such Claim is based on, arises out or relates to Damages suffered or allegued to have been suffered by a Natus Indemnified Person derived from the adaptation or reconciliation of the Company’s practices and policies up to Closing (including without limitation business, taxing, employment, accounting and auditing practices and policies), with different policies or practices applied by Natus after Closing, unless and to the extent the Company’s practices and policies up to Closing violate the law or entail a breach by the Selling Shareholders to any of their representations and warranties hereunder.

35

Except as provided in the following sentence, the period during which claims for indemnification under this Article VIII may be initiated (the “Claims Period”) for indemnification from the Escrow Cash shall commence at the Closing Date and terminate at the one-year anniversary of the Closing Date. Notwithstanding anything contained herein to the contrary, any claims for Damages for indemnification from the Escrow Cash specified in any Notice of Claim delivered to the Shareholders’ Agent prior to expiration of the applicable Claims Period with respect to facts and circumstances existing prior to expiration of the applicable Claims Period shall remain outstanding until such claims for Damages have been resolved or satisfied, notwithstanding the expiration of such Claims Period. Until the expiration of the applicable Claims Period, no delay on the part of Natus in giving the Shareholders’Agent a Notice of Claim shall relieve the Shareholders’ Agent from any of its obligations under this Article VIII unless (and then only to the extent that) Selling Shareholders are materially prejudiced thereby.

SECTION 8.05 Defense of Third-Party Claims.

(a) Natus, at its option and at any time, determine and conduct the defense or settlement of any Third-Party Claim. Natus’ counsel with respect to any such Third-Party Claim shall be elected by the Shareholders’ Agent (in reasonable time so as not to affect the defense of the claim) among the following Argentine law firms: (i) Marval O’Farrell & Mairal; (ii) Perez Alati, Grondona, Benites, Arntsen & Martinez de Hoz(H); (iii) Bruchou, Fernández Madero & Lombardi; (iv) Estudio Alegria, Buey Fernández, Fissore y Montemerlo; or (v) Brons & Salas, provided that the elected law firm, prior to being confirmed as suitable to defend the Third-Party Claim, shall have to deliver to Natus a written statement confirming that it has no conflict of interest to participate in that Third-Party Claim as counsel of Natus, and to be elected to do so by the Selling Shareholders through the Sharheolders Agent (since that statement shall mention the names of the Selling Shareholders, it will be kept confidential both by Natus and by the law firm).

If Natus is entitled to indemnification under this Article VIII, the reasonable costs and expenses reasonably incurred by Natus in connection with such defense or settlement (including reasonable attorneys’ fees, other professionals’ and experts’ fees and court or arbitration costs (other than judicial fees of its counsel, professionals and experts determined by the court on top of the reasonable fees agreed to be paid by Natus)) shall be included in the Damages for which Natus may seek indemnification pursuant to this Agreement.

(b) The Shareholders’ Agent shall have the right to receive from Natus copies of all pleadings, notices and communications with respect to the Third-Party Claim, and shall be kept up-to-date with respect to the developments of the Third-Party Claim, to the extent that receipt of such documents and information by the Shareholders’ Agent does not affect any privilege relating to the Natus Indemnified Person. The Shareholders’ Agent may participate in, but not determine or conduct, any defense of the Third-Party Claim or settlement negotiations with respect to the Third-Party Claim. If the Shareholders’ Agent decides to participate in the defense, the Shareholders’ Agent shall employ separate counsel in any such action or claim and participate in the defense thereof, but the fees and expenses of such counsel shall not be at the expense of Natus.

(c) No settlement, acquiescence (allanamiento), waiver of defenses or rights or acknowledgement of debt of any such Third-Party Claim with any third party claimant shall be made nor and shall be determinative of the existence of the Selling Shareholders’ obligation to indemnify under this Article VIII, except the Shareholders’ Agent had consented in writing to such settlement, acquiescence (allanamiento), waiver of defenses or rights or acknowledgement of debt, which consent shall not be unreasonably withheld, conditioned or delayed and which shall be deemed to have been given unless the

36

Shareholders’ Agent shall have objected within 30 days after a written request for such consent by Natus. In the event that the Shareholders’ Agent has consented to any such settlement, acquiescence (allanamiento), waiver of defenses or rights or acknowledgement of debt, the Selling Shareholders shall be deemed to have accepted to indemnify the Natus Indemnified Person for such Third-Party Claim, but only to the extent of such consent.

SECTION 8.06 Contents of Notice of Claim. Each Notice of Claim by Natus given pursuant to Section 8.04 shall contain a description, in reasonable detail (to the extent available to Natus), of the facts, circumstances or events giving rise to the Third-Party Claim, including the identity and address of any third-party claimant (to the extent available to Natus) and copies of any formal demand or complaint, the amount of Damages, the basis for such anticipated liability, and the specific representation or warranty made in Article III of this Agreement which was allegedly breached by the Selling Shareholders.

SECTION 8.07 Resolution of Notice of Claim. Within 60 Business Days of the determination of the amount of any claims for Damages (for which Natus is entitled to receive indemnification under this Agreement), the validity and amount of which shall have been the subject of a settlement or a final judicial determination as per Section 8.05, the Selling Shareholders, severally and propotionally to their pro rata share as indicated in Schedule I – Part B, by so instructing in writing to the Escrow Agent, shall pay out of the Escrow Cash such determined amount to Natus by wire transfer to the bank account designated in writing by Natus, which designation shall be provided to the Shareholders’ Agent and the Escrow Agent not less than 10 Business Days prior to such payment.

SECTION 8.08 Release of Remaining Escrow Cash. Notwithstanding anything to the contrary in this Agreement, on the date of the one-year anniversary of the Closing Date, the Escrow Agent shall deliver to the Selling Shareholders (proportionally to their pro-rata share as indicated in Schedule I – Part B and C) all of the remaining Escrow Cash ; provided, however, that if any claims subject to indemnification under this Article VIII are unresolved, unsatisfied or disputed as of such date, then the Escrow Agent shall retain possession and custody of that amount of Escrow Cash that reasonably equals the amount of Damages being claimed as of such date in all such unresolved, unsatisfied or disputed claims, and immediately upon any such claims are resolved, the Escrow Agent shall deliver to the Shareholders’ Agent the proportional amount of Escrow Cash (if any) not required to satisfy such claims, until all Escrow Cash is entirely released to the Selling Shareholders.

SECTION 8.09 Tax Consequences of Indemnification Payments. All payments (if any) made to Natus pursuant to any indemnification obligations under this Article VIII will be treated as adjustments to the Purchase Price for tax purposes and such agreed treatment will govern for purposes of this Agreement, unless otherwise required by law.

SECTION 8.10 Shareholders’ Agent.

(a) At the Closing, [REDACTED] shall be constituted and appointed as the Shareholders’ Agent. For purposes of this Agreement, the term “Shareholders’ Agent” shall mean the agent for and on behalf of the Selling Shareholders to: (i) execute, as Shareholders’ Agent, this Agreement and any agreement or instrument entered into or delivered in connection with the transactions contemplated hereby; (ii) give and receive notices, instructions, and communications permitted or required under this Agreement, the Escrow Agreement, or any other agreement, document or instrument entered into or executed in connection herewith, for and on behalf of any Selling Shareholder, to or from Natus relating to this Agreement or any of the transactions and other matters contemplated hereby or thereby (except to the extent that this Agreement expressly contemplates that any such notice or communication shall be given or received by each Selling Shareholder individually and not by the Shareholders’ Agent); (ii) review, negotiate and agree to and authorize Natus to reclaim cash from the Escrow Cash in satisfaction

37

of claims asserted by Natus pursuant to this Article VIII; (iv) review, negotiate and agree on behalf of the Selling Shareholders regarding the Earnout Amounts and the Purchase Price Adjustment pursuant to Sections 2.01 and 2.02; (v) consent or agree to, negotiate, enter into, or, if applicable, contest, prosecute or defend, settlements and compromises of, and demand arbitration and comply with orders of courts and awards of arbitrators with respect to, such claims, resolve any such claims, take any actions in connection with the resolution of any dispute relating hereto or to the transactions contemplated hereby by arbitration, settlement or otherwise, and take or forego any or all actions permitted or required of any Selling Shareholder or necessary in the judgment of the Shareholders’ Agent for the accomplishment of the foregoing and all of the other terms, conditions and limitations of this Agreement; (vi) consult with legal counsel, independent public accountants and other experts selected by it, solely at the cost and expense of the Selling Shareholders; (vii) consent or agree to any amendment to this Agreement or to waive any terms and conditions of this Agreement providing rights or benefits to the Selling Shareholders (other than with respect to the payment of the Purchase Price) in accordance with the terms hereof and in the manner provided herein; and (viii) take all actions necessary or appropriate in the judgment of the Shareholders’ Agent for the accomplishment of the foregoing, in each case without having to seek or obtain the consent of any Person under any circumstance. Natus and its affiliates (including without limitation, after the Closing Date, the Company) shall rely on the appointment of [REDACTED] as the Shareholders’ Agent and treat such Shareholders’ Agent as the duly appointed attorney-in-fact of each Selling Shareholder having the duties, power and authority provided for in this Section 8.10. The Selling Shareholders shall be bound by all actions taken and documents executed by the Shareholders’ Agent in connection with this Article VIII, and Natus shall rely on any action or decision of the Shareholders’ Agent.

(b) Any notice or communication given or received by, and any decision, action, failure to act within a designated period of time, agreement, consent, settlement, resolution or instruction of, the Shareholders’ Agent that is within the scope of the Shareholders’ Agent’s authority under Section 8.10(a) shall constitute a notice or communication to or by, or a decision, action, failure to act within a designated period of time, agreement, consent, settlement, resolution or instruction of all the Selling Shareholders and shall be final, binding and conclusive upon each such Selling Shareholder; and subject to the foregoing, Natus shall rely upon any such notice, communication, decision, action, failure to act within a designated period of time, agreement, consent, settlement, resolution or instruction as being a notice or communication to or by, or a decision, action, failure to act within a designated period of time, agreement, consent, settlement, resolution or instruction of, each and every such Selling Shareholder.

(c) The Selling Shareholders may replace the Shareholders’ Agent at any time by giving written notice to Natus.

ARTICLE IX

GENERAL PROVISIONS

SECTION 9.01 Notices. All notices, requests, claims, demands and other communications hereunder shall be in writing and shall be given (and shall be deemed to have been duly given upon receipt) by delivery in person, by overnight courier, or by registered or certified mail (postage prepaid, return receipt requested) to the respective parties at the following addresses (or at such other address for a party as shall be specified in a notice given in accordance with this Section):

if to Natus:

Natus Medical Incorporated

1501 Industrial Road

San Carlos, CA 94070

Telecopier No.: +1(650) 802-0401

Attention: James B. Hawkins

38

with a copy to:

Fenwick & West LLP

801 California Street

Mountain View, CA 94041

Telecopier No.: +1(650) 938-5200

Attention: Daniel J. Winnike

if to Shareholders’ Agent:

Lisandro de la Torre 668

B1638ALL Vicente López

Provincia de Buenos Aires, Argentina

with copy to the Selling Shareholders to the addresses indicated below

and copy to:

Allende & Brea Abogados

Maipú 1300, 10^th floor

(C1006ACT) City of Buenos Aires,

Argentina

Attention: Valeriano Guevara Lynch

if to the Selling Shareholders:

[SHAREHOLDER 1]

[SHAREHOLDER 2]

[SHAREHOLDER 3]

[SHAREHOLDER 4]

39

with a copy to:

Allende & Brea Abogados

Maipú 1300, 10^th floor

(C1006ACT) City of Buenos Aires,

Argentina

Attention: Valeriano Guevara Lynch

SECTION 9.02 Severability. If any term or other provision of this Agreement is invalid, illegal or incapable of being enforced by any rule of law, or public policy, all other conditions and provisions of this Agreement shall nevertheless remain in full force and effect so long as the economic or legal substance of the Transaction is not affected in any manner materially adverse to any party. Upon such determination that any term or other provision is invalid, illegal or incapable of being enforced, the parties hereto shall negotiate in good faith to modify this Agreement so as to effect the original intent of the parties as closely as possible in a mutually acceptable manner in order that the Transaction be consummated as originally contemplated to the fullest extent possible.

SECTION 9.03 Entire Agreement; Assignment. This Agreement constitutes the entire agreement among the parties with respect to the subject matter hereof and supersedes all prior agreements and undertakings, both written and oral, among the parties, or any of them, with respect to the subject matter hereof, including, without limitation, the Medix I.C.S.A. Sale of Shares Summary Term Sheet entered into by the parties. This Agreement shall not be assigned (whether pursuant to a merger, by operation of law or otherwise), except that Natus may assign all or any of its rights and obligations hereunder to any affiliate of Natus, provided that no such assignment shall relieve Natus of its obligations hereunder. All Annexes, Schedules (including the Disclosure Schedule) and Exhibits to this Agreement shall be considered an integral part of the Agreement.

SECTION 9.04 Parties in Interest. This Agreement shall be binding upon and inure solely to the benefit of each party hereto and the successors of such parties, and nothing in this Agreement, express or implied, is intended to or shall confer upon any other person any right, benefit or remedy of any nature whatsoever under or by reason of this Agreement.

SECTION 9.05 Specific Performance. The parties hereto agree that irreparable damage would occur in the event any provision of this Agreement were not performed in accordance with the terms hereof and that the parties shall be entitled to specific performance of the terms hereof, in addition to any other remedy at law or equity.

SECTION 9.06 Governing Law; Dispute Resolution. This Agreement shall be governed by, and construed in accordance with, the laws of the Republic of Argentina. Any unresolved disputes between the parties relating to the interpretation, performance or alleged breach of this Agreement, whether before or after termination of this Agreement, shall be resolved by final and binding arbitration. If the parties shall decide to decide to institute arbitration proceedings, it shall give written notice to that effect to the other party. The arbitration shall be held in Buenos Aires, Argentina, according to the commercial rules of the International Chamber of Commerce (“ICC”). The arbitration will be conducted by a panel of three arbitrators appointed in accordance with ICC rules; provided that each of Natus and the Shareholders’ Agent shall within thirty (30) days after the institution of the arbitration proceedings appoint an arbitrator, and such arbitrators shall together, within thirty (30) days, select a third arbitrator as the chairman of the arbitration panel. If the two initial arbitrators are unable to select a third arbitrator within such thirty (30) day period, the third arbitrator shall be appointed in accordance with ICC rules. If one party fails to appoint its arbitrator within such 30 days period, such party’s arbitraitor shall be appointed in accordance

40

with ICC rules. The arbitrators shall render their opinion within thirty (30) days of the final arbitration hearing. No arbitrator (nor the panel of arbitrators) shall have the power to award punitive damages under this Agreement and such award is expressly prohibited. Decisions of the panel of arbitrators shall be final and binding on Natus, the Shareholders’ Agent and the Selling Shareholders. Judgment on the award so rendered may be entered in any court of competent jurisdiction.

SECTION 9.07 Waiver of Jury Trial. Each of the parties hereto hereby waives to the fullest extent permitted by applicable Law any right it may have to a trial by jury with respect to any litigation directly or indirectly arising out of, under or in connection with this Agreement or the Transaction. Each of the parties hereto (a) certifies that no representative, agent or attorney of any other party has represented, expressly or otherwise, that such other party would not, in the event of litigation, seek to enforce that foregoing waiver and (b) acknowledges that it and the other hereto have been induced to enter into this Agreement and the Transaction, as applicable, by, among other things, the mutual waivers and certifications in this paragraph.

SECTION 9.08 Headings. The descriptive headings contained in this Agreement are included for convenience of reference only and shall not affect in any way the meaning or interpretation of this Agreement.

SECTION 9.09 Counterparts. This Agreement is executed and delivered in one or more counterparts, and by the different parties hereto in separate counterparts, each of which when executed shall be deemed to be an original but all of which taken together shall constitute one and the same agreement.

IN WITNESS WHEREOF, Natus and each of the Selling Shareholders have caused this Agreement to be executed as of the date first written above in five counterparts, save for the exhitibts which are executed in two counterparts.

NATUS MEDICAL INCORPORATED
By
	Name:
	Title:
SELLING SHAREHOLDERS
By
	[SHAREHOLDER 1]
By
	[SHAREHOLDER 2]
By
	[SHAREHOLDER 3]
By
	[SHAREHOLDER 4]

41

SCHEDULE I

PART A

Selling Shareholders’ respective shareholding in the Company

Selling Shareholder	Number of Shares	Share Percentage
[Shareholder 1]	935,994	83.7%
[Shareholder 2]	70,451	6.3%
[Shareholder 3]	55,914	5%
[Shareholder 4]	55,914	5%

PART B

Selling Shareholders’ respective pro rata share in the Purchase Price

Selling Shareholder	Share in the Purchase Price
[Shareholder 1]	68.7%
[Shareholder 2]	11.3%
[Shareholder 3]	10%(*)
[Shareholder 4]	10%(*)

The Selling Shareholders declare that the pro rata share in the Purchase Price of the minority shareholders [REDACTED] and [REDACTED] is higher than their pro rata shareholding in the Company as a result of the negotiations held with [REDACTED] as majority shareholder of the Company to induce such minority shareholders to agree to this Transaction.

PART C

Bank accounts where the Purchase Price shall be payable

1) Any portion of the Purchase Price payable to [REDACTED] shall be paid (A) 93.95% to the bank account indicated in writing by [REDACTED] to Natus prior to Closing (or any other bank account indicated in writing to Natus by [REDACTED]), and (B) 6.05% irrevocably to the bank account detailed in paragrpagh 4) below (or any other bank account indicated in writing to Natus by [REDACTED]).

2) Any portion of the Purchase Price payable to [REDACTED] shall be paid (A) 93.95% to the bank account indicated in writing by [REDACTED] to Natus prior to Closing (or any other bank account indicated in writing to Natus by [REDACTED]), and (B) 6.05% irrevocably to the bank account detailed in paragrpagh 4) below (or any other bank account indicated in writing to Natus by [REDACTED]).

42

3) Any portion of the Purchase Price payable to [REDACTED] shall be paid (A) 93.95% to the bank account indicated in writing by [REDACTED] to Natus prior to the Closing (or any other bank account indicated in writing to Natus by [REDACTED]), and (B) 6.05% irrevocably to the bank account detailed in paragraph 4) below (or any other bank account indicated in writing to Natus by [REDACTED]).

4) Any portion of the Purchase Price payable to [REDACTED] shall be paid (A) 93.95% to the bank account indicated in writing by [REDACTED] to Natus prior to the Closing (or any other bank account indicated in writing to Natus by [REDACTED]), and (B) 6.05% irrevocably to the bank account detailed in paragraph 4) below (or any other U.S. bank account indicated in writing to Natus by [REDACTED]):

5) The details of the bank account referred in sub-clauses (B) of paragraphs 1) to 3) above are the following:

[REDACTED]

43

EX-21.1

EXHIBIT 21.1

SIGNIFICANT SUBSIDIARIES OF THE REGISTRANT

	STATE or JURISDICTION of INCORPORATION	PERCENT of OWNERSHIP
Natus Medical Incorporated	Delaware
Deltamed S.A.	France		100	%
Excel Tech Ltd. (Xltek)	Canada		100	%
Natus Europe Gmbh (dba Fischer-Zoth Diagnosesysteme & Schwarzer Neurology)	Germany		100	%
Alpine ApS	Denmark		100	%
Medix I.C.S.A.	Argentina		100	%

EX-23.1

EXHIBIT 23.1

CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM

We consent to the incorporation by reference in Registration Statements Nos. 333-65584 and 333-133657 on Form S-8 and Registration Statements Nos. 333-133480, 333-150503 and 333-171489 on Form S-3 of our report dated March 14, 2011, relating to the consolidated financial statements and financial statement schedule of Natus Medical Incorporated, which report expresses an unqualified opinion and includes an explanatory paragraph relating to the adoption of Accounting Standards Codification Topic 805, Business Combinations (formerly SFAS 141R), and of our report dated March 14, 2011, relating to the effectiveness of Natus Medical Incorporated’s internal control over financial reporting appearing in the Annual Report on Form 10-K of Natus Medical Incorporated for the year ended December 31, 2010.

/s/    Deloitte & Touche LLP

San Francisco, CA

March 14, 2011

EX-31.1

EXHIBIT 31.1

CERTIFICATION

I, James B. Hawkins, certify that:

1. I have reviewed this report on Form 10-K of Natus Medical Incorporated, (the “Registrant”);

2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the Registrant as of, and for, the periods presented in this report;

4. The Registrant’s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the Registrant and have:

a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the Registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

c) Evaluated the effectiveness of the Registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

d) Disclosed in this report any change in the Registrant’s internal control over financial reporting that occurred during the Registrant’s most recent fiscal quarter (the Registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the Registrant’s internal control over financial reporting; and

5. The Registrant’s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the Registrant’s auditors and the audit committee of the Registrant’s board of directors (or persons performing the equivalent functions):

a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the Registrant’s ability to record, process, summarize and report financial information; and

b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the Registrant’s internal control over financial reporting.

Date: March 14, 2011
	/s/    James B. Hawkins
	James B. Hawkins
	President and Chief Executive Officer

EX-31.2

EXHIBIT 31.2

CERTIFICATION

I, Steven J. Murphy, certify that:

1. I have reviewed this report on Form 10-K of Natus Medical Incorporated, (the “Registrant”);

2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the Registrant as of, and for, the periods presented in this report;

4. The Registrant’s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the Registrant and have:

a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the Registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

c) Evaluated the effectiveness of the Registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

d) Disclosed in this report any change in the Registrant’s internal control over financial reporting that occurred during the Registrant’s most recent fiscal quarter (the Registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the Registrant’s internal control over financial reporting; and

5. The Registrant’s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the Registrant’s auditors and the audit committee of the Registrant’s board of directors (or persons performing the equivalent functions):

a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the Registrant’s ability to record, process, summarize and report financial information; and

b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the Registrant’s internal control over financial reporting.

Date: March 14, 2011
	/s/    Steven J. Murphy
	Steven J. Murphy
	Vice President Finance and Chief Financial Officer

EX-32.1

EXHIBIT 32.1

CERTIFICATIONS OF CHIEF EXECUTIVE OFFICER AND CHIEF FINANCIAL OFFICER

PURSUANT TO TITLE 18, UNITED STATES CODE, SECTION 1350, AS ADOPTED

PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

In connection with the Annual Report of Natus Medical Incorporated (the “Company”) on Form 10-K for the year ended December 31, 2010 as filed with the Securities and Exchange Commission on the date hereof (the “Report”), I, James B. Hawkins, President and Chief Executive Officer of the Company, certify, pursuant to Title 18, United States Code, Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that:

(1) The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

(2) The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

/s/    James B. Hawkins
Print Name: James B. Hawkins
Title:	President and Chief Executive Officer
Date:	March 14, 2011

In connection with the Annual Report of Natus Medical Incorporated (the “Company”) on Form 10-K for the year ended December 31, 2010 as filed with the Securities and Exchange Commission on the date hereof (the “Report”), I, Steven J. Murphy, Vice President Finance and Chief Financial Officer of the Company, certify, pursuant to Title 18, United States Code, Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that:

(1) The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

(2) The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

/s/    Steven J. Murphy
Print Name: Steven J. Murphy
Title:	Vice President Finance and Chief Financial Officer
Date:	March 14, 2011